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Abstract 
 
Between 70-80% of colorectal cancer (CRC) patients present with non-metastatic 
disease and can potentially be cured with surgical resection. However, between 5-60% of 
these patients will suffer a recurrence, generally in the form of late-occurring metastatic 
disease. For this reason, most professional-society guidelines recommend intensive extra-
colonic-focused surveillance (CT scans and routine testing for tumor-markers) of these 
patients for 3-5 years post-diagnosis with the aim of detecting recurrence at an earlier 
stage when it is more likely to be amenable to salvage surgery with a curative intent. 
Until recently, this practice was corroborated by the results of meta-analyses of 
randomized control trials (RCTs) comparing more intensive with less intensive (or no) 
surveillance. However, the negative results of two large recently-published RCTs – the 
UK FACS trial and the Italian GILDA trial - and of subsequently updated meta-analyses 
have cast doubt on the value of aggressive follow-up and ultimately the value of 
aggressive treatment of recurrent CRC. 
In this dissertation I use a modeling analysis to argue that the results of these two 
trials have been misinterpreted. Accordingly, the conclusions of the most recent meta-
analyses are misguided and calls to throw in the towel on intensive follow-up are 
premature. The negative trial results are not surprising given the low recurrence rates of 
contemporary practice and thus the small proportion of patients who could potentially 
benefit from aggressive follow-up. I show that, if aggressive follow-up were to confer a 
survival advantage in virtue of increasing the chances of salvage therapy with a curative 
iii 
 
intent, the average benefit would be very small. Moreover, the two trials would have had 
essentially no chance to detect an effect of that size, and this problem of insufficient 
power was likely exacerbated in at least one of the trials by a sizable chance recurrence 
imbalance. I further show that it is unlikely that a RCT with adequate power could ever 
or will ever be possible. However, I argue there is reason to take seriously the hypothesis 
that aggressive use of follow-up testing and subsequent salvage therapy can offer a small 
survival advantage on average. Finally, I report the results of a modeling-based cost-
effectiveness analysis to identify follow-up strategies that would be cost-effective if this 
hypothesis is correct. 
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CHAPTER 1: BACKGROUND & INTRODUCTION 
CLINICAL BACKGROUND 
 Colorectal cancer (CRC) is the third most common form of cancer among US men 
and women, with about 150,000 new cases diagnosed per year.1 Almost 80% of cases are 
confined to the bowel with the possible exceptions of direct extension beyond the bowel 
wall to adjacent abdominal or pelvic organs (depending upon where the primary tumor is) 
and/or regional lymph nodes metastases. In the absence of contraindications (poor health 
due to old age or serious comorbidities), these patients (stage I-III) will undergo curative 
resection and possibly receive adjuvant chemotherapy or, for rectal patients, neoadjuvant 
(chemo)radiation therapy. However, depending upon the stage and other factors, between 
5%-60% of patients will suffer a recurrence.2 3 In the absence of surgical cure, CRC 
recurrence results in serious morbidity and death. 
 In colon cancer patients, recurrence generally presents as metastatic disease. The 
most common site is the liver, but other common sites are the lungs (particularly for 
distal colon cancer), the peritoneal cavity, or distant lymph nodes.4 When colon cancer 
recurrence is confined to the same quadrant of the abdomen as the primary tumor, it is 
considered local-regional recurrence and is possibly the result of surgical failure.5 
Although late-occurring metastatic disease receives most of the focus in the literature, 
about 10-20% of colon-cancer recurrences represent local-regional recurrence.5 Strict 
local recurrence confined to the bowel, i.e., intraluminal recurrence, used to occur more 
frequently6, but in contemporary practice it is extremely rare (<2% chance).7 
In rectal cancer, the liver is also the most common site of recurrence, but pulmonary 
metastases are almost as common.4 Although the risk of local-regional failure (in the 
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pelvis) has decreased dramatically over the last 30 years due to better surgery and 
neoadjuvant treatment8, pelvic recurrence also presents in 15-35% of all rectal cancer 
patients who suffer recurrence9. Like with local-regional recurrence in colon cancer, 
pelvic recurrence generally presents as primarily extracolonic disease and, though it may 
involve parts of the lumen, is very rarely confined to remaining portions of the bowel at 
the time of detection.10 Pelvic recurrence causes serious morbidity and can quickly 
become unresectable due to the constricted nature of the pelvis. In particular, the disease 
may become appended to the sacrum or nervous tissue.10 In the absence of surgical or, 
very rarely irradiating, cure, pelvic recurrence will lead to death within 5 years in 90-95% 
of cases, presumably through metastatic spread to vital organs.8 11 Thus from a clinical 
perspective, unresectable pelvic disease is ultimately just as damming as unresectable 
distant disease. Though 50-60% of patients who present with pelvic recurrence will also 
present with (or soon after) distant disease anyway.9 
 Because of the high morbidity and mortality burden associated with recurrence, 
follow-up surveillance is a common component of modern oncological care. After the 
primary resection and any (neo)adjuvant therapy for stage I-III colon and rectal cancer 
patients, routine clinical visits are important for managing treatment-related morbidity 
and symptoms and providing psychosocial support for patients.12 However, for the last 40 
years, it has also been theorized that early detection of recurrent disease before it is 
symptomatic can increase the chance of salvage surgery and thereby reduce the morbidity 
and mortality associated with recurrence. In particular, the hope is to discover the disease 
while it is isolated in the liver, lungs, or locally and limited enough for salvage surgery 
with a curative intent. 
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 Currently, the American Society for Clinical Oncology (ASCO)13,  the American 
Society of Colorectal Surgeons (ASCRS)14, the American Cancer Society (ACS)15, the 
National Comprehensive Cancer Network (NCCN), the European Society for Medical 
Oncology (ESMO)16, and the UK’s National Institute for Health and Care Excellence 
(NICE)17, among others, recommend at least 3 years, and up to 5 years, of intensive 
follow-up for patients at high risk for recurrence (stage II and III patients) who are 
otherwise healthy and would be candidates for salvage surgery. Follow-up efforts are 
concentrated in the first few years after primary surgery because the risk of recurrence is 
highest then. Depending on the stage and adjuvant treatment received, 65-95% of 
recurrences will present within 5 years.2 3 18-20 Because the majority (97%-99%) of 
recurrences are primarily extracolonic in nature21, follow-up generally involves 
surveillance modalities targeting extramural disease: blood tests for tumor markers such 
carcinoembryonic antigen (CEA) levels and imaging tests. 
 CEA is a glycoprotein produced by cells in the gastrointestinal tract which often rises 
in patients with CRC.12 CEA levels generally return to normal levels 4-6 weeks after 
curative surgery, but, in 50-80% of patients with recurrent disease, levels rise prior to the 
onset of clinical symptoms.22 23 Among the patients who exhibit an elevated CEA level 
prior to onset of clinically recurrent disease, the median lead time of CEA is estimated to 
be between 3-11 months.24 25 CEA rises before symptom onset in most patients with liver 
disease and retroperitoneal masses (such as in the kidney), but it is less helpful in the case 
of pelvic and peritoneal disease and a particularly poor indicator for pulmonary 
recurrence.26 27 False positive alerts are also a major problem with CEA levels, 
particularly among smokers, and so repeated high readings require confirmation with 
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radiological imaging.23 Guidelines (Table A.1) recommend CEA monitoring every 3-6 
months for at least 3 years and up to 5 years. These are normally performed at routine 
clinical visits. 
 To compliment routine CEA testing and clinical exam, guidelines recommend 
incorporating imaging studies of the liver and lungs (and pelvis for rectal cancer). 
Abdominal and thoracic (and pelvic) computed tomography (CT) scans are generally 
used for this purpose, but cheaper options6- abdominal ultrasound (US) and chest x-ray - 
and more expensive options28 – magnetic resonance imaging (MRI), positron emission 
tomography (PET), or PET/CT combination scan - options are available. Current 
guidelines (Table A.1) mostly recommend annual thoracic and abdominal 
(abdominal/pelvic for rectal cancer) CT scans for 3-5 years for stage II and III patients. 
Thoracic CT was only recently incorporated in the recommendations because of the 
dissemination and apparent success29 of the practice of pulmonary metastasectomy. 
 The final component of routine surveillance is endoscopy. In addition to a possible 
clearing colonoscopy for patients who undergo emergency primary surgery, the US 
Multi-Society Task Force recommends a colonoscopy for patients of all stages at 1 year 
and then every 3-5 years if the first colonoscopy is negative.30 The primary motivation 
for colonoscopy is to detect missed ‘synchronous’ and newly developed ‘metachronous’ 
high-risk lesions and thereby prevent the development of a second primary CRC. A 
secondary goal is to detect any recurrence at the site of the surgical anastomosis, though 
this is extremely rare in current practice.7 
A REVIEW OF THE CURRENT EVIDENCE 
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 While these recommendations were informed by systematic review and meta-analysis 
of randomized control trials (RCTs), the strength of evidence was low at best. Moreover, 
in the last 3 years the evidence has become even more mixed and the optimal surveillance 
program even more unclear. To date, the results of 16 RCTs comparing alternative 
surveillance practices have been reported, though only 13 compared more intensive to 
less intensive surveillance regimens. Two of these 13 trials specifically evaluated 
alternative endoscopy regimens, i.e., more vs less colonoscopy. The other 11 primarily 
compared alternative extracolonic-focused regimens. Details of these 13 trials are given 
in Tables A.2 and A.3. The first trials began enrolling patients in the early-to-mid 1980’s 
31-34, and the most recent trial’s results were published in 2016.35 
 From the late 1990’s through 2015, a series of systematic reviews and meta-analyses 
found an overall mortality benefit from ‘intensive’ surveillance compared to ‘minimal’ or 
no surveillance.6 36-40 The meta-analyses included various subsets of up to eleven RCTs. 
Most of the trials reported a mortality reduction in the intensive arm, but this result was 
only statistically significant in two studies33 41. Working with available data, the earlier 
meta-analyses found an overall mortality reduction at 5 years on average in terms of an 
odds-ratio, relative-risk, or risk-difference comparing the chances of dying in the 
intensive arm to the control arm. However, those analyses failed to account for censuring 
and the relevance of event timing. The last meta-analysis published in that period 
(2015)37 used established methods42 43 to estimate all-cause mortality hazard-ratios (HR), 
when unreported by authors, using the data presented in the trials. Based on eleven 
studies, the reviewers found a 25% reduction in mortality hazards associated with 
intensive surveillance (HR = 0.75; 95% CI: 0.66-0.86). Similar to earlier reviews, they 
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also found that intensive surveillance decreased the time to diagnosed recurrence, 
increased the chances of asymptomatic detection of recurrence, and, importantly, 
increased the chances of salvage surgery of recurrence. This finding was taken to 
corroborate the theory that increased salvage surgery was driving this remarkably large 
mortality benefit (very similar in magnitude to that observed for adjuvant 
chemotherapy).3 Somewhat alarmingly, although there was limited data concerning 
disease-specific survival, among the trials that did report relevant information, they found 
no difference between arms. 
 As a result of these trials and meta-analyses, a near-consensus developed (as 
evidenced by the professional society guidelines) that intensive CEA follow-up and 
imaging – modalities directed at detecting pre-clinical extracolonic recurrence – were 
likely driving the mortality reduction. In spite of the consensus, many questions 
remained44 and the quality of evidence was acknowledged to be suspect40. However, this 
consensus was soon to crumble. 
 In the last 3 years, two large, recent RCTs - the UK FACS trial45 46 and Italian 
GIDLA trial35 - that evaluated intensive follow-up regimens with particularly intensive 
imaging reported no overall survival benefit in the intensive arm. The FACS trial used a 
2x2 factorial design to compare 5 years of biannual or annual CT scans vs. just 1 CT scan 
at 12-18 months and intensive CEA vs. no CEA follow-up. There were thus 4 different 
arms: intensive CT and CEA, intensive CT alone, intensive CEA + 1 CT scan, and 
minimal surveillance (1 CT scan). They found that the 3 more intensive arms (CT & 
CEA, CT Only, and CEA + 1 CT) were more likely to detect recurrence while 
asymptomatic and more likely to perform salvage surgery ‘with a curative intent’ than the 
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minimal surveillance arm (i.e., 1 CT scan only). However, somewhat surprisingly, there 
was a small, non-significant overall and cancer-specific survival advantage for the 
minimal surveillance arm.  
 The GILDA trial compared more frequent to less frequent abdominal ultrasound, 
colonoscopy, chest x-ray, and, for rectal patients, abdominal/pelvic CT. Both arms were 
subjected to intensive CEA testing. The more intensive arm detected disease earlier on 
average, but it did not significantly increase the rate of asymptomatic detection or salvage 
surgery. Cancer-specific survival is not reported, but again there was a slight, non-
significant mortality advantage for the less-intensive arm. 
 Moreover, the results of an old, previously unpublished and prematurely terminated 
RCT from the l980’s and early 1990’s – the CEA Second Look (CEASL) trial – were 
recently published. The CEASL trial enrolled roughly 1,500 patients with routine CEA 
assessment. A little over 200 patients with repeated elevated CEA measurements were 
randomized to a conservative strategy that waited for symptoms to develop or an 
aggressive strategy that, after poorly-defined clinical assessments, performed exploratory 
laparotomy (‘second-look surgery’). This trial reported no survival benefit from CEA-
driven second-look surgery among those randomized to aggressive treatment. 
 After incorporating these recent trial results and making alternative exclusion 
decisions (different than earlier reviewers), two47 48 subsequent meta-analyses have 
concluded that intensive surveillance does not provide an all-cause or disease-specific 
mortality benefit. The disappointing results of these trials and the new meta-analytic 
perspectives have unsurprisingly lead for calls to throw in the towel on intensive follow-
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up. Discussing the professional-society recommendations (Table A.1), the authors of the 
report on the GILDA trial conclude that  
“Results from GILDA, FACS and CEA Second-Look randomized trials failed to support such 
recommendations and they undermine the paradigm that earlier detection of recurrences may translate 
into either longer survival duration or enhanced quality of life in patients with colorectal cancer treated 
with curative intent”35  
The authors of the two latest meta-analyses dismiss the logic behind intensive 
surveillance and even express skepticism towards any role for follow-up with the goal of 
detecting recurrences earlier:  
“The information we have now suggests that there is little benefit from intensifying follow-up…We do 
not know what is the best way to follow patients treated for non-metastatic colorectal cancer, or if we 
should at all.”47 
“Based on pooled data from randomized trials published from 1995 to 2016, the anticipated survival 
benefit from surgical treatment resulting from earlier detection of metastases has not been achieved.”48 
 Critics have theorized that the reason (intensive) surveillance does not provide a 
survival benefit is because metastasectomy is unlikely to improve survival, at least in 
most cases.49 They dismiss the many surgical case-series reporting favorable outcomes 
among patients receiving hepatic and pulmonary resections as the result of extreme 
patient selection and suggest that many of these patients would have been long-term 
survivors in the absence of resection due to a slow-moving disease natural history.50-52 
 Another consistent and less extreme explanation would be that hepatic, pulmonary, 
and local resection do benefit a limited number of patients but that these patients have 
slow moving disease that, in general, would have been similarly salvageable if detected 
later by less intensive surveillance. Moreover, the extra-intensive surveillance regimens 
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investigated in these necessarily non-blinded trials had the result of lowering the bar for 
what is considered salvageable disease. Surgeons detect disease earlier than normal and 
so, as believers in their own craft, more aggressively attempt salvage surgery. Thus 
salvage rates go up. However, at the margin, these additional salvages are not helpful 
because these patients have a disease with a more aggressive biology or that is already 
more widely disseminated. Thus, at the margins, there is no survival benefit and 
potentially a limited harm due to surgical-related morbidity and mortality. 
 The FACS trial investigators hypothesized that much of the overall mortality benefit 
picked up in earlier meta-analyses could be due to early detection of patients with 
residual macro-metastases or local disease after surgery for the primary CRC tumor.46 
That is, they speculated that intensive surveillance was helpful when it picked up missed 
synchronous metastatic disease (stage IV) but less so when it picked up newly-appearing 
metachronous metastatic disease. This is relevant because the accuracy of diagnostic 
imaging and staging has improved over the last 30 years and both the GILDA and FACS 
trials enrolled patients after any adjuvant treatment (up to 6 months after primary 
surgery) and used extensive diagnostic imaging to rule out missed systemic disease. 
However, it’s difficult to reconcile this hypothesis with the observations that 
metachronous metastases fare better than synchronous metastases53 and that, even among 
metachronous cancers, for the first 3 years, time-to-recurrence is inversely correlated 
with survival after recurrence.54-56 
 Whatever the explanation, critics have pointed to the negative results of the GILDA 
and FACS trials and reasonably argued that, if we do not see any benefit in these trials, 
we are unlikely to find a benefit in future research. This is because these trials (a) are by 
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far the largest, (b) evaluate the most intensive imaging regimens, and (c) are the most 
recent trials and thus best reflect the modern surgical capabilities for salvage and the 
modern disease process. This last component is important because the disease has 
changed dramatically over the last 40 years with the adoption of modern (neo)adjuvant 
therapies and improved primary surgery.  
 It is likely that future iterations of professional guidelines will incorporate these 
results and conclusions into their recommendations, and this in principle could lead to a 
large-scale change in oncological practice in North America and Europe. Because of the 
large decline in recurrence rates, the disease-specific excess mortality hazard faced by 
non-metastatic CRC patients has declined notably over the last 35 years for all stages and 
for both colon and particularly rectal cancers.57 This is likely due to better surgery, e.g., 
Total Mesorectal Excision9, (neo)adjuvant therapy18, and stage-migration58. One 
important consequence of this heartening development has been an increasing number of 
survivors of stage I-III colorectal cancer. A recent estimate puts the current number of 
CRC survivors in the US at almost 1.5 million.59 Thus any change in surveillance 
recommendations could have large-scale implications on practice patterns and resource 
utilization. It is therefore paramount that available evidence, as problematic as it is, is 
interpreted appropriately. The stakes are particularly high for younger CRC patients 
(<55) - a group on the rise (particularly for rectal cancer)60 – who, in the absence of CRC, 
could expect to live multiple additional decades. 
REEXAMINING THE LOGIC OF FOLLOW-UP 
 In this dissertation, I argue that the current discussion of available evidence 
surrounding intensive surveillance suffers from a failure to carefully work through the 
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implications of the logic underpinning CRC follow-up. As mentioned above, intensive 
follow-up has been theorized to lead to earlier detection of recurrent disease that is more 
likely to be isolated and salvageable. However, it is unclear that this theory is consistent 
with the sizable all-cause mortality benefit that was reported in older meta-analyses and 
that recent trials were powered to detect. A simple back of the envelope calculation 
highlights the problem. Assuming a 5-year cumulative incidence of recurrence of roughly 
30% among stage III colon cancer patients (treated with FOLFOX adjuvant 
chemotherapy)19, and assuming that 5-10% of recurrences (almost all local-regional) will 
be salvageable in the absence of follow-up (when clinically-indicated)5 11 61, then, if an 
intensive follow-up regimen was able to achieve macroscopically and microscopically 
clear margins (R0 resection) in 50% of patients with recurrence, at most 12-14% of a 
cohort could benefit from intensive follow-up.1 If we consider a more realistic situation - 
intensive versus less intensive follow-up, a mix of stage I-III patients (20% recurrence), 
and a more realistic R0 salvage rate of around 40% in the intensive arm (vs. 15% in 
minimal arm) – we might expect only about 5% of patients to benefit.2 
 This simple thought experiment suggests an alternative explanation for the negative 
results of the two recent trials. Perhaps the absence of any significant mortality benefit in 
the intensive follow-up arms of recent trials is not due to the failure of salvage surgery 
(resulting from earlier, asymptomatic detection of recurrence) to confer any benefit to 
such patients. Rather, perhaps it is due to the small proportion of patients who can 
possibly benefit from such treatment.  
                                                          
1 0.3 * (0.5 – 0.1) = 0.12  &  0.3 * (0.5 – 0.05) = 0.14 
2 0.2 * (0.4 – 0.15) = 0.05 
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 In Chapter 3 of this dissertation, I argue for this latter explanation. I first argue there 
is reason to believe in the efficacy of salvage surgery for isolated recurrent disease, even 
when performed at the aggressive levels seen in the FACS and GILDA trials. Moreover, I 
use a modeling analysis to show that the failure of these trials to detect any significant 
mortality reduction is not surprising and should not be interpreted as incompatible with 
the hypothesized efficacy of follow-up-induced salvage surgery. In particular, I estimate 
the true incremental mortality benefit we could expect in moving from the FACS 
minimal follow-up arm to the more intensive arms. I perform a similar analysis in the 
GILDA trial. I also highlight and evaluate a potential source of bias in the FACS trial that 
would likely have favored the minimal follow-up arm: a recurrence-imbalance. In light of 
this bias and the low recurrence rates, I argue that the trials were severely underpowered 
to detect the small hypothesized true benefit. 
 The analyses of Chapters 3 and 4 rely on a microsimulation model of CRC 
recurrence, detection, treatment, and mortality. The model has been constructed to 
embody the hypothesis that more aggressive extra-colonic follow-up of patients can 
increase the proportion of recurrences that are amenable to curative resection and thereby 
improve the survival of such patients. However, it is also empirically grounded in the 
sense that (a) it can replicate many important features of the natural history process of 
recurrence, (b) the increase in salvage rates attributable to intensive follow-up in the 
model are consistent with meta-analytic results, and (c) the survival experience of 
patients treated with salvage surgery is consistent with that observed in unselected cohort 
studies and, importantly, the FACS trial. 
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 If I am right that, while intensive-surveillance-induced salvage surgery can benefit 
select patients, in current practice the ex-ante expected benefit of (intensive) surveillance 
for any given patient will be too small to detect in any realistically-powered RCT, the 
practice is likely to be dismissed as not clinically relevant or at least unlikely to be cost-
effective. However, the same is true in many cases of cancer screening.3 For example, a 
trial with more than 68,000 participants failed to find an overall-mortality reduction from 
fecal occult blood testing62 yet it is considered a cheap and effective screening method in 
some populations.63 When a treatment benefit is (very) small, whether or not to use it and 
at what dosage are questions that require a decision-analysis that considers both the 
incremental benefits and incremental costs of varying intensities of the intervention and 
incorporates our uncertainty about these benefits and costs into the analyses. A priori, it 
does seem very unlikely that the level of intensive imaging tested in the CT arms of the 
FACS trial (7 CT scans in 5 years) would be cost-effective given the likely diminishing 
returns associated with each additional CT scan. However, that does not preclude the 
possibility that the expected benefit procured by one, two, or even three CT scans (over 
and above routine CEA testing) might be considered worth the cost. Either way, a careful 
decision analysis is needed. 
 In Chapter 4 of this dissertation, I use a modeling analysis to conduct a cost-
effectiveness analysis of several follow-up strategies. In particular, I consider (i) no 
follow-up, (ii), a single CT scan at 12-18 months, (iii) guideline-level CEA testing and a 
single CT scan at 12-18 months, and guideline-level CEA testing and annual CT scans 
                                                          
3 This point was suggested to me by Professor Karen Kuntz. 
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for (iv) 2, (v) 3, and (vi) 5 years. I conduct these analyses separately for stage II and III 
patients and colon and rectal patients. Analyses use a lifetime time horizon and are 
undertaken from the perspective of the US healthcare system. 
 The remainder of the Dissertation is organized as follows. In the next chapter I 
describe the model that was developed for this dissertation. This includes a discussion of 
the model structure, data sources, and calibration efforts and results. Chapters 3 and 4 
assume the reader has read the above chapter as well as Chapter 2. 
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CHAPTER 2: THE MICROSIMULATION MODEL 
OVERVIEW OF THE MODEL 
 I developed a discrete-event microsimulation model of CRC recurrence, recurrence-
detection, treatment, and mortality. The model was constructed and, when necessary, 
calibrated in the open source R software.64 The model simulates the life-course of 
colorectal cancer patients who have successfully underwent and survived curative 
resection of the primary tumor. The main processes of the model involve (i) the natural 
history of extracolonic recurrence, (ii) surveillance testing and detection of recurrence, 
(iii) treatment of recurrence, and (iv) death from cancer or other causes based upon the 
treatment received. The natural history process of recurrence is modeled separately for 
rectal and colon cancer patients, for each stage (I, II, and III), and, in the case of colon 
cancer, by adjuvant treatment received.4 Unless otherwise stated, the other processes are 
identical for rectal and colon cancers, for each stage, and regardless of any adjuvant 
therapy received. 
 The model focuses on extramural disease and does not currently include intraluminal, 
e.g., anastomotic, recurrence or surveillance (endoscopy). With current surgical practice, 
isolated intraluminal recurrences are very rare. For example, in the FACS trial, less than 
2% of recurrences were detected by endoscopy. Endoscopic surveillance is generally 
                                                          
4 As will be described below, more and better targets were available for colon cancer recurrence. For stage 
II-III rectal cancer, the targets represent the risk of recurrence for patients undergoing neoadjuvant and/or 
adjuvant treatment. For stage II-III colon cancer, targets were available for patients treated with surgery 
alone as well as for patients treated with adjuvant therapy.  
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justified for the purposes of detecting and preventing second primary lesions and thus 
represents an extension of the logic of CRC screening.30  
 The model also does not distinguish between local-regional (extra-colonic) disease 
and metastatic disease. In the case of rectal cancer, this choice might be questioned. 
However, for the purposes of this dissertation, the two types of disease are sufficiently 
similar to be represented as one process. In particular, both forms of disease are fatal in 
the absence of surgical cure, both forms of disease are routinely detected by CEA 
measurement and imaging studies, a roughly similar proportion of cases are amenable to 
curative resection, and the survival experience of patients after curative resection is 
comparable.11 45 61 65-67 However, due to the higher incidence of local-regional disease in 
rectal cancer patients, the hazard of any recurrence is higher in stage I and II rectal cancer 
patients than in comparable colon cancer patients. The model incorporates this difference 
by modeling colon and rectal cancer patients separately. 
 A microsimulation approach was selected over a Markov cohort model because of the 
importance of incorporating heterogeneity in several component disease processes and 
correlation among those processes. For example, from the perspective of evaluating 
surveillance testing, an important phenomenon of the natural history process of 
recurrence is that patients who develop clinical disease earlier face a higher mortality 
hazard than do patients who develop recurrence later.56 A discrete-event framework was 
chosen over the classic state-transition approach because of its speed and flexibility.68 A 
discrete-event model is organized around events rather than disease-states and transitions 
between those states.69 
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 In what follows, I describe each of the main model components mentioned above: (i) 
recurrence natural history, (ii) surveillance testing and detection of disease, (iii) treatment 
of recurrence, and (iv) death from cancer depending upon the treatment received. In each 
section, I describe key phenomenon the model is meant to capture, how this is 
implemented in the model, and parameters governing the process. When possible, 
parameters were taken from the literature. However, in some cases, I used calibration, 
i.e., ‘reverse estimation’ to derive parameter values that lead to model output that best fit 
data targets in some sense. The logic here is that some parameters are not directly 
estimable for ethical or logistical reasons. For example, parameters governing the 
distribution of sojourn times for a cancer (the period during which the disease is 
potentially detectable but pre-clinical) cannot generally be directly estimated because 
once a disease is detected it will inevitably be treated. In this case, a calibration approach 
uses indirect evidence to constrain such parameters, and thus the model, to at least be 
consistent with (able to recreate) observable data. 
THE NATURAL HISTORY OF RECURRENCE 
 Even in the case of stage 3, most patients who receive modern (neo)adjuvant therapy 
regimens will not develop a recurrence. Analogous to the principles of cure models that 
have been used recently for survival analysis70, the microsimulation model initially 
divides patients into ‘cured’ and ‘not cured’. The latter patients are disease free for the 
entirety of the model simulation and will die of other causes. The non-cured patients will 
develop clinical recurrent disease in the absence of surveillance within the next 15 years. 
Although most recurrences occur within 5 years, late-occurring recurrence (after 5 years 
and up to as late as 15 years) has been documented as more common than previously 
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thought.2 3 18 71 The chances of suffering a recurrence over the next 15 years vary by 
stage, location (rectal vs. colon), adjuvant treatment, and (as explained below) period (old 
vs. newer). These parameters are presented in Table 1 along with recurrence rates at 5-
years for comparison. Both the 5-year and 15-year recurrence rates were taken from the 
recurrence-targets discussed below. In the case of survival curves, these values were 
readily available. In the case of time-varying hazard functions, I used numerical 
integration to estimate them. 
 Table 1: Cumulative Incidence of Recurrence at 5 and 15 Years by Disease and 
Adjuvant Status 
Disease 
Adjuvant 
Therapy 
Proportion 
Recurring within 
5 Years 
Proportion 
Recurring within 
15 Years 
Sources 
Stage III Colon No Adjuvant 0.555 0.597 3 18 
Stage III Colon 5-FU + LV 0.366 0.412 3 18 19 
Stage III Colon FOLFOX 0.298 0.349 3 18 19 
Stage II Colon 
(New) 
No Adjuvant 0.180 0.210 3 18 19 58 
Stage II Colon 
(Old) 
No Adjuvant 0.225 0.267 3 18 
Stage II Colon 
(New) 
5-FU + LV 0.144 0.176 3 18 19 
Stage II Colon 
(Old) 
5-FU + LV 0.197 0.228 3 18 58 
Stage II Colon FOLFOX 0.097 0.130 3 18 19 
Stage I Colon 
(New) 
- 0.056 0.085 2 3 18 20 
Stage I Colon 
(Old) 
- 0.077 0.114 2 3 18 20 
Stage III Rectal 
Neoadjuvant 
Chemoradiation 
Therapy and 
Adjuvant 
Chemotherapy 
Therapy with 
FOLFOX 
0.289 0.320 9 72 
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Stage II Rectal 
Adjuvant 5-FU 
+ LV  & 
Possibly 
Neoadjuvant 
Radiation 
Therapy 
0.204 0.232 9 73 
Stage I Rectal --- 0.083 0.115 20 74 
 
BACKGROUND THEORY 
 Most patients who develop recurrence after primary surgery present with 
metachronous metastatic disease. By ‘metachronous’ I mean to refer to late-occurring 
metastatic disease as opposed to synchronous (same-time occuring) metastatic disease, 
i.e., stage IV CRC. The current theory is that these patients have dormant micro-
metastases implanted in some part of the body (in an organ, tissue, cavity, or lymph 
nodes) or at least circulating in the blood prior to the detection and surgical resection of 
their primary CRC. While these cancer cells likely have already infiltrated the organ, they 
lie dormant for some latency period because the micro-environmental and genetic 
conditions of the new location are not conducive for lesion growth. In the cases where the 
micro-metastases have no or only a very short latency period, the disease develops 
quickly and presents as synchronous metastatic disease. Initially, these micro-metastases 
(possibly just a few malignant cells) are undetectable by surveillance tests (e.g., CT 
imaging) and thus are referred to as ‘occult’. However, at some point the micro-
environmental and genetic conditions will align for the disease to begin to colonize the 
organ and transition into a pre-clinical and then clinical macro-metastasis.75 
 A small percentage of recurrences (particularly for stage III patients) will actually 
represent missed synchronous metastases, i.e., misdiagnosed stage IV disease. That is, 
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these patients will have a macro-metastasis in say the liver which was missed by 
diagnostic imaging (imperfect sensitivity) done prior to surgery (or after emergency 
surgery). These patients will generally present with clinical disease within 6 months.46 
The remaining patients who suffer a recurrence (other than metachronous or missed 
synchronous metastatic disease) will present with local-regional disease. This is located 
in the pelvis for rectal cancer and the abdomen for colon cancer, and it is thought to be a 
result of surgical failure or failure to detect regional lymph node metastases and treat 
accordingly.5 67 
 The model explicitly focuses on the development of metachronous metastases. There 
are three key processes after the initial implantation of the micro-metastasis in a distant 
organ: (a) initiation of growth, e.g., the cell division rate overtakes the cell death rate, (b) 
the continuous growth process, and (c) the onset of clinical disease. For the purposes of a 
model evaluating surveillance testing, it is useful to represent the above set of processes 
as two periods (Figure 1): (1) the latency period - the time during which the (possibly 
dormant) micro-metastasis is undetectable by surveillance modalities - and (2) the 
sojourn period – the time during which the macro-metastasis is growing, is detectable by 
surveillance tests, yet is pre-clinical, i.e., asymptomatic. The first period is demarcated by 
the beginning of the simulation model and the simulated time at which the metastasis 
becomes ‘detectable’. The second period is demarcated by the simulated time between 
which the disease becomes detectable and the disease becomes ‘clinical’. Here we 
assume that the patient suffers symptoms and seeks care and/or would show signs of 
recurrence upon clinical examination. The process of lesion growth and progression is 
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relevant for detection by surveillance and the prospects of salvage surgery, respectively, 
and so is covered in a latter section. 
 
MODEL STRUCTURE & PARAMETERS 
 I note that, although the model is meant to represent metachronous metastases, the 
above representation should be sufficiently abstract to adequately capture the 
development of local-regional recurrence. Moreover, the model implicitly accommodates 
missed synchronous metastatic disease by allowing significant heterogeneity in the time-
to-detectable and time-to-clinical disease processes and correlation among those 
processes. Thus, some individuals in the model will develop detectable disease 
immediately (within less than a month), and these individuals will also tend to have a 
shorter sojourn time. More specifically, the model includes three heterogeneity terms 
(i.e., random effects). One for the time-to-detectable-disease process (duration of latency 
period) and one for the time-to-clinical-disease process (duration of sojourn period). A 
third heterogeneity term is also included for time-to-death processes and is described 
below. The heterogeneity terms are assumed to modify the respective baseline hazard 
rates multiplicatively (additively on the log scale). They are simulated on the log-scale 
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from a mean-zero multivariate normal distribution with a single shared correlation 
parameter. 
 The key processes to simulate in the natural history model of recurrence are thus the 
time to detectable disease and the time to clinical disease (conditional on the disease 
being detectable) among those who will eventually suffer a recurrence. I chose to directly 
model the hazard rates for each process because the best available targets (indirect 
evidence) were generally hazard rates of recurrent disease. These targets are discussed 
below. One disadvantage of using a discrete-event simulation framework is that a 
modeler is generally forced to rely on parametric models for ease of simulation. 
However, in the absence of direct evidence on the time-to-detectable and time-to-clinical 
disease processes (among those suffering a recurrence), it is difficult to anticipate what 
parametric survival models might be appropriate. 
 The microsimulation model avoids the problem of selecting a parametric model by 
relying on nonparametric methods to model the hazard rates for the development of 
detectable and clinical disease among those who will ultimately develop a recurrence. In 
particular, I used cubic B-splines as they have been used successfully in the survival 
literature to model hazard functions.76 Splines are piecewise polynomials of degree k that 
are continuous at intersecting points (‘knots’) in the sense that derivatives are continuous 
up to degree k-1. Cubic B-splines are convenient and efficient basis functions with which 
any spline function of degree 3 (for a given set of knots) can be uniquely represented.77 
Therefore, a wide range of functions can be efficiency approximated by a linear 
combination of cubic B-splines. For a given set of points in the function domain (a grid 
of times in the domain of the hazard function in our case), set of knots (breakpoints), and 
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function degree (cubic in our case), a basis matrix can be generated using R’s spline 
package. The key parameters governing the hazard rate models are thus a set of linear 
coefficients, and so parameterizing the model requires calibrating these. 
 In order for a non-parametric model of the hazard function to be useful in a discrete-
event context, it must be possible to simulate from the implied distribution. A convenient 
feature of using cubic B-splines is that an analytic solution exists (and is available in R) 
for definite integrals of the hazard rate. The definite integrals of the hazard function 
represent the cumulative hazard and can easily be converted to a survival function. Thus 
the key modeling task is to simulate from the survival function. In early modeling efforts, 
I relied on rejection sampling78 to sample from the implied density function (equal to the 
product of the hazard and survival functions). However, because of the unwieldy form of 
calibrated density functions, this method was very inefficient. I instead opted for a 
discretization approach in which event times were simulated to fall within roughly 3-day 
intervals (one tenth of a month). A comparison of methods suggested this resulted in only 
trivial bias. 
CALIBRATION TARGETS AND METHODS 
 The main obstacle to parameterizing the time-to-detectable- and clinical-disease 
processes (among those who would eventually suffer a recurrence) was the lack of any 
direct evidence on the distributions characterizing these two processes. Available targets 
provide an estimate of the hazard rate at which patients present with recurrent disease, 
i.e., the time-to-diagnosed-recurrence process. However, they do not provide information 
about when a patient’s disease became detectable and thus the duration of each 
component process. If we condition simply on the time-to-diagnosed-recurrence data 
24 
 
targets, in addition to being inestimable, the parameters governing these two component 
processes are obviously non-identifiable.79 In a calibration setting, this means that 
multiple different parameter sets will be able to reproduce target data equally well and 
thus it is unclear which set to prefer. The constraint of having to be able to reproduce 
additional data targets – meta-analytic rates of asymptomatic detection and salvage 
surgery from the surveillance trials – can be expected to constrain the feasible parameter 
space, but the parameters are still likely to remain nonidentifiable. 
 When confronted with nonidentifiable parameters in need of calibration, several 
options are available. One is to place constraints on the parameter space, ideally guided 
by theory or content knowledge so that they become identified. Another option is to use 
informative priors and utilize Bayesian calibration methods.79 However, in our case, these 
would likely be arbitrary and poorly informed. Another option is to calibrate one 
acceptable parameter set and simply use that. A weakness of this approach is that 
different sets of equally well-fitting calibrated parameters might lead to different 
modeling conclusions. A superior approach follows the principles of Bayesian model 
averaging80 and attempts to average over this uncertainty. This is the approach I selected 
to calibrate the natural-history model of recurrence. In what follows, I first describe the 
data targets and then provide details of the calibration process. 
 The linear coefficients governing the time-to-detectable- and time-to-clinical-disease 
hazards among those who will ultimately suffer a recurrence were calibrated to two data 
targets: (i) continuous-time hazard functions or survival curves of recurrence taken from 
RCTs of (neo)adjuvant treatment and (ii) meta-analytic rates and odds-ratios (comparing 
treatment arms) of asymptomatic detection of recurrence and salvage surgery from the 
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intensive surveillance trials. In some cases, the time-to-diagnosed-recurrence targets 
represented the incidence of disease in the absence of routine follow-up, and in other 
cases the trial protocols called for routine surveillance. In the latter case, calibration was 
performed with the same follow-up structure in the model as was described in the target 
source. The surveillance schedules used for the purposes of calibration are described in 
the captions under the figures depicting the time-to-diagnosed-recurrence targets 
(Appendix B). These are described in the results section below. Forest plots of the meta-
analytic targets are given in Figures B.1-B.4. They were based upon my own meta-
analytic analyses of trials that evaluated intensive extracolonic surveillance strategies. 
The purpose of these meta-analytic targets is to constrain the distributions of the two 
component processes (time-to-detectable- and clinical-disease) such that realistic levels 
of surveillance-based detection and salvage of recurrence can occur. I chose not to use 
the meta-analytic all-cause mortality hazard-ratio as a target because, conditional on the 
rate of surveillance-based detection and salvage targets, cancer-related mortality is 
largely determined by processes governed by other parameters and thus is only 
tangentially related to the underlying development of recurrence. 
 For colon cancer, more detailed and precise time-to-recurrence targets were available. 
Stage II and III colon targets were derived from publications by the Adjuvant Colon 
Cancer End Points (ACCENT) Collaborative Group.81 The ACCENT database was first 
conceived in the 1990’s by researchers at Mayo Clinic and has grown to contain 
individual-patient level data for over 40,000 patients from 27 RCTs of adjuvant 
chemotherapy for colon cancer conducted between 1977 and 2009. Using this database, 
researchers have published multiple analyses of aspects of adjuvant chemotherapy 
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treatment pooling individuals from across all relevant trials. I took time-to-diagnosed-
recurrence targets from several such publications. In particular, I used the open-source 
software PlotDigitizer to digitize continuous-time hazard functions or, if not available, 
survival curves for recurrence and then implemented them in R using spline interpolation. 
In most cases multiple sources were used to construct a target hazard function or survival 
curve that extended to 15 years. 
 For stage III colon cancer, continuous-time hazard-function targets were available for 
patients treated with surgery only, Fluorouracil and Leucovorin (5-FU/LV), and 
FOLFOX (5-FU/LV + Oxaliplatin). The target hazard function for stage III colon cancer 
patients treated with surgery alone came from a pooled meta-analysis of Fluorouracil-
based regimens in an adjuvant setting.3 In particular, years 1-8 of the target were backed 
out from the combination of a disease-free-survival (DFS) hazard function for stage III 
patients (N > 1,600), a recurrence hazard function combining both stage II and stage III 
patients (N = 2,500), and information about stage-specific background mortality and 
recurrences. These patients were enrolled in trials in the 1970’s and 1980’s and were 
assumed to undergo no routine surveillance testing. The full constructed target is depicted 
in Figure B.5. Years 9-15 were backed out from a pooled hazard function combining 
stage II and III patients3 and information concerning the relative risk of late-occurring 
recurrence.18 This latter component was not specific to any adjuvant treatment as there is 
no evidence of any benefit from adjuvant therapy with regards to late-occurring 
recurrence.3 18 19 It was therefore used (often in a slightly adjusted form) for all other 
disease targets. For stage III patients treated with 5-FU/LV and FOLFOX, years 1-5 of 
the target hazard functions were taken from a patient-level meta-analysis19 of five RCTs 
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of FOLFOX with N > 2,400 and N > 7,500 stage III patients, respectively. Years 5-8 
were taken from the same source as was used for surgery alone. The corresponding 
targets are depicted in Figures B.6 and B.7, respectively. 
For stage II colon cancer, hazard functions (or survival curves) were available for 
patients treated with surgery alone and again for patients treated with 5-FU/LV and 
FOLFOX. Moreover, there was evidence of a reduction in the hazard of recurrence in 
newer trials that was unrelated to treatment (both among patients treated with surgery 
alone and those treated with 5-FU/LV).58 This was likely the result of stage migration due 
to improved diagnosis of regional lymph node metastases, and so I calibrated both a new 
and old set of hazard functions. The old target for stage II colon cancer treated with 
surgery alone came from the same sources (N > 800) as described for stage III colon 
cancer with no adjuvant and is depicted in Figure B.8. The first 2.5 years of the 
corresponding new target (Figure B.9) came from the same source3 but was adjusted by a 
HR (representing the effect of stage-migration) from a second source58 using the 
ACCENT database. The remainder of the target replicated the equivalent portion of the 
new target for stage II colon cancer treated with 5-FU/LV (described below) as there is 
no evidence of a chemotherapeutic-induced recurrence reduction after 2-3 years for stage 
II patients.3 Years 1-6 of the (new) target hazard functions for stage II patients treated 
with 5-FU/LV (Figure B.11) and FOLFOX (Figure B.12) were taken from the 
previously-mentioned patient-level meta-analysis3 of 5 RCTs (ACCENT database) 
investigating FOLFOX in an adjuvant setting. The targets represented the disease 
experience of N = 800 and N = 1,450 stage II patients, respectively. Years 6-8 were taken 
from the previously described meta-analysis of 5-FU-based regimens.3 Finally, Figure 
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B.10 depicts the survival curve target characterizing the (old) recurrence experience of 
stage II patients treated with 5-FU/LV.58 
 It was necessary to calibrate different sets of hazard functions (time-to-detectable and 
clinical-disease) for different adjuvant therapies (even within the same stage) because the 
benefit of adjuvant therapy in terms of avoided recurrences appears to fall almost 
exclusively within the first 2 years after primary surgery.3 A simple adjustment to the 
model’s cure rate or an adjustment of the hazard function with a constant hazard ratio 
(HR) would therefore misrepresent the recurrence hazard under adjuvant therapies and 
potentially limit the validity of subsequent modeling analyses comparing alternative 
surveillance schedules. 
 For stage I colon and rectal cancer, a time-to-recurrence survival function was taken 
from a large hospital database.20 For colon cancer, there was again evidence of a 
reduction in the risk of recurrence over time, and so I calibrated a new and old set of 
hazard functions.2 The targets are shown in Figures B.13-B.15. For locally-advanced 
rectal cancer (stage II9 73 and III72), targets represented the disease experience of patients 
treated with Total Mesorectal Excision surgery. The target for stage II rectal cancer 
(Figure B.16) was derived from a RCT evaluating 5-FU/LV in mostly stage II rectal 
patients (N > 1,450). Patients were treated with adjuvant 5-FU/LV and possibly 
neoadjuvant radiation therapy. The target for stage III rectal cancer (Figure B.17) came 
from a RCT evaluating FOLFOX and represented the disease experience of patients (N > 
450) treated with both neoadjuvant chemoradiation therapy and adjuvant chemotherapy 
using FOLFOX. Separate targets for different combinations of neoadjuvant and adjuvant 
therapy were unfortunately not available. 
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The basic outline of my approach to calibration for each disease location (colon vs. 
rectal), stage, and adjuvant therapy (when available) combination was as follows. I firstly 
identified a set of pairs of vectors of linear coefficients that together could reproduce the 
appropriate time-to-recurrent-disease target. The goal was to select a set of pairs of time-
to-detectable- and time-to-clinical-disease hazard functions (among those getting a 
recurrence) that covered the feasible range of latency times and sojourn times while still 
matching the target. The next step was to assign a discrete probability distribution to these 
pairs of parameters. To do this, each such pair was weighted by the product of a measure 
of its degree of fit with the time-to-recurrent-disease target and a measure of its 
compatibility with meta-analytic targets. Finally, the set of weights were normalized to 
sum to 1. 
 In what follows I provide a more detailed sketch of the calibration process. I evaluated 
pairs of vectors of linear-coefficients (one for each disease process) by quantifying the 
discrepancy between the model-output they produced and the respective targets. In order 
to identify a wide range of pairs of plausible time-to-detectable- and time-to-clinical-
disease hazard functions, I firstly calibrated a baseline pair assuming they were equal. That 
is, I applied an equality constraint to coefficients for the detectable and clinical disease 
processes so that the hazard functions of both processes would be identical. I then used a 
variant of simulated annealing available in R’s optim routine to find the set of coefficients 
and the two relevant heterogeneity variance parameters5 that minimized the mean absolute 
                                                          
5 Early exploratory analyses suggested that a very strong positive correlation among heterogeneity terms 
would need to be assumed to match targets (described below) concerning the relationship between time to 
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difference between the model-produced time-to-diagnosed-recurrence hazard function (or 
survival function) and the data target, evaluated at a grid of time-points. Simulated 
annealing is a stochastic optimization approach that can provide good approximations to a 
global optimum.82 Exploratory analyses suggested a Monte Carlo size of 300,000 per 
model run was sufficient to achieve stable results. In the case of a hazard-function target, 
model-produced times of diagnosed recurrence were smoothed using nonparametric 
methods (R’s bshazard package) just as they were in the target sources. This smoothed 
hazard function was then compared to the target at a fine grid of time points. In the case of 
a target (recurrence-free) survival function, I used model-output to construct a Kaplan-
Meier (KM) survival curve which was then compared with the target curve over a grid of 
points. 
 This first step provided one good set of parameters: both heterogeneity variances and 
linear coefficients for the baseline hazard functions. However, as stated above, the goal of 
the calibration exercise was to cover a sufficiently wide range of good parameter sets so 
that the non-identifiability problem could essentially be averaged over. For convenience, I 
used the heterogeneity variances calibrated in the first step for all additional parameter sets. 
This was deemed inconsequential because, over a relatively wide range of values, variation 
in these parameters had very little impact on model fit with respect to time-to-recurrent-
disease targets. Moreover, their value was later adjusted to fit a different target (discussed 
below). Thus for the second step, I semi-formally adjusted the calibrated linear coefficients 
in opposite directions to construct parameter sets which lead to longer latency periods and 
                                                          
recurrence and time to death.  I thus calibrated the heterogeneity variances for detectable/clinical disease 
using a working correlation of 0.8 
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shorter sojourn times as well as parameter sets which lead to longer sojourn times and 
shorter latency periods. In general I did this by multiplying the baseline pair of coefficients 
by incrementally larger (smaller) factors (increments of +/- 5%) until there was serious 
deterioration in fit as judged subjectively.6 Occasionally some manual tuning and/or formal 
calibration of one or more coefficients was needed to preserve reasonable fit. In particular, 
when sojourn times were increased significantly on average (meaning the disease spent 
longer developing into clinical disease), relatively much larger decreases in latency times 
on average were required to preserve fit (meaning the speed with which occult disease grew 
into potentially detectable macro-metastases had to be greatly accelerated). 
 The final step was to assign these (generally 15-25) parameter sets a discrete 
probability mass function. For this purpose, I used a product of (a) the goodness-of-fit of 
the model-produced hazard function (or survival curve) with the data target (mean 
absolute difference across a grid of points) and (b) a multivariate likelihood value based 
upon fit to meta-analytic targets. For both (a) and (b), values were normalized to sum to 
1. Finally, the resulting product of the two normalized values was itself normalized to 
sum to 1. At this point, any set of coefficients with a probability mass of less than 0.01 
was excluded and weights were renormalized. 
For component (b), I used meta-analytic predictive distributions to evaluate the 
model-produced (1) proportion of recurrences that could be (R0) salvaged in an 
intensive-surveillance arm representative of the admittedly heterogeneous set of 
                                                          
6 While the reliance on subjective judgment might be concerning to some, these judgments were eventually 
supplanted by a formal rule that excluded parameter sets with an assigned probability of less than 0.01. 
This is discussed below. 
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interventions investigated in the RCTs and (2) odds ratio comparing the intensive arm to 
a representative minimal arm. The respective surveillance schedules used are depicted in 
Table B.1. Similar likelihood values (based on the meta-analytic predictive distribution) 
were assigned to the model-produced (3) proportion of recurrences detected 
asymptomatically, i.e., by extracolonic-focused surveillance (CEA assays and CT tests), 
in the intensive arm and (4) the analogous odds ratio.7 A meta-analytic predictive 
distribution combines our uncertainty of the location of the population-average effect 
with the heterogeneity estimated to exist in the population (and, by using a T-distribution, 
our uncertainty surrounding our estimate of the heterogeneity).83 It thus represents the 
range of possible true parameter values we would expect to see in the real world. Table 2 
gives the relevant meta-analytic population-average point estimates, 95% confidence 
intervals for the population-average effect, and 95% prediction intervals using a random-
effects model. 
Table 2: Meta-Analytic Targets for Calibration of Time-to-Detectable- and -Clinical 
Disease 
TARGET 
Population-
Average 
Point 
Estimate 
95% 
Confidence 
Interval 
95% 
Prediction 
Interval 
Number of 
Studies 
Proportion of Recurrences 
Amenable to R0 Salvage 
in the Intensive Arm 
0.35 (0.23, 0.49) (0.10, 0.71) 8 
Odds Ratio for R0 Salvage 2.1 (1.3, 3.3) (0.8, 5.7) 8 
Proportion of Recurrences 
Detected while 
0.71 (0.62, 0.80) (0.55, 0.84) 6 
                                                          
7 Strictly speaking, I first calibrated the linear coefficients to the time-to-recurrent-disease targets and the 
rate (odds ratio) of asymptomatic disease detection. I then calibrated the required parameters governing the 
resectabe/not-resectable disease process (described below) using these initial probability distributions for 
the linear coefficients. I then re-weighted pairs of linear coefficients based upon their fit to all 3 targets.  
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Asymptomatic in Intensive 
Arm 
Odds Ratio for 
Asymptomatic Detection 
3.5 (1.3, 9.2) (0.32, 37.8) 6 
The studies used are shown in the forest plots of Figures B.1-B.4 of Appendix B. 
CALIBRATION RESULTS 
 The results of the calibration of the natural history model of recurrence are portrayed 
in two formats in Appendix B: a set of figures (Figures B.5-B.17) and Table B.2. For 
each location (rectal vs colon), stage (I-III), adjuvant therapy (FOLFOX, 5-FU + LV, or 
none), and period (old vs new) combination that was available, a figure depicts the time-
to-recurrent-disease target (black) and the corresponding model-produced output (blue) 
using the parameter set with the highest probability mass (thus referred to as ‘Best 
Model’). Model-output based on the other included parameter sets is depicted in dashed 
brown lines. I remind the reader that each parameter set was evaluated by both the fit 
between the corresponding model-output (smoothed hazard function or KM survival 
curve) and the target and between model-produced surveillance output and the 4 meta-
analytic targets of Table 2. I also note again that in each case the model-produced output 
is simulated using the surveillance schedule reported in the target source (if there was 
one). In some cases, the target resulted from a pooled analysis using patient level data, 
and thus this involved a mix of different follow-up regimens. In other cases, the regimen 
was only vaguely described in the protocol(s). 
 It should be noted that the y-axis scale varies across some figures. This might give the 
impression that, in some cases, the model-produced output does not fit the targets well. 
However, this is mostly an illusion of scale. In general, the model fit the targets well. For 
example, for stage II and III colon cancer patients treated with FOLFOX adjuvant therapy 
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(the fit of which might appear suspect), the model- and target-implied survival curves that 
correspond to the depicted hazard functions are within 1 and 2 percentage points, 
respectively, over the entire domain of the function when using the highest-probability 
parameter set. So for example, if the target-implied survival curve was 0.75 at some time 
point, the model-implied survival curve (using the best parameter set) would be 
guaranteed to fall within 0.74-0.76 or 0.73-0.77 for stage II and III patients, respectively. 
 Still, in general there was better fit between model-produced output and targets when 
the targets represented the disease experience of patients without intensive follow-up. 
This is likely due to three factors: uncertainty (due to non-reporting) regarding the 
follow-up adherence levels of included patients, a more widely dispersed scheduling of 
follow-up tests among actual trial patients than was assumed in the model, and 
differences in the degree of smoothing in hazard function estimation. Unfortunately, none 
of the time-to-recurrent-disease targets were accompanied by confidence bands in the 
literature, so it is difficult to judge to what degree there is any discrepancy between the 
curves that falls outside of the bounds of random variation. Though given the above-
noted small deviation in survival curves, it is likely that such a discrepancy would have 
only a trivial impact on the results of analyses. 
 Table B.2 provides information about the distribution of sojourn times (in months) for 
each disease location, stage, adjuvant therapy, and period combination. As a reminder, 
the sojourn time is the length of time the disease is potentially detectable by surveillance 
tests yet pre-clinical. This is the period during which follow-up could detect 
asymptomatic disease and thereby increase the chances that salvage surgery could be 
performed. In particular, the table gives information about the mean, median, and first 
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and third quartiles of the distribution of sojourn times. Each pair of hazard functions 
(time-to-detectable- and time-to-clinical-disease) lead to a different distribution of 
sojourn times, and some pairs of hazard functions were better (higher-probability) than 
others. Thus, I calculated a weighted average for each moment/quartile of the distribution 
of sojourn times using the discrete probabilities derived from calibration as weights. 
These overall quantities (based on the weighted-average) are the primary result of the 
table and represent the model’s best prediction concerning the mean/quartiles of the 
distribution of sojourn times. However, I also include (in parentheses) the range (over the 
different parameter sets) of each moment/quartile produced by the model. It should be 
noted that estimates are precise (with respect to Monte Carlo error) to the second decimal 
place, and thus Monte Carlo error can be ignored. 
SURVEILLANCE TESTING AND DETECTION OF DISEASE 
TEST SENSITIVITY 
 The key phenomenon the model seeks to accurately yet parsimoniously capture here 
is the ability (or lack-thereof) of extracolonic-focused surveillance tests (CT scans and 
CEA assays) to detect pre-clinical disease that is no longer dormant and has begun to 
develop. In the case of CT imaging, there is clear evidence of variation in the sensitivity 
of the test based upon the size of the largest lesion.84 85 Thus while it would be convenient 
to use an average sensitivity value in the model for a CT scan, this could potentially lead 
to misleading results. Moreover, such an average sensitivity value will inevitably be 
biased upwards with respect to its accuracy for small lesions since they will often not be 
detected and thus not included in studies of diagnostic accuracy. It was therefore 
necessary to model the size and thus growth of the largest lesion during the sojourn 
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period. While many patients will present with multiple lesions and possibly at multiple 
sites, the largest lesion would generally be the determinant of the sensitivity of a CT scan 
to detect asymptomatic disease. I thus model the disease as 1 lesion. However, the 
tendency for disease to colonize an organ and spread to other organs over time is relevant 
to the potential for salvage surgery. The resectability of disease is described in the next 
section. 
 About 65-75% of all recurrences will involve disease in the liver and or lungs4 45 86 so 
the model tried to capture the development of a hepatic or pulmonary lesion. Studies of 
CRC metastases in animals suggest that the tumor-development process is initially slow 
at small tumor volumes but then transitions to exponential-like growth (due to improved 
access to the circulatory system and the consequent resources) until it again slows down 
due to external limitations (e.g., runs out of space, insufficient access to resources, 
limited vascularization given the size of the tumor).87 These observations suggest that a 
sigmoid-shaped parametric form is a reasonable choice to represent growth of the 
tumor.88 In particular, I model tumor volume with a Gompertz growth curve (Equation 1)  
𝑉(𝑡) = 𝑉0exp⁡(
𝛼
𝛽
(1 − 𝑒−𝛽𝑡))                (1) 
For the purposes of modeling the (possible) detection of disease by CT imaging, the 
diameter of the tumor is more relevant than the volume. If we assume the lesion is 
spherical, there is a one-to-one relationship between the volume and diameter given by 
the equation: 𝑉 =⁡
4
3
𝜋(𝑑/2)3. 
 The primary feature of the Gompertz growth model is that its relative growth rate 
(
𝜕𝑉(𝑡)
𝜕𝑡
⁄
𝑉(𝑡)
) decays exponentially. The rate of decay is controlled by the parameter 𝛽 while 
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the parameter 𝛼 represents the initial proliferation rate.89 It is useful to define the limit of 
this function as 𝑡 becomes large (the maximum achievable volume, or the carrying 
capacity), 𝑉∞ =⁡𝑉𝑜exp⁡(
𝛼
𝛽
), where 𝑉𝑜 is the volume at time 0. Given information 
(assumptions) about 𝑉𝑜 and 𝑉∞, a classic Gompertz growth model depends only on (is 
fully specified by) the value of 𝛽. 
 In reality, the growth and progression of hepatic and pulmonary lesions during the 
sojourn period will be doubly heterogeneous: (a) the rate of growth and (b) the size at 
which disease becomes clinical will vary from person to person (and possibly within a 
person).88 That is, even in the absence of surveillance testing, most lesions will not 
actually grow to their true carrying capacity since the disease will become clinically-
indicated prior to that. However, there is insufficient empirical evidence to parse out the 
heterogeneity of these two processes. Thus, in order to make this modeling task tractable, 
I assume that all lesions become symptomatic at the same size, with a diameter of 5.5 cm. 
Moreover, I assume that the sojourn period begins (i.e., the disease becomes potentially 
detectable) when the largest lesion is 1 mm. Before that, the disease is assumed 
undetectable and so the size is irrelevant. 
 I selected 1 mm as the beginning of the sojourn period because a diameter of 1 mm 
was the smallest reported lesion I could find in the literature.90 While the choice of a 
diameter of 5.5 cm as the size at which all lesions become symptomatic is necessarily 
arbitrary, it is not unreasonable. The vast majority (75%) of hepatic resections involve 
lesions of a smaller size91, and this is almost always true for pulmonary 
metastastecomies.90 Moreover, while a lesion of this size might not always be large 
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enough to affect hepatic or pulmonary function to a degree that causes symptoms, it is 
likely the disease will have spread beyond the original organ by this point. Apparently, 
patients with clinically-indicated metastatic disease more often than not present with 
symptoms resulting from wide-dissemination of the disease rather than loss of hepatic or 
pulmonary function.92 Unfortunately, I was unable to find helpful information in the 
literature concerning the size of lesions in local-regional e.g., pelvic, recurrences, and so I 
am unable to evaluate the reasonableness of the selection of 5.5 cm for such patients.  
 To recap, the natural history model of tumor growth tracks the development of a 
metachronous lesion during its sojourn period as it grows from 1 mm in diameter to 55 
mm in diameter and thus becomes symptomatic. The total time this process takes is 
determined by the time-to-clinical-disease simulation for each individual. As a 
consequence, at any given time in the simulation, different individuals with recurrence 
will have different size lesions. However, all lesions will be the same size after a given 
proportion of the patient’s sojourn time. That is, all individuals with a recurrence will 
have the same size lesion after say 50% of their sojourn time has elapsed, however long 
that process takes. Thus in the simulation model, the size of a lesion at the time of a CT 
imaging study, and thus the sensitivity of the test, will be determined by what proportion 
of the patient’s sojourn time has elapsed. The model was therefore in need of two 
empirical inputs: a (1) Gompertz curve characterizing the growth of the tumor from an 
initial volume with a diameter of 1 mm (0% of the sojourn time) to a final volume with a 
diameter of 5.5 cm (100% of the sojourn time) and (2) the sensitivity of CT imaging for 
different sized lesions. 
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 For the first of these, I turned to previous empirical work88 that used CT scans to 
measure the volume of two groups of hepatic metastases (a set of occult tumors and a set 
of larger, surgically-identified tumors) in patients at two or more time points. Using a 
Gompertz growth model, the authors estimated the average age of both groups of tumors 
for which a mean volume was available. I used these two mean tumor-volumes (implied 
diameters of 2.6 and 3.6 cm) and corresponding estimated average tumor-ages (2.3 and 
3.7 years, respectively) to calibrate a Gompertz growth curve. To do this, I followed the 
previous authors and further assumed the tumor started as 1 cell with a volume of 
1𝑥10−9⁡𝑐𝑚3 and had a carrying capacity of 1000⁡𝑐𝑚3 (a diameter of about 12.4 cm). 
These assumptions combined with the two data points implied a unique exponential 
decay parameter 𝛽 and thus Gompertz growth curve. However, because I was only 
interested in the size of the tumor once it was potentially detectable, i.e., once it had at 
least a 1 mm diameter, I rescaled the time domain 𝑡 to 
𝑡−𝜏1
𝜏55−𝜏1
, where 𝜏1 and 𝜏55 are the 
times at which the calibrated Gompertz function was equal to an implied diameter of 1 
mm and 55 mm, respectively. The resulting function (Figure C.1) is defined over the 
interval [0, 1] and identifies a tumor volume (diameter) at any fraction of elapsed sojourn 
time. 
 The above function maps from the proportion of elapsed sojourn time to the diameter 
of the largest lesion. The next step was to construct a function that maps from the lesion 
diameter to CT sensitivity. I did this by fitting a LOWESS curve93 to a set of data points 
taken from the literature giving the estimated sensitivity of a CT scan for different sized 
lesions (Figure C.2). I found two sources which provided estimates of average CT 
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sensitivity for different size-categories of hepatic lesions: a meta-analysis85 and a single 
institution study84 which categorized sizes differently than the meta-analysis. Similar 
sources were not available for pulmonary or local lesions. These values and the size-
ranges to which they applied are given in Table 3. I assumed that the sensitivity of a CT 
scan for a lesion at 1 mm (55 mm) was 0.10 (0.98) because this was the smallest (largest) 
sensitivity reported in the literature.85 
 The final step for the CT scan was to construct a composition of the two above-
mentioned mappings: (i) from fraction of sojourn time elapsed to lesion diameter and (ii) 
from lesion diameter to CT sensitivity. The resulting function (Figure 2) identifies a CT 
sensitivity value for any fraction of elapsed sojourn time between [0, 1]. 
 It is noteworthy that this implicitly assumes that an abdominal & thoracic CT scan is 
performed in the case of colon cancer patients and an abdominopelvic & thoracic CT 
scan in the case of rectal cancer patients. In real life, an abdominal CT scan would not 
fully visualize the lungs and so would not be able to detect pulmonary metastases. Thus, 
the effective sensitivity to detect any recurrence would be lower than assumed here. As 
previously noted, in the interest of simplicity and convenience, the model does not 
distinguish among different recurrence locations. Thus as currently implemented, ideally 
the model should only be used to simulate and evaluate the full CT combinations 
previously mentioned. Although it might provide for a reasonably approximate 
representation of the combination of abdominal ultrasound and chest x-ray or of an 
abdominal CT scan (ultrasound) performed at 6 or 12 months after primary resection. 
This is because over 75% of pulmonary recurrences present after one year.4  
Table 3: Estimates of CT Sensitivity by Hepatic Lesion Size 
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AVERAGE 
SENSITIVITY 
(95% CI) 
LESION SIZE 
RANGE 
(DIAMETER) 
ASSIGNED SIZE 
(range for 
sensitivity analysis) 
SOURCE 
0.10 
(0.05, 0.20)* 
- 1 mm Assumption 
0.352 
(0.218, 0.488) 
1-10 mm 
7.5 mm 
(6-9) 
Ichikawa (2010)84 
0.702 
(0.605, 0.798) 
11-20 mm 
15.5 mm 
(14-17) 
Ichikawa (2010) 
0.888 
(0.805, 0.970) 
21-30 mm 
25.5 mm 
(24-27) 
Ichikawa (2010) 
0.962 
(0.910, 1.000) 
31+ mm 
40.5 mm 
(35.5-45.5) 
Ichikawa (2010) 
0.473 
(0.401, 0.545) 
1-9 mm 
7 mm 
(5.5-8.5) 
Niekel (2010)85 
0.867 
(0.776, 0.925) 
10+ mm 
36 mm 
(31-41) 
Niekel (2010) 
0.744 
(0.687, 0.793) 
All lesions 
31 mm 
(26-36) 
Niekel (2010) 
0.98 
(0.90, 1.00)*
 - 55 mm Assumption 
* = Range for Sensitivity Analysis rather than 95% CI; CI = confidence interval 
 For the CEA assay, I constructed a similar function that mapped from the fraction of 
sojourn time that had elapsed to the sensitivity of a CEA test. Unfortunately, there was no 
information in the literature on the lesion-size-specific sensitivity of CEA tests. I 
therefore constructed the curve as follows. I assumed that the sensitivity of a CEA test 
was 50% greater than that of a CT scan at the beginning of the sojourn period as there is 
evidence of elevated CEA-levels anticipating micro-metastases that were missed by CT 
scans.94 I further assumed that, by the end of the sojourn period (when the disease was 
clinical), 30% of recurrences would never have triggered elevated CEA levels (an 
assumption corroborated by the literature22 23). Finally, I used an adjusted meta-analytic 
estimate of the sensitivity of CEA assays for colorectal cancer recurrence – 0.54 (95% 
CI: 0.46-0.62) - and assumed this applied to the same mean-sized lesion (31 mm 
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diameter) as in Niekel (2010). A Gompertz curve was fit using these three points and is 
depicted in Figure 2. 
 A recent systematic-review and meta-analysis27 highlighted the high risk of bias in 
most reported estimates of the sensitivity of CEA due to the retrospective methods used 
to estimate this quantity and the questionable relationship between common study criteria 
for retroactively classifying CEA readings as detecting or missing disease and actual 
prospective clinical practice of interpreting CEA readings. To get the estimate given 
above, I thus combined the only study in that review that was assigned a low risk of 
bias95 with a more recent high-quality secondary analysis23 of the FACS trial which 
estimated the sensitivity of a single CEA assay test (with a repeat measurement to 
confirm elevated scores) used prospectively to determine appropriate follow-up. In both 
cases, estimates of the sensitivity were based on using the threshold of 5 μg/L for 
elevated CEA levels.  
IMPLEMENTATION OF SURVEILLANCE & FALSE POSITIVES 
 The model simulates follow-up testing in all patients who are alive and ostensibly 
disease free. While guidelines suggest CEA tests and clinical visits (CT exams) every 3-6 
(12) months, it is unlikely that patients would stick to that exact schedule even if they 
were 100% compliant. The model thus randomly assigns a follow-up time (time at which 
the test is performed) for each test using a truncated normal distribution with a mean 
equal to guideline time, a standard deviation of 3 months, and truncation points of +/- 1.5 
months for CEA exams performed in the first 3 years and +/- 3 months for CEA exams 
performed after 3 years and for all CT exams. 
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 A schematic representation of the implementation of surveillance in the 
microsimulation model is given in Figure 3. Any surveillance tests are necessarily wasted 
in patients who are disease free (cured) and in patients who have micro-metastases that, 
while currently undetectable, will eventually begin to grow and spread. Both of these 
types of patients can fall victim to false-positive findings however. Other than the 
possibility of false positives, the model assumes there are no potential personal harms 
associated with noninvasive follow-up testing as there would be with say endoscopic 
follow-up tests. While the exposure to ionizing radiation from an abdominopelvic and 
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chest CT scan is non-trivial, the lifetime risk of developing cancer from radiological 
imaging is very small among older patients (like CRC patients) who generally don’t live 
long enough for subsequent disease to develop.96 
 
 For patients who have detectable but pre-clinical disease, a given surveillance test has 
a chance of detecting their disease equal to the sensitivity associated with the respective 
modality (CT scan or CEA test) and the proportion of their sojourn time that has elapsed 
(see Figure 2). Pseudo-random simulation of a Bernoulli variable is used to determine 
whether a patient’s recurrence is actually detected or not by the given test. Once the 
disease is detected, be it clinically-indicated or surveillance-detected, follow-up testing is 
discontinued and the patient is treated for recurrent disease (next section). 
 In the case of a CT scan, a true positive result means the patient has diagnosed 
recurrence and proceeds to treatment. It is unclear from the literature how commonly 
laparoscopy (or thoracoscopy for pulmonary findings) or imaging-guided biopsies are 
needed, but it is likely that some proportion of patients require these before surgical 
resection is considered due to equivocal imaging results. I therefore arbitrarily assumed 
5% of patients with a true-positive CT scan get a laparoscopy (or thoracoscopy) and 5% 
45 
 
get a CT-guided fine-needle aspiration (FNA). This is simply a cost added to follow-up 
testing and does not influence a patient’s trajectory through the model. Moreover, the 
model currently assumes a pelvic MRI is performed after one of every four true-positive 
CT scans identifying recurrent disease in rectal cancer patients. The point of this is to rule 
out false-positive findings in the pelvis and better determine the appropriateness of 
salvage surgery.97 98 As with the laparoscopy/FNA, there is no simulation associated with 
the MRI; it simply represents a cost. The one-in-four value was selected because 
approximately 20-25% of recurrences seen in rectal cancer appear in the pelvis.4 45 In its 
current form, the model does not implement a PET scan or PET/CT combination scan 
after a true-positive CT scan as might be used to help identify widely-disseminated 
(extrahepatic abdominal) disease to avoid unhelpful surgery.99 100 This is because it is 
unclear how common this procedure is in actual clinical practice. Moreover, the model 
currently allows for failed surgical resection. 
 In the case of a CEA assay, a true positive represents two consecutive elevated 
readings (> 5 μg/L) 2 weeks apart and leads to a chest and abdominal (abdominopelvic) 
CT scan. The sensitivity of a CEA test and subsequent CT test are assumed independent 
conditional on the fraction of elapsed sojourn time. The CT scan identifies the disease 
with probability equal to the previously described sensitivity, and the patient proceeds to 
treatment (with the added cost of a pelvic MRI for 25% of rectal cancer patients and a 
laparoscopy or CT-guided FNA for 10% of all patients). If, however, the CT scan fails to 
identify the disease, no further tests are performed until there is another positive routine 
CT or CEA test. That is, the patient’s disease is missed (a false negative). In its current 
form, the model does not implement a PET Scan in these circumstances (elevated CEA 
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levels but negative CT imaging) as might be considered94 98 again because it is unclear 
that this is representative of general clinical practice in the US. 
A major cost of follow-up testing is the apparently relatively common occurrence of 
false-positives.23 101 102 The costs of false-positives are wasted resources and potential 
psychological harms to the patient. Currently, the model does not include the latter as 
reliable information is not available in the literature. For false-positives, there were two 
cases to consider: (i) non-malignant findings on a routine CT scan and (ii) elevated CEA-
levels and a subsequent CT scan. For a routine CT scan, a patient has a false-positive 
with probability equal to 1-specificity. For specificity, I use an estimate from the hepatic 
imaging literature – 0.949 (95% CI8 0.929-0.963)85 - because better information exists, 
but comparable results have been reported for multidetector pelvic CT scans103. I assume 
that a false-positive CT scan requires further follow-up. In particular, I arbitrarily assume 
that patients get one of four options in equal proportion: (1) repeat CT scan (of the 
abdomen or chest), (2) an MRI (of the pelvis or abdomen), (3) a CT-guided FNA, or (4) a 
laparoscopy or thoracoscopy. 
 In the case of CEA, I use a specificity of 0.93% (95% CI: 90.6–95.3%), which was 
estimated using a threshold of 5 μg/L.23 95 A false positive leads to a CT scan (just as a 
true positive does). However, the model uses a different specificity for a CT scan 
undertaken to discover suspected recurrence (because of elevated CEA levels) – 0.74 
(95% CI: 0.67-0.82) - than for a routine CT scan as there is evidence of a higher 
                                                          
8 The 95% CIs are used for a sensitivity analysis 
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incidence of false-positives in this context.104 False positive CT findings lead to 
additional investigations as described above. 
TREATMENT OF RECURRENCE 
 Patients with recurrence are either treated with curative intent or with the intent to 
prolong life and reduce symptoms. For convenience, I refer to the latter as palliative 
treatment. Figure 4 depicts a flow diagram for patients diagnosed with recurrence. The 
primary modeling task is the determination of which form of treatment a patient gets. In 
order for a recurrence to be a candidate for salvage surgery with a curative intent, in 
general the disease must be isolated (in one organ) and, in the case of liver and lung 
metastases, sufficiently isolated and concentrated within the organ to allow the organ to 
function after resection. As time progresses, the disease is likely to further colonize the 
initial organ (e.g., lesions increase in volume, more lesions develop, disease spreads to 
another lobe of the liver) and spread to other parts of the body. Thus, over the course of 
the sojourn period, the chances the disease is salvageable will decrease dramatically. 
 Mimicking the above-described model of the growth of the largest lesion, I modeled 
the trajectory of the chances the disease is unresectable upon detection (during the 
sojourn period) using a Gompertz function. I assumed that around 25%5 and 35%11 of 
clinically-indicated, isolated local-regional recurrences in colon and rectal cancer patients 
are salvageable, respectively, and that isolated local-regional recurrence constitutes about 
15%5 and 20%4 11 of all recurrences among colon and rectal cancer patients, respectively. 
I further assumed that only 5% of distant metastases are salvageable once symptomatic. 
Together these assumptions entail a salvage rate of roughly 8% and 11% for clinically-
indicated recurrences in colon and rectal cancer patients, respectively, i.e., at the end of 
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the sojourn period. It is unknown what proportion of recurrences are salvageable at some 
point during their sojourn period, but it is likely that some never are. I therefore assumed 
that 10% of recurrences are never resectable. Thus the probability a recurrent disease is 
unresectable if discovered at the beginning of the sojourn time is 10%. 
Figure 4: Flow Diagram of Treatment of Recurrence 
 
 
 In order to estimate a best-fit Gompertz curve, I calibrated a third point at an arbitrary 
timepoint of 70% of the sojourn period. This proceeded as follows. Using a mix (equal 
proportion) of colon and rectal cancer patients, stage II and III patients, and, for colon 
cancer patients, no adjuvant chemotherapy and adjuvant chemotherapy (5-FU/LV and 
FOLFOX), I selected a reasonable starting value for the unknown parameter and 
simulated two cohorts of patients for five years: one undergoing the ‘intensive’ and one 
undergoing the ‘minimal’ follow-up regimen used in the calibration of the natural history 
model mentioned above (Table B.1). For each subgroup of patients, e.g., stage III colon 
treated with FOLFOX, I used the highest probability parameter set, i.e., set of time-to-
detectable-disease and time-to-clinical-disease hazard functions. As mentioned in 
footnote 4, the initial probability distribution for the different pairs of parameter sets 
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(hazard functions) was based off an initial calibration exercise using only the time-to-
diagnosed-recurrence targets and the two meta-analytic targets (Table 2) associated with 
detection of asymptomatic recurrence (and thus not those associated with salvage rates). 
For 44% (56%) of patients undergoing a salvage surgery, I used the new (old) 
distribution of surgical outcomes (Table 4: explained below). This was based on the fact 
that 44% (56%) of the meta-analytic weight for the salvage targets came from trials 
conducted after (before) 2000. The main difference between the new and old distributions 
of surgical outcomes is that the proportion of salvage surgeries which end in R0 resection 
has increased over time, increasing the expected benefit of attempted salvage surgery. For 
each simulation, I evaluated the model-produced intensive-arm proportion of recurrences 
undergoing R0 salvage and the odds ratio comparing the two arms. In particular, these 
two model produced statistics were evaluated with the corresponding meta-analytic 
predictive-distribution likelihoods described above. I again used R’s simulated annealing 
(available in the function optim) to find the parameter (the proportion of recurrences that 
are unresectable after 70% of the sojourn time has elapsed) that maximized the product of 
the two likelihood scores. 
 The resulting function relating the probability that a diagnosed recurrence is 
unresectable with the proportion of the sojourn time that has elapsed is depicted in Figure 
5. A patient with diagnosed recurrence receives palliative treatment with probability 
equal to the chance the disease is unresectable and receives curative resection with 
probability equal to one minus the probability the disease is unresectable. For patients 
treated palliatively, the model simply simulates a time-to-cancer-death variate as 
described in the next section. Costs for such a patient are discussed in Chapter 4. 
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 For patients treated surgically with a curative intent, there is a small risk of 30-day 
surgical-related mortality (2%) and a larger risk of surgical-related morbidity. The 2% 
figure was selected as a reasonable balance between the higher rate reported for hepatic 
resections (2.5%)65 and the lower rate reported for pulmonary resections (0.9%)66 in a 
population setting. This value applies to patients under 75. For patients 75 and old, there 
is evidence of a higher 30-day mortality rate (5%).105 Surgical-related morbidity is 
discussed in Chapter 4. 
 
 Patients who survive salvage surgery are then assigned a surgical outcome. These 
include a terminated resection due to the discovery of widely-disseminated disease or an 
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incomplete resection with residual macroscopic disease that is visible to the surgeon 
(which I group as an R2 resection), microscopically-positive surgical margins (R1 
resection), and macroscopically- and microscopically-clear margins (R0 resection). The 
distribution of these three surgical outcomes differs for metastasectomies (generally the 
liver and lungs) and surgical resection of local-regional recurrence (isolated pelvic 
disease for rectal cancer or isolated abdominal recurrence in colon cancer). The former is 
more favorable. This is likely due to the constricted space of the pelvis and the potential 
for disease to be appended to nerves and/or bones.61 Since a sizeable proportion of local-
regional recurrences that present as clinical disease are salvageable5 11 102, and since 
symptomatic metastatic disease is essentially never salvageable6, the model uses the 
distribution of surgical outcomes associated with metastasectomies for surveillance-
indicated disease and the distribution associated with local-regional disease for clinically-
indicated disease. These are given in Table 4. They are taken from an (author-updated) 
meta-analysis. It is of note that both distributions have improved over time. 
Table 4: Distribution of Surgical Outcomes among Patients Undergoing Salvage Surgery  
DETECTION 
METHOD 
Probability of 
R0 Resection 
Probability of 
R1 Resection 
Probability of 
R2 Resection 
Sources 
(New) 
Clinically-
Indicated 
Disease 
0.605 0.282 0.113 
61 106 
(Old) Clinically-
Indicated 
Disease 
0.436 0.204 0.360 
(New) 
Surveillance-
Indicated 
Disease 
0.822 0.149 0.029 
91 107-118 
(Old) 
Surveillance-
0.596 0.108 0.296 
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Indicated 
Disease 
New = Study published after 2000; Old = Study published before 2000. 
DEATH FROM CANCER 
 The model simulates the life-course of patients from immediately after curative 
surgery for the primary tumor to death, be it from cancer or other causes. Patients who do 
not experience a recurrence (those who are cured) die from other causes. The rate at 
which this happens depends upon the application of the model. For the purposes of 
Chapter 4, I simulate death times from the most recent (age- and sex-specific) US 
lifetables available from the National Center for Health Statistics119 in the Center for 
Disease Control and Prevention (CDC). Patients who suffer a recurrence can die from 
cancer or other causes, whichever happens first. The rate at which patients die from 
cancer depends upon the treatment they receive: palliative treatment or resection with a 
curative intent. Patients treated palliatively or who receive an R2 attempted salvage 
surgery are considered to have terminal disease and face a grim outlook. Patients who 
receive an R1 or R0 salvage surgery can be cured, but most will eventually suffer a 
recurrence and die from cancer. The re-recurrence process is not explicitly modeled. 
Instead patients who are uncured simply die a cancer-specific death at a time simulated 
from an appropriate distribution described below. In what follows, I describe the time-to-
cancer-death processes for patients treated curatively and for patients treated palliatively. 
PALLIATIVELY TREATED PATIENTS 
 Patients treated palliatively face an extremely high mortality rate and so will almost 
all die from cancer before they would have otherwise died. The length of their remaining 
lifetime (in a world where the only mortality risk is CRC-specific death) is simulated 
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from a calibrated survival curve adjusted for individual-specific frailty terms. I again 
used a discretization approach to simulate from the survival curve as it was significantly 
faster than rejection sampling and lead to only trivial bias. Calibration of the time-to-
death frailty variance and the correlation with other heterogeneity terms is discussed 
below. The baseline survival curve was taken from a meta-analysis of randomized control 
trials of systemic chemotherapy for terminally-ill CRC patients. The curve characterizes 
the survival experience of a mix of patients who were deemed to have unresectable 
metastatic disease, some with clinical disease and some with surveillance-detected 
disease. The latter patients will tend to live longer from the time of diagnosis simply by 
virtue of the lead time. For the purposes of the simulation model, the baseline survival 
curve thus needed to be adjusted to ensure patients with surveillance-detected disease 
were not penalized for earlier detection of disease. 
 This time-to-death (from terminal disease) process is implemented in the 
microsimulation model as follows. Patients with clinically-indicated, unresectable disease 
are given a remaining (CRC-specific) lifetime simulated from the adjusted (calibrated) 
survival curve. Patients with surveillance-detected disease are also given a remaining 
(CRC-specific) lifetime simulated from the same survival curve but which is added onto 
their lead time – the time interval between detection of their disease and the onset of 
symptoms. The latter is available since the microsimulation model uses a discrete-event 
framework. Thus all such patients at least live to the time at which their disease would 
have become clinical had it not been detected asymptomatically. In the current form of 
the model, there is no survival advantage conferred from asymptomatic detection of 
unsalvageable disease. 
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 Two different survival curves were taken from the literature and calibrated. The first 
was from a meta-analysis using patient-level data and represented the disease-experience 
of terminally-ill patients treated with single-agent fluoropyrimidines (5-FU or 
capecitabine).120 The second was a weighted average of a meta-analytic curve using 
patient-level data120 and a new randomized control trial121 and represented the disease-
experience of terminally-ill patients treated with the double-agent regimen of FOLFOX . 
The latter is more common in contemporary clinical practice. In each case, overall-
survival curves were digitized using PlotDigitizer and implemented in R using spline 
interpolation. 
 Cancer-specific survival (CSS) curves were backed out from these overall-survival 
curves using the following approach. Details of the theory behind this approach can be 
found in Chapter 2 of Klein and Moeschberger.122 I assumed that death from cancer and 
death from other causes were independent competing risks. Under the assumption of 
independent competing risks, marginal and cause-specific hazard rates are the same. 
Using lifetables from the Human Lifetable Database, a marginal other-cause mortality 
hazard rate (equal to the cause-specific hazard rate by the assumption of independence) 
was estimated for the period covered by the overall-survival curve. The definite integral 
of the product of this hazard rate and the overall-survival function provides an estimate of 
the crude cumulative incidence of other-cause mortality. Moreover, with independent 
competing risks, the negative integral of the ratio of the derivative of this crude 
cumulative incidence (for other-cause mortality) to the overall-survival function provides 
an estimate of the cumulative hazard function for cancer-specific mortality in the absence 
of competing risks. The target survival curves were only available for up to 5-7 years. 
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Because the cumulative hazard functions were roughly linear at the end of that period 
(signifying a constant hazard rate), I used linear extrapolation to extend the function to 10 
years. Finally, this was easily converted to the cancer-specific (net) survival function (in 
the absence of competing risks). 
The above-described CSS functions served as data targets for the next step which 
required calibration. The CSS functions were adjusted with a calibrated HR (assuming 
proportional hazards) to better represent the mortality experience of a cohort of patients 
with clinically-indicated disease. Thus each patient’s time-to-death from unresectable 
disease is the sum of a simulation from this distribution and their lead time (0 for 
clinically-indicated patients). The value of this HR was selected so that, among a cohort 
of patients undergoing intensive surveillance, the mortality experience of the subgroup of 
patients with unresectable terminal illness (both clinically- and surveillance-indicated) 
best mimicked the target curves. The HR was calibrated in the presence of heterogeneity 
(adjustment of baseline risk by personal frailty terms). 
 Figure 6 depicts the two target CSS curves and the two calibrated CSS curves for 
patients with clinically-indicated unresectable disease. For symptomatic palliative 
patients treated with single-agent fluoropyrimidines (referred to as 5-FU in Figure 6), the 
median cancer-specific survival is estimated to be 10.4 months. This is consistent with 
the median overall survival of 10.8 months observed in the FACS trial among patients 
treated palliatively in the minimal surveillance arm. Almost all of these patients presented 
with symptomatic disease. It is also consistent with the median relative survival of 9.2 
months observed among recent stage IV patients in the Surveillance, Epidemiology, and 
End Results (SEER) registry who underwent no surgery for primary disease (for reasons 
56 
 
other than comorbidity). Such patients are likely to have presented with clinical, 
unresectable disease as otherwise the primary tumor should have been resected. Note that 
this statistic excludes patients who did not undergo resection due to other comorbidities 
because such patients would not be included in surveillance cohorts. For symptomatic 
patients treated palliatively with FOLFOX, the median survival was 15.8 months. 
PATIENTS TREATED WITH A CURATIVE INTENT 
 In the simulation model, patients treated with an attempted salvage surgery that ends 
in an R2 (incomplete or stopped) surgical resection receive no survival benefit from the 
procedure and are considered equivalent to palliatively-treated patients. Patients who 
undergo an R0 or R1 margin surgical resection are considered to have been treated with a 
curative intent. They have a chance of cure. Following other authors in the literature, I 
assumed that 10-year survival after salvage surgery indicates cure.123 124 Ten-year 
survival rates for patients with an R0 resection were taken from an author-updated meta-
analysis. 
 There is evidence of a better prognosis among patients who present initially with a 
node-negative disease (stage I/II) than for patients with node-positive disease (stage 
III).91 125 I therefore backed out cure rates (Table 5) for each subgroup of patients using 
an estimated meta-analytic OR (0.46; 95% CI = 0.26-0.79) of the chances of surviving to 
10 years comparing node-positive disease to node-negative disease125 and assuming that 
about 60% of salvages involved patients with node-positive primary disease91 125 126. 
There was also evidence of an increase in the cure rate over time, and so I calculated rates 
for publications prior to 2005 and for those after 2005. Table 5 also provides implied 
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95% credible intervals (used for sensitivity analyses) for each cure rate based upon the 
compounded uncertainty of potentially multiple parameters. 
 
  Table 5: Cure Rates after Salvage Surgery 
PERIOD PATIENTS 
CURE 
PROBABILITY 
IMPLIED 95% 
CREDIBLE 
INTERVAL 
SOURCES 
After 2005 
(New) 
R0 Salvage 
Stage I/II 
0.427 (0.180, 0.717) 
65 66 91 123 
125 
R0 Salvage 
Stage III 
0.255 (0.090, 0.544) 
Before 2005 
(Old) 
R0 Salvage 
Stage I/II 
0.351 (0.219, 0.503) 
R0 Salvage 
Stage III 
0.199 (0.110, 0.325) 
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After 2005 
(New) 
R1 Salvage 
Stage I/II 
0.141 (0.000, 0.274) 
123 124 
R1 Salvage 
Stage III 
0.070 (0.000, 0.154) 
Before 2005 
(Old) 
R1 Salvage 
Stage I/II 
0 0 
R1 Salvage 
Stage III 
0 0 
 
  Although the evidence is somewhat equivocal, a shorter disease-free interval 
(time from resection of primary tumor to recurrence) appears to portend a worse 
prognosis after salvage surgery for both hepatic65 and pulmonary29 metastases. This is 
presumably due to a more aggressive biology of the disease, and this phenomenon is 
implemented in the model via correlated heterogeneity terms. However, the disease-free 
interval evidently does not predict 10-year survival rates.125 Cure rates are therefore not 
adjusted for the disease-free interval. 
 Less evidence was available with regards to long-term survival among patients who 
receive an R1 resection. It was traditionally thought to rule out the possibility of cure.124 
While some recent sources have found encouraging results at 3 or 5 years when patients 
are also treated with (neo)adjuvant chemotherapy112 123, most studies did not include 
sufficient follow-up to estimate 10-years survival rates. I therefore used the only estimate 
available123 and assumed that in contemporary practice 10% of patients undergoing R1 
resections will be cured. 
 Patients who undergo an R0 or R1 salvage surgery but are not cured will, in the 
absence of other causes of mortality, die from re-recurrent disease within 10 years. This 
appears to happen at a very similar rate among patients who undergo hepatic65, 
pulmonary66, and pelvic resection67. To simulate this process among the uncured, I 
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constructed four CSS curves from the literature with which to simulate a time-to-cancer-
death. The four curves were based on two factors: margin status (R0 vs. R1) and nodal 
status of the primary disease (stage I/II vs. stage III). Again, the effect of disease-free 
interval was implicitly modeled by adjusting the baseline risk of death (among the 
uncured) by a personal mortality-related frailty term that is strongly correlated with other 
time-to-disease processes. For a baseline curve, I used a digitized 5-year cancer-specific 
survival curve for patients who underwent salvage surgery for hepatic metastatic disease 
in a community setting in 2005 or after.65 From this I constructed the four separate curves 
using (a) knowledge of the proportion of patients with stage III disease and who 
underwent R0 resection and (b) meta-analytic all-cause mortality hazard ratios. The latter 
were 2.02 (95% CI: 1.65-2.48)126 - comparing R1 to R0 resections – and 1.6 (95% CI 1.4-
1.7)91 126 – comparing stage III to stage I/II disease.9 The four curves were then extended 
to 10 years by linear extrapolation of the cumulative hazard so that the 10-year cancer-
specific survival rates were equal to the respective cure rates. They are depicted in Figure 
7. Finally, survival probabilities were renormalized to apply to only those who were 
uncured, i.e., survival probability of 0 at 10 years. 
HETEROGENEITY VARIANCES AND CORRELATION 
 The correlation among log-frailty terms and the variances of each term (time-to-
detectable-disease, time-to-clinical-disease, and time-to-cancer-specific-death) were 
calibrated10 to target HRs from the ACCENT database comparing the all-cause mortality 
                                                          
9 The actual implemented HRs were adjusted via calibration until model output (simulated in the presence 
of heterogeneity) exhibited a cancer-specific mortality hazard ratio equal to 2.02 and 1.6, respectively. 
  
10 In the case of time-to-detectable disease and time-to-clinical disease terms, they were re-calibrated 
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hazard by year of recurrence.56 The targets, model-output, and calibrated parameters are 
given in Table 6. Since the relationship between disease-free interval and survival after 
recurrence appears to be primarily a feature of the natural history of recurrence among 
patients with stage III colon cancer56, I calibrated the heterogeneity parameters using 
stage III colon cancer patients treated with one of FOLFOX, 5-FU/LV or surgery alone. 
However, the model uses the same parameters for all forms of disease. Moreover, since 
nearly 80% of patients described by the target HRs were randomized to treatment prior to 
1993, I calibrated the heterogeneity parameters using a cohort of patients undergoing 
intensive follow-up with CEA testing only. 
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Table 6: Targets and Model Output for Heterogeneity Parameters 
TIMING OF 
RECURRENCE 
TARGET HR56 
(95% CI) 
MODEL-
PRODUCED HR 
CALIBRATED 
PARAMETER 
VALUES 
1-12 Months 1 (reference) 1 (reference) TTDD Var = 0.210 
TTCD Var = 0.10 
TTCSD Var = 0.11 
Correlation = 0.71 
13-24 Months 0.82 (0.77, 0.88) 0.79 
25-36 Months 0.69 (0.63, 0.75) 0.67 
37+ Months* 0.60 (0.54, 0.69) 0.60 
Table 6 gives all-cause mortality HRs associated with the disease-free interval. Patients 
who present with disease later (e.g., after the first year) face a reduced mortality hazard. 
*I included recurrences up to 7 years after the primary resection. 
CI = Confidence Interval; TTDD = time-to-detectable-disease; TTCD = time-to-clinical-
disease; TTCSD = time-to-cancer-specific-death; Var = variance. 
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CHAPTER 3: AN EVALUATION OF THE LOGIC AND 
EVIDENCE BEHIND INTENSIVE FOLLOW-UP 
 
INTRODUCTION 
 It is this author’s contention that, while some skepticism towards the value of 
intensive surveillance is certainly justified, the conclusions of the above critics and calls 
for a radical reassessment of CRC surveillance practices are premature. As discussed 
above, critics of intensive follow-up have generally explained the negative results of 
recent trials by questioning the existence of a survival benefit from aggressive use of 
salvage surgery. However, there is reason to take seriously the theory that, when 
performed on patients with isolated disease, it is effective at improving survival and that 
this level of efficacy is attainable even in the context of salvage rates as high as 30-50%. 
 Many large case-series reports and systematic reviews have documented significant 
long-term survival (5/10 year overall survival of 25-65%/15-35%) after R0 salvage of 
hepatic91 123 125, pulmonary29, and local (pelvic)67 127 recurrences. In the case of hepatic65 
128 and pulmonary66 metastectomy, these results have been reproduced in a community-
practice setting (as opposed to just at centers of excellence). Moreover, multiple studies 
have shown that outcomes have improved with time65 66 91 127 as case-volume has 
increased. While these case-series might be dismissed as involving highly-selected 
patients, these results have been reproduced in multiple modern cohorts of unselected 
patients undergoing intensive follow-up including routine CEA testing and imaging 
studies (Table 7). While this obviously does not definitely establish the benefit of salvage 
surgery, it shows that the impressive survival results seen in case-series cannot be 
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dismissed as due to selection of a small percentage of patients with non-aggressive 
disease. 
 The skeptical reader might question whether the results from the non-randomized, 
retrospective cohort studies identified in Table 7 (all but the FACS trial) are favorable 
because of selection of the patients involved in the analyses. However, there is little 
reason to suspect this. In general, the studies included all or almost all patients who 
underwent surgical resection for primary CRC (possibly just stage II-III patients and 
possibly just rectal) at the respective institution during the enrollment period. Arriola et 
al., (2006) and Kobayashi et al., (2007) included all patients of the included stages (II-III 
and I-III, respectively) treated at their center over the relevant period. The report by 
Ikoma et al., (2017) did the same with the exception of excluding patients who underwent 
emergency surgery for their primary tumor. Since the study focused on rectal cancer 
patients only, this might include around 10% of cases.129 It should be noted that 
emergency surgeries are necessitated by obstruction and/or perforation and are more 
likely to lead to R2 or at least R1 surgical margins for the primary disease130 131, and so it 
is likely that many of such patients would be excluded from a randomized trial evaluating 
intensive follow-up as they would not be considered potentially cured. Anyhow, this is 
likely less selective than both the FACS and GILDA trials which excluded patients who 
presented with (were found to have) recurrence prior to completing their adjuvant 
therapy. 
Laubert et al., (2010) included all patients but divided the sample into three cohorts 
based upon the surveillance they actually received: ‘intensive’, ‘minimal’, and ‘none’. 
The minimal group contained patients who received less than 70% of the tests included in 
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the institution’s protocol. The result presented in Table 7 is for the intensive arm patients 
only. It is unclear what degree of compliance was typical among the minimal arm 
participants, but it could plausibly be argued that the minimal arm participants should be 
included with the intensive arm participants since lack of adherence appears in some 
trials and is likely a reality of follow-up. In this case, the salvage rate of 30% would drop 
to 27%. However, it seems inappropriate to include the no-surveillance cohort given 
likely explanations of no follow-up are that patients were old or had serious 
comorbidities. It is unlikely that these patients would have been included in a RCT. 
 More importantly, the results for the FACS trial intensive arms are comparable with 
these results (Table 7). Two recent studies based on large community-practice case-series 
reported a median survival after hepatic65 (52 months) and pulmonary66 (51 months) 
salvage surgery (when limiting results to 2005 and after) that was nearly identical to that 
observed after curative resection in the FACS trial (52.3 months). The 8 patients treated 
in the minimal follow-up arm (1 CT only) had the most favorable survival experience 
(median OS = 76.9 months) likely due to the necessity that such patients had slow-
moving disease since otherwise they probably would not have been candidates for 
salvage surgery. The 21 patients in the routine CT and CEA arm had the second best 
prognosis (median OS = 58.7 months) followed by the 19 patients in the routine CEA-
only (+1 CT scan) arm (median OS = 51.2 months) and then the 28 patients in the routine 
CT-only arm (median OS = 43.6 months). The median OS was not given for the 3 
intensive arms alone (excluding the 8 patients in the minimal arm), but the value was 
52.0 months among the two routine CT arms (which includes the patients from the worst-
performing arm: the CT-only arm). 
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This suggests the benefits of salvage surgery can be reproduced among a relatively 
high percentage of patients who suffer a recurrence in the context of intensive follow-up. 
Moreover, if selection of patients with less aggressive disease was responsible for this 
promising survival statistic observed in the FACS trial among patients undergoing 
curative resection, we would expect to observe a more favorable survival experience 
among palliatively-treated patients (non-curatively) in the FACS minimal follow-up arm 
than among the same group of patients in the intensive arms. This is because the patients 
with the less aggressive disease would have been selected out of this group in the 
intensive arms but not in the minimal group. That is, all the slowest-moving cases of 
disease would have been selected into the ‘surgically-resected’ group and the remaining 
cases would be the most aggressive. Thus we should see a worse prognosis in the 
intensive arm group of patients who did not undergo salvage surgery. However, the 
opposite was observed. In the 3 intensive arms, median survival after recurrence among 
those treated non-curatively ranged from 13-22 months while the same figure for the 
minimal arm was 10.6 months. 
Table 7: Salvage Rates and Survival After Recurrence in Unselected Cohort Studies 
STUDY 
INDEX 
YEARS 
COHORT 
N 
RECURRENCE 
N (%) 
SALVAGEN 
(%) 
5 YEAR & MEDIAN 
OVERALL 
SURVIVAL AFTER 
RECURRENCE 
Ikoma132 
(2017) 
1993-
2008 
735 151 (20.5%) 70 (46.4%) 
5 Yr. = 51% 
Median = 61.2 months 
Laubert133 
(2010) 
Overall 
1990-
2006 
1469 211 (14.4%) 64 (30.0%) 
5 Yr. Hepatic = 47% 
5 Yr. Pulmonary = 66% 
5 Yr. Local = 57% 
Kobayashi21 
(2007) 
1991-
1996 
5230 
906 (17.3%) 
379 (41.8%) 
5 Yr. Hepatic = 45% 
5 Yr. Pulmonary = 48% 
5 Yr. Local = 30% 
Arriola134 
(2006) 
1993-
1999 
583 208 (35.7%) 73 (35.1%) Median = 62 months 
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FACS45 
(2014) 
2003-
2009 
901 165 (18.3%) 68 (41.2%) Median = 52.3 months 
Index years are the years during which patients were enrolled with index primary CRCs. 
Missing statistics were not available. Survival is broken out by location of disease when 
it was not available in a combined format. 
 
 Several other details of the FACS trial results corroborate the hypothesis that salvage 
surgery resulted in a survival benefit on average for treated patients. In the intention-to-
treat-analysis, the median survival after any recurrence was greater in the collapsed 
intensive arms (combining the CT & CEA arm, the CT-only arm, and the CEA-only arm) 
than the minimal arm, although not significantly so (27.3 vs 14.6 months; P = 0.11). 
However, in the per-protocol analysis, this result was borderline significant (P = 0.051), 
and the same comparison for the two CT arms vs the two no-CT arms was significant (P 
= 0.039). The per-protocol analysis is potentially informative in this case because there 
was a non-trivial degree of contamination, mostly in the form of those in the minimal 
follow-up arm, and to a lesser extent the CEA-only arm, receiving additional CT scans. 
Finally, the ratio of the number of cancer-specific deaths to the number of recurrences 
was significantly lower in the three intensive arms than in the minimal follow-up arm (P 
= 0.003), suggesting that a smaller proportion of patients suffering recurrence died in the 
intensive arms. 
 While the benefit of aggressive salvage-surgery has not been established in an 
experimental setting, the above considerations corroborate the usage of salvage surgery 
when patients present with resectable, isolated disease. However, given that we might 
expect only 2-12% of a modern cohort of unselected patients to benefit from intensive-
surveillance-induced salvage surgery (15%-30% recurrence rate and 15-40 percentage-
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point increase in the salvage rate), it’s unclear what kind of mortality benefit we could 
expect to see when averaged over the entire cohort. Moreover, if there were only a small 
benefit associated with intensive follow-up, it may not be surprising that recent trials 
failed to detect any mortality reduction. 
 In this paper, I use a modeling analysis to examine these issues. The analyses are 
based on the microsimulation model of CRC, recurrence-detection, treatment, and 
mortality described in Chapter 2. This model embodies the hypothesis that more 
aggressive extra-colonic follow-up of patients can increase the proportion of recurrences 
that are amenable to curative resection and thereby improve the survival of such patients. 
However, as described in Chapter 2, the model is also empirically grounded in the sense 
that the increase in salvage rates attributable to intensive follow-up in the model are 
consistent with meta-analytic results (Table 2) and the survival experience of patients 
treated with (without) salvage surgery is consistent with that observed in unselected 
cohort studies – Table 7 - where patients were treated aggressively (randomized control 
trials of systemic chemotherapy121) and, importantly, the FACS trial. Thus, a priori, the 
model, and therefore the underlying hypothesis it embodies, is theoretically consistent 
with many details of the FACS trial results. What remains to be determined is whether 
the primary outcome of the FACS trial – an all-cause mortality HR of 1.15 (95% CI: 
0.87, 1.50) comparing a collapsed intensive arm to the minimal arm – and of the GILDA 
trial (HR = 1.14; 95% CI: 0.87-1.48) - is consistent with the causal theory embodied by 
the model. That is, the question is whether the primary results of these trials could be 
plausibly reproduced in a world characterized by the model. 
69 
 
 In what follows, I demonstrate that the underlying causal theory of the model is in 
fact consistent with the results of the FACS and GILDA trials and that this realization 
should influence our interpretation of them and prompt reappraisal of recent criticisms of 
intensive follow-up. I first show that given the current low recurrence rates and the 
incremental salvage rates associated with intensive follow-up, any benefit is likely to be 
small and would require an impractically large trial to detect. To do this, I use Monte 
Carlo analyses to estimate what magnitude incremental benefit we would expect from the 
interventions under study in the trials if I am right that the benefit of intensive follow-up 
is limited by the low number of potential beneficiaries rather than the inefficacy of 
salvage surgery. I then use this result to perform a sample size calculation for a future 
hypothetical trial trying to detect the same effect. Secondly, I show that, in the case of the 
FACS trial, what was already a terribly underpowered study was further derailed by a 
sizeable imbalance in the recurrence rates between the arms. While some level of 
imbalance in the detection of recurrences may be expected given the asymmetrical 
follow-up intensities, I show that the observed level of recurrence imbalance is 
implausibly attributed to earlier diagnosis of recurrence in the intensive arms. In 
particular, I show that even after accounting for asymmetrical follow-up intensities a 
residual imbalance remains. I also quantify the expected bias and loss of power resulting 
from this recurrence imbalance. Finally, I perform a formal goodness-of-fit test 
comparing the model to the results of the FACS trial. 
METHODS  
 The analyses of this paper involve the microsimulation model described in Chapter 2 
and include (1) generating Monte Carlo estimates of the model-implied efficacy of the 
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surveillance regimens evaluated in the FACS trial and performing a sample size 
calculation for a hypothetical future trial, (2) an assessment of the degree to which the 
observed recurrence imbalance in the FACS trial could be explained away by earlier 
detection of recurrence due to more intensive follow-up, (3) performing a power analysis 
of the FACS trial given the observed recurrence levels but ignoring the recurrence 
imbalance, (4) an assessment of the expected bias and loss of power in the FACS trial 
from the chance recurrence imbalance, and (5), in light of the aforementioned power 
issues, a formal evaluation of the consistency of the model (and its underlying 
hypothesis) with the results of the FACS trial with a goodness-of-fit-test. 
Estimation of Efficacy Parameters 
 To clarify what magnitude mortality reduction we could expect from intensive 
surveillance if the benefit arose exclusively from the survival advantage conferred by 
curative resection of recurrent disease, I conducted a Monte Carlo analysis comparing 
two of the surveillance regimens under study in the FACS trial. In particular, I compared 
the most intensive schedule – the use of routine CEA testing and CT studies - to the 
minimal regimen of 1 CT scan. The surveillance regimens for all 4 arms of the trial are 
shown in Table 8. I estimated location-, stage-, and adjuvant-therapy-specific all-cause 
and disease-specific mortality HRs at 5 years using US life-tables for background 
mortality. Monte Carlo precision was quantified with 95% confidence intervals. For all 
analyses, I simulated a cohort of patients that was 70 years old (the median age at 
diagnosis) and was 60% male.59 
 I also estimated the approximate sample size that would be required in a future 
hypothetical RCT comparing routine CT and CEA testing to minimal follow-up (as 
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depicted in Table 8) in order for the trial to have an 80% chance of detecting the model-
estimated all-cause mortality hazard reduction at 5 years. I assumed a type-I error of 0.05 
and, for convenience, that there would be no loss to follow-up. I further assumed the trial 
would enroll stage II and III colon and rectal cancer patients only and after any adjuvant 
therapy (so beginning at 6 months). For stage III patients, I assumed 95% would receive 
adjuvant therapy (85% FOLFOX and 10% 5-FU/LV). While in a population setting about 
one-third of stage III patients receive no adjuvant therapy135 136, it is likely that this figure 
would be significantly higher among patients who would enroll in a randomized control 
trial. For stage II patients, I assumed an equal proportion of patients would use FOLFOX, 
5-FU/LV, and no adjuvant since the survival benefit of adding oxaliplatin to 5-FU/LV in 
stage II colon cancer patients is more controversial.19 I further assumed that 60% of 
enrollees would be male and that ages would vary from 40 to 78 with mean age of 68. I 
used this age distribution to mimic the likely age-distribution of a future trial (based on 
past trials). Finally, I estimated the statistical power of an alternative hypothetical trial 
comparing routine CT and CEA testing to the CEA-only (+1 CT scan) protocol with the 
above calculated sample size.   
Table 8: Surveillance Schedule for the 4 Arms of the FACS Trial 
Follow-up 
Arm 
Test 3 6 9 12 15 18 21 24 30 36 42 48 54 60 
CT + CEA CT  X  X  X  X  X  X  X 
CT-Only CT  X  X  X  X  X  X  X 
CEA-Only CT     X          
Minimal CT     X          
CT + CEA CEA X X X X X X X X X X X X X X 
CT-Only CEA               
CEA-Only CEA X X X X X X X X X X X X X X 
Minimal CEA               
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Table 8 depicts the follow-up schedule for each of the four arms in the FACS trial. The 
‘CT + CEA’, ‘CT-Only’, and ‘CEA-Only’ arms are the intensive arms. 
 
 The above analyses are meant to provide detailed information about how big the 
benefit of an intensive follow-up regimen like that studied in the FACS trial might be in a 
US clinical practice setting, how the benefit might vary with disease location (rectal vs 
colon) and stage and adjuvant treatment, and what sized RCT would be required to detect 
such a benefit. In order to facilitate direct comparison of the model output with the results 
of the FACS trial, I conducted a second set of Monte Carlo analyses that mimicked the 
mix of patient and disease characteristics of the FACS trial. In particular, I estimated an 
all-cause and cancer-specific mortality HR at 5 years comparing (a) routine CT and CEA 
testing to minimal follow-up and (b) routine CT and CEA testing to CEA-only (+ 1 CT 
scan) testing (again as shown in Table 8). However, in this set of analyses, cohorts were 
simulated with the same mix of stage (I-III), adjuvant therapy utilization, and location 
(rectal vs colon) as reported in the FACS trial. Moreover, to better recreate the actual trial 
design, the life-course of all patients receiving adjuvant therapy was simulated for 5.5 
years, but only the last 5 years were included in the analysis. As in the real trial, any of 
these patients who presented with recurrence within 6 months of the simulation were 
excluded from the analysis. For background mortality, I initially used lifetables from the 
UK for the period under study taken from the Human Life Table Database. However, 
observed mortality in the trial unrelated to CRC was much lower than would be predicted 
for the general population. I therefore injected mortality from other causes into the 
simulation by randomly assigning death times (from other causes) to individuals from an 
exponential distribution calibrated to match the cumulative incidence of non-cancer-
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related mortality during the trial period (6.6%). Finally, since the primary outcome of the 
FACS trial was actually an all-cause mortality HR comparing the 3 intensive arms 
(collapsed into one arm) with the minimal arm, I replicated the above analyses for this 
comparison. Thus, one-third of patients in the intensive arm received intensive CEA and 
CT, one-third received intensive CT only, and the other third received intensive CEA and 
one CT scan. I also estimated the difference in five-year overall-survival probabilities 
between these two cohorts. 
 For the GILDA trial, I performed a similar analysis, but the capacity of the model to 
replicate the study design was somewhat limited. In its current form, the model does not 
distinguish recurrence by location, e.g., liver, lungs, local, peritoneum, etc, and thus it is 
difficult to mimic the protocol of the GILDA trial which involved the use of abdominal 
ultrasounds and chest x-rays at staggered intervals for colon cancer patients. For 
surveillance, the model currently can mimic the performance of CEA testing and an 
abdominal/thoracic (abdominal/thoracic/pelvic for rectal cancer) CT scan. As noted in 
Chapter 2, there is little chance of pulmonary recurrence in the first 12 months after 
primary resection, and so abdominal ultrasound without chest x-ray would reasonably be 
approximated by a CT scan in the simulation model. I thus simulated cohorts with a 
follow-up regimen that I thought would best represent the actual schedules offered in the 
trial given the constraints of the model. Table 9 displays the follow-up schedules of the 
actual trial and those used in the simulation study. On average, participants in the trial 
faced an annual cumulative probability of dying from other causes of about 0.5%, so I 
randomly selected 5 of every 1,000 participants to die each year. 
Table 9: Surveillance Schedule for 2 GILDA Trial Arms 
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Follow-up 
Arm 
Test 4 8 12 16 20 24 30 36 42 48 60 
Intensive 
Arm: Real 
Ultrasound/CT* X X X X  X  X  X X 
Intensive 
Arm: Real 
Chest X-ray   X   X  X  X X 
Intensive 
Arm: 
Simulation 
CT X X X X  X  X  X X 
Minimal 
Arm: Real 
Ultrasound/CT  X  X        
Minimal 
Arm: Real 
Chest X-ray   X         
Minimal 
Arm: 
Simulation 
CT  X  X        
Intensive 
Arm 
CEA X X X X X X X X X X X 
Minimal 
Arm 
CEA X X X X X X X X X X X 
Table 9 lists the extracolonic-focused components of the 2 follow-up regimens under study in the 
GILDA trial. Colonoscopy and Proctoscopy are not listed. 
*The GILDA trial protocol called for substituting some ultrasounds with abdominal/pelvic CT 
scans for rectal patients in the experimental arm and allowed 1 abdominal/pelvic CT scan for 
rectal patients in the control arm. 
 
An Evaluation of Recurrence Imbalances 
 Over the course of the FACS trial, 12.6% of patients randomized to the minimal arm 
were diagnosed with any type of recurrence, and 18.3% of patients in the three more 
intensive arms suffered a recurrence. When time on study and censoring were accounted 
for, the respective 5-year net cumulative incidences of recurrence were 14.1% and 
19.4%.11 Among the 3 intensive arms, the routine CEA testing and CT scan arm 
                                                          
11 I calculated these cumulative incidence values from curves using the previously mentioned PlogDigitizer 
software. 
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exhibited a 17.1% cumulative incidence while 20.5% of the CT-only and CEA-only (+ 1 
CT) arms developed recurrence. These represent a 21% and 45% increase in the observed 
recurrence rate relative to the minimal arm, respectively. 
 To investigate whether this recurrence asymmetry could be explained by a more 
intensive follow-up regimen simply detecting recurrences earlier, I performed the 
following analyses. I first simulated the 5-year experience of a cohort of patients 
mimicking the disease and adjuvant-treatment characteristics of the patients in the FACS 
trial as well as the design features described above. Individuals were assigned in equal 
proportion to one of the three intensive follow-up schedules in the trial. Moreover, each 
individual’s chance of suffering a recurrence (over the course of 15 years)12 was adjusted 
by a calibrated factor such that, after 5 years, the cumulative incidence of recurrence in 
the absence of competing risks13 produced by the model matched that observed in the 
collapsed intensive follow-up arm of the FACS trial (19.4%). I then re-simulated the 
same cohort except this time they were subject to the minimal surveillance schedule 
(Table 8). This allowed estimation of the five-year cumulative incidence of recurrence 
that would be expected given the same underlying propensity for disease but only 
minimal follow-up. That is, this analysis served to quantify the difference in observed 
recurrence rates we would expect between the 3 intensive arms and the minimal arm in 
virtue of different follow-up intensities. Any further difference (over and above that) 
                                                          
12 See Chapter 2 for details of the model. Recall that recurrence was simulated as a binary process (recur 
within 15 years or not) and then, conditional on eventually recurring, a time to recurrent disease process 
was simulated.  
13 The cumulative incidence rates reported in the trial were estimated using Kaplan Meier methods that 
censored patients at the time of death from other causes.  
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would then represent a recurrence imbalance between arms. Finally, I repeated this set of 
analyses using just the routine CEA and CT arm as the intervention arm. This was done 
to evaluate whether this specific treatment-arm (which appeared to suffer less of a 
recurrence imbalance) would allow a less-biased comparison with the minimal-arm. 
 The GILDA trial exhibited a small recurrence asymmetry at 5 years as well. This was 
also in favor of the control arm (18.8% vs 22.0% in the intensive arm). I therefore 
repeated the above simulation analysis for the GILDA trial. 
Power, Bias, and Goodness-of-Fit Analyses 
 Based upon the results of the above Monte Carlo analyses, I performed a simulation 
study to estimate the statistical power of the FACS trial to detect a mortality benefit of 
the size projected by the model. Since the primary outcome of the study was the all-cause 
mortality HR comparing the collapsed intensive arm (N = 901) to the control arm (N = 
301), I conducted the power analysis for this comparison. I performed the simulation 
study twice, and in each study I simulated 2000 replications of the trial. In both cases, I 
simulated the protocol follow-up schedule and not the observed degree of follow-up. That 
is, lack of compliance and contamination were ignored for these analyses.  
 In the first simulation study, in both arms, I adjusted each individual’s risk of 
recurrence by the factor that was previously calibrated to reproduce the trial-observed 5-
year cumulative incidence of recurrence (19.4%) in the collapsed intensive arm. This 
means that simulated patients in the minimal arm were adjusted by the same factor and so 
had the same propensity for recurrence as those in the collapsed intensive arm. Thus the 
first set of analyses ignored any underlying recurrence imbalance. I further used the 
results of the first simulation study to construct a sample distribution of the all-cause 
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mortality HR estimator and the observed 5-year cumulative incidence of recurrence in the 
minimal arm. I calculated the 0.025 and 0.975 quantiles of each distribution. I also 
determined the empirical quantile (i.e., quantile of the sample distribution) of the actual 
FACS-trial-observed all-cause mortality HR estimate and minimal-arm recurrence rate. 
 The second power-analysis differed only in the adjustment to the risk of recurrence. 
In this simulation study, I specified the number of patients recurring in both the minimal 
arm and the collapsed intensive arm. These numbers were calibrated to ensure that the 
collapsed intensive arm (minimal arm) exhibited a 5-year cumulative incidence of 19.4% 
(14.1%) in the absence of background mortality and using the FACS design. In order to 
select which patients in each arm suffered a recurrence, I (pseudo)randomly sampled 
from a discrete distribution where each person’s chance of being selected was equal to 
their risk of recurrence renormalized so that all such probabilities summed to 1. Thus, in 
each of the 2000 simulations of the trial, the arm-specific recurrence rates at 5 years 
matched those observed in the FACS trial.14 Moreover, any underlying recurrence 
imbalance backed out in the previous section (over and above what would be expected 
due to asymmetrical follow-up intensity) was present in every simulation. 
 The first simulation study serves to estimate the statistical power a trial like the FACS 
trial would have to detect a mortality reduction the size of the model-predicted all-cause 
mortality HR. It is based on the sample distribution of the HR estimator assuming the 
model-predicted HR is the true parameter and that both arms had the same underlying 
                                                          
14 Strictly speaking, there was a small amount of variation due to variation in when a few patients’ disease 
was detected (within 5 years or not). However, this was no more than +/- 0.4 %. 
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propensity for disease. Though, given the small number of recurrences, the actual 
observed recurrence rates in each arm will vary from sample to sample. 
 The second simulation study estimates the power the FACS trial had to detect the 
same magnitude mortality reduction except now conditional on the backed-out arm-
specific recurrence rates so that the actual 5-year cumulative incidence of diagnosed 
disease in each arm matched that observed in the trial. It is thus based on the sample 
distribution of the HR estimator conditional on the model and the actual underlying 
recurrence imbalance. The difference between the results of the two simulation studies 
quantifies the loss of statistical power due to the observed underlying recurrence 
imbalance, conditional on the model-predicted true efficacy. 
Using the second simulation study described above, I also estimated the bias induced 
by the chance recurrence imbalance and performed a goodness-of-fit test comparing the 
model with the observed FACS trial results. By bias, I mean the difference between the 
large-sample (or true) model-implied HR and the average HR estimated across repeated 
trial simulations, conditional on any underlying recurrence imbalance. I estimated both 
the absolute bias and the relative bias, and I calculate both on the log scale. The latter is 
defined as the absolute bias divided by the true parameter. Finally, using the resulting 
sample distribution for the all-cause mortality HR estimator (conditional on any 
underlying recurrence imbalance), I calculate the probability of observing a result at least 
as extreme as the actual HR estimate reported for the trial. This probability is analogous 
to a frequentist two-sided p-value. Following the logic of predictive model checking, the 
point is to formally assess whether, given the recurrence imbalance, there are “systematic 
differences between the model and some aspects of the data”.137 
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RESULTS 
Estimation of Efficacy Parameters 
 Table 10 contains the location-, stage-, and adjuvant-therapy-specific simulation 
results. The fourth column of Table 10 lists the average (across parameter sets) 
proportion of recurrences presenting within 5 years for which R0 salvage was possible in 
the intensive (CT + CEA) arm. These varied from 0.37 for stage III colon cancer with no 
adjuvant treatment to 0.47 for stage II colon cancer with FOLFOX. Disease-specific 
mortality HRs comparing the intensive arm to the minimal arm varied from about 0.89 
(stage II colon no adjuvant) to 0.95 (stage II colon FOLFOX). These were influenced by 
the difference between the R0 salvage rate in the intensive arm and the minimal arm, the 
stage of the patients (the expected benefit of salvage is greater on average for stage I/II 
patients), and most importantly the proportion of patients who suffered a recurrence. All-
cause mortality HRs at 5 years ranged from about 0.93 (stage III colon with no adjuvant 
treatment) to 0.99 (stage I colon). These were influenced by the disease-specific hazard 
ratio and the ratio of noise (background mortality) to cancer-specific mortality. 
 For a hypothetical future trial comparing the CT + CEA follow-up regimen to 
minimal follow-up (as depicted in Table 8) and enrolling only stage II and III colon and 
rectal patients, we could expect about 21% of patients to suffer a recurrence within 5 
years and the intensive arm to procure about a 25 percentage-point increase in the R0 
salvage rate. This translates into about a 9% reduction in disease-specific mortality and, 
assuming background mortality rates equivalent to US lifetables, a 5% reduction in 
overall mortality (Table 10). I estimated that in order for such a trial to have an 80% 
chance of detecting that effect (p < 0.05) it would need about 18,000 (+/- 1,000) 
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participants per arm. Thus even assuming there would be no loss to follow-up, the trial 
would need at least 34,000 enrollees. For the comparison of the CT + CEA to CEA-only 
(+ 1 CT scan) follow-up schedules, we could expect about a 6 percentage-point increase 
in the R0 salvage rate and only about a 1% reduction in disease-specific and overall 
mortality hazards at 5 years. At a sample size of 18,000 participants per arm, I estimated 
such a trial would have less than 1% power to detect an effect of such a small magnitude. 
 The model was able to replicate the results of the FACS and GILDA trials reasonably 
well. In general, the model-estimated R0 salvage proportions for each of the four follow-
up regimens of the FAC trial depicted in Table 8 were within a few percentage points of 
the actual FACS-observed rates (Table 10). The only exception to this was the CT-only 
arm. The model-estimated R0 salvage rate – 38% - was quite a bit lower than the rate 
observed in the FACS trial - 46% (95% CI: 34%-58%). However, the trial estimates were 
very imprecise and the model-estimate was within the range of the 95% confidence 
interval. The model-estimated minimal-arm R0 salvage-rate of 17% was closer to the rate 
reported in the per-protocol analysis (14%) of the FACS trial than to the rate reported for 
the intention-to-treat analysis (21%). The latter was influenced by non-trivial 
contamination in the form of additional CT-scans. As can be seen in Table 10, the model-
predicted true effects of the interventions under study were small. We could expect a 6% 
all-cause mortality-hazard reduction in upgrading from the minimal follow-up arm (1 CT 
scan) to the most intensive arm (CT + CEA). For the comparison involving the collapsed 
intensive-arm, this figure was 5%. Moreover, the chance of patients in the collapsed 
intensive arm surviving to 5 years was approximately 1 percentage point greater than that 
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of patients in the minimal arm. For the GILDA trial, we could only expect about a 1-2% 
mortality hazard reduction. 
Table 10: Cohort-Specific All-Cause and Disease-Specific Mortality Hazard Ratios at 5 
Years 
Cohort 
All-Cause Mortality 
HR 
(95% Monte Carlo 
CI) 
Disease-Specific 
Mortality* HR 
(95% Monte Carlo 
CI) 
Model-Estimated 
(Trial-Observed) 
Intensive-Arm Salvage 
Rate# 
Disease-Specific Simulation Results Comparing CT + CEA vs Minimal Follow-up Using US 
Lifetables## 
Stage III Colon 
(FOLFOX) 
0.951  
(0.947, 0.955) 
0.927 
(0.922, 0.932) 
0.39 
Stage III Colon (FU + 
LV) 
0.935 
(0.932, 0.940) 
0.910 
(0.906, 0.915) 
0.38 
Stage III Colon 
(No Adjuvant) 
0.926 
(0.922, 0.930) 
0.909 
(0.905, 0.913) 
0.37 
Stage III Rectal 
0.946 
(0.941, 0.952) 
0.923 
(0.918, 0.927) 
0.41 
Stage II Colon 
(FOLFOX) 
0.980 
(0.975, 0.986) 
0.953 
(0.943, 0.963) 
0.47 
Stage II Colon (FU + 
LV) 
0.957 
(0.952, 0.963) 
0.904 
 (0.896, 0.911) 
0.42 
Stage II Colon 
(No Adjuvant) 
0.938 
(0.932, 0.944) 
0.886  
(0.878, 0.893) 
0.39 
Stage II Rectal 
0.941 
(0.936, 0.946) 
0.897 
(0.889, 0.905) 
0.43 
Stage I Colon 
0.986 
(0.980, 0.992) 
0.941 
(0.929, 0.953) 
0.46 
Stage I Rectal 
0.973  
(0.967, 0.980) 
0.910  
(0.903, 0.917) 
0.44 
Model-Predicted True Effects for a Hypothetical Future Trial Using US Lifetables^ 
Future Trial: CT + 
CEA vs Minimal 
0.948  
(0.945, 0.951) 
0.912  
(0.909, 0.916) 
CT+CEA = 0.41 
Minimal = 0.16 
Future Trial: CT + 
CEA vs CEA 
0.988  
(0.986, 0.991) 
0.978 
 (0.975, 0.982) 
CT+CEA = 0.41 
CEA = 0.35 
Model-Predicted True Effects for FACS & GILDA Trial Simulations** 
FACS Trial 
(CT + CEA vs 
Minimal) 
0.940 
 (0.936, 0.944) 
0.912  
(0.907, 0.917) 
CT+CEA = 0.41 
(0.44;  
95% CI: 0.31-0.58) 
Minimal = 0.17 
(0.21;  
95% CI: 0.11-0.36) 
FACS Trial 
(CT + CEA vs CEA) 
0.992 
 (0.989, 0.996) 
0.986  
(0.981, 0.992) 
CT+CEA = 0.41 
(0.44;  
95% CI: 0.31-0.58) 
CEA = 0.35 
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(0.34;  
95% CI: 0.23-0.47) 
FACS Trial: Collapsed 
Intensive vs Minimal 
0.948 
 (0.945, 0.951) 
0.923  
(0.921, 0.926) 
Intensive = 0.38 
(0.41;  
95% CI: 0.34-0.49) 
Minimal = 0.17 
(0.21;  
95% CI: 0.11-0.36) 
GILDA TRIAL 
0.987  
(0.982, 0.991) 
0.981 
 (0.978, 0.985) 
Intensive = 0.42 
(0.42;  
95% CI: 0.34-0.51) 
Minimal = 0.35 
(0.40;  
95% CI: 0.32-0.49) 
* The disease-specific mortality hazard ratio was calculated in the absence of competing risks.  
# The R0 curative rate in the intensive arm averaged across different parameter sets. 
## Patients in each cohort were 70 years old and 60% were male. 
^ Cohorts were split evenly between stage II and III disease. For Stage III patients 85%, 15%, and 5% were 
assumed to have received FOLFOX, 5-FU/LV, and surgery-only, respectively. These figures were one-
third each for stage II patients. Sixty-percent of patients were male and ages ranged from 40-78 with a 
mean of 68.  
**Follow-up regimens for the FACS (GILDA) trial are given in Table 8 (Table 9). Demographic disease 
characteristics mimicked those in the trial. 
 
An Evaluation of Recurrence Imbalances 
 The model-simulated collapsed intensive arm of the FACS trial had a 5-year 
cumulative incidence of recurrence of 19.2%. This was very close to the 19.4% observed 
in the actual trial. The factor of adjustment was thus only trivially different from 1. The 
corresponding model-simulated 5-year recurrence rate in the minimal arm was 17.7% 
(compared with 14.1% in the real trial). Thus, while we would expect about a 9% 
reduction in the observed recurrence rate in the minimal arm compared to the intensive 
arms in virtue of patients only undergoing 1 CT scan, we observed a 27% reduction. In 
absolute terms, the respective figures are a 1.7 percentage-point reduction and a 5.3 
percentage-point reduction. For the CT + CEA vs CEA only (+ 1 CT scan) comparison in 
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the FACS trial, there was less of an unexplained recurrence imbalance. After the model-
simulated 5-year cumulative incidence of recurrence in the CT + CEA arm was adjusted 
down to 17.1% (from roughly 20%), the model-simulated minimal arm exhibited a 5-year 
recurrence rate of 15.3% (as opposed to 14.1%). For the GILDA trial, the model-
simulated recurrence rate in the intensive arm was 21.4%. This was minimally readjusted 
to get a recurrence rate of 22.0% (that actually observed in the intensive arm of the trial). 
The associated recurrence rate in the control arm predicted by the model was 21.2%. The 
actual observed rate in the GILDA trial was 18.8%. Thus, in all 3 cases the trial control 
arms exhibited a greater drop in recurrence rates compared to the experimental arm than 
would be expected in virtue of asymmetrical follow-up intensity alone. 
Power, Bias, and Goodness-of-Fit Analyses 
 Given the small size of the model-estimated mortality hazard reduction associated 
with the FACS intensive arms, the results of the power calculations are unsurprisingly 
discouraging. Given the recurrence rates exhibited in the 3 intensive arms but ignoring 
the recurrence imbalance, the FACS trial likely had between 1-3% power to detect the 
5% all-cause mortality reduction. The actual point estimate reported in the trial (HR = 
1.15) was barely consistent with the model-estimated sample distribution of the HR 
estimator: 2.5th and 97.5th percentiles equal to 0.74 and 1.15, respectively. However, this 
is less problematic for the causal theory embodied in the model when we consider that 
the observed recurrence rate in the minimal arm of the FACS trial was also extreme. The 
model-estimated 2.5th and 97.5th percentiles of the sample distribution of the minimal-
arm recurrence rate were 13.7% and 22.0%, respectively. The observed rate of 14.1% 
represents the 3.1 percentile of the distribution. However, the observed recurrence rate in 
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the collapsed intensive arm (19.4%) represents the 54th percentile of its corresponding 
sample distribution. It is worth restating that these results assume that participants in 
different arms had an identical underlying propensity for disease (namely that observed in 
the intensive arms) as would be expected across repeated samples of a well-designed 
RCT. The variation in recurrence rates from sample to sample is simply the result of 
randomness and of a small number of patients suffering a recurrence. 
Conditional on the observed chance recurrence imbalance15, the FACS trial had 
essentially 0% power (95% CI: 0%, 0.7%) to detect the 5% mortality reduction. Though, 
I showed above that it would have also had close to 0% power in the absence of the 
recurrence imbalance. Moreover, the log-HR estimator was biased upwards by 0.19 (95% 
Monte Carlo CI: 0.18-0.21) due to the low recurrence rate in the control arm. The 
magnitude of this bias is 3-4 times the size of the model-estimated true effect (-0.05). On 
the HR scale, the trial-reported point estimate of a 15% increase in the mortality hazard in 
the intensive arm was identical to the model-predicted expected value of the estimator 
conditional on the recurrence imbalance: 𝐸[𝐻?̂?] = 1.15 (95% Monte Carlo CI: 1.14-
1.17). There was thus no evidence of inconsistency between the predictions of the 
simulation model and the results of the trial (P = 0.95). 
DISCUSSION 
                                                          
15Strictly speaking, by ‘conditional on the observed chance recurrence imbalance’, I mean conditional on 
the discrepancy between arms in terms of the underlying propensity for disease that was backed out so as to 
lead to the observed recurrence imbalance (taking into account the arms faced asymmetrical follow-up 
intensities) 
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 The above results illustrates three main points. The first is that, if the benefit of 
intensive surveillance comes from earlier detection of recurrence leading to increased 
chances for curative resection, the benefit is small. Depending on the disease stage and 
location and the adjuvant chemotherapy received, providing patients with routine CT 
scanning and CEA testing can be expected to reduce overall-mortality hazards by about 
1-8 percent compared to offering just 1 CT scan at 12-18 months. In the case of the 
FACS and GILDA trials, the hypothesized true benefits of the interventions under study 
were roughly a 5 and 1 percent reduction in mortality hazards at 5 years, respectively. 
The second point is that although the FACS and GILDA trials were the largest and 
most relevant trials they had no chance to detect the above hypothesized effects. The 
authors of the report on the FACS trial estimated that they had a 31% chance of detecting 
a 5 percentage-point increase in the survival proportion at 5 years. However, the model-
predicted survival risk-difference at 5 years was only 0.01 (rather than 0.05), and the trial 
had less than a 2% chance of detecting that effect. While I did not perform a formal 
power analysis on the GILDA trial, it is obvious that the chance of detecting a 1-2% 
mortality hazard reduction at 5 years with a trial of roughly 1,230 patients is trivial. 
The third point is that it is very unlikely that a trial with adequate power to detect 
such a small hypothesized effect would ever or could ever be performed. There are 
roughly 150,000 new cases of CRC per year in the US. In order to enroll 36,000 patients 
over the course of 5 years, this would require enrolling approximately 5% of new cases 
per year. In this context, it is worth noting that only about 3% (1.5%) of US adult cancer 
patients under 65 (≥65) years old participant in any randomized control trials, let alone a 
single trial.138 In reality, such a trial would likely require coordination across North 
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America, Europe, and likely Asia. It is worth noting that the FACS (confined to the UK) 
trial had originally planned to enroll a sufficient number of patients to have 80% power to 
detect a 5 percentage-point risk difference in survival at 5 years but, because of poor 
enrollment, was forced to abandon that goal and change its primary endpoint to a risk 
difference of R0 salvage rates. Similarly, the GILDA trial had originally planned to enroll 
around 4,000 participants with the hopes of detecting an overall mortality reduction of 
20% (HR = 0.8) at 5 years but also had to drop that goal due to poor enrollment. The 
hypothetical trial considered here would require roughly 6-10 times as many patients. 
Finally, it is also unclear if such a logistically complex and inevitably expensive trial 
would even be worth the cost and thus whether it should ever be performed. 
 Given contemporary recurrence rates, it is unlikely that an RCT of intensive follow-
up will ever settle this issue. The most efficient and probably only realistic way to 
determine if intensive follow-up could even offer the small benefit hypothesized to be 
associated with an increased rate of curative resection would be to investigate the 
efficacy of salvage surgery directly. The idea would be to aggressively follow-up a large 
cohort of CRC patients after curative resection of primary disease and then randomize all 
patients identified as having ‘resectable’ recurrent disease to attempted curative resection 
or conservative treatment. If the trial failed to show a benefit for salvage surgery, we 
could seriously consider throwing in the towel on intensive follow-up. On the other hand, 
a documented survival advantage from surgical resection with a curative intent would 
corroborate the thesis of this paper and support the use of intensive follow-up. Though 
the question of what follow-up regimen to use would remain an open question. A 
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feasibility study is currently underway in the UK to assess whether it will be possible to 
conduct a RCT to assess the efficacy of pulmonary metastectomy.139 
 My results suggest that there was indeed a chance recurrence imbalance between the 
collapsed intensive arm and the minimal follow-up arm of the FACS trial. Given the 
main two points made above (a small benefit and essentially no power), the recurrence 
imbalance is really an issue of secondary importance. However, it is relevant to one 
possible criticism. Most of the trials in earlier meta-analyses found a non-significant 
mortality reduction from intensive follow-up compared to minimal or no follow-up. It 
might be expected that we should see a similar small benefit, even if nonsignificant, in 
the FACS and GILDA trials, but instead we saw the opposite (HR > 1). By examining the 
likely effect of the recurrence imbalance, I have shown that the results we saw in the 
FACS trial are exactly what the model would have predicted in the presence of such a 
recurrence imbalance. 
The recurrence imbalance was notably smaller when comparing the routine CT and 
CEA arm to the minimal follow-up arm. It is likely that a direct comparison of these two 
arms would represent a less biased estimate of the true effect. Unfortunately, this result is 
not reported in any of the reports of the FACS trial. When I used methods described in 
Parmar et al., (1998)42 and Tierney et al., (2007)43 to estimate the HR based upon 
digitized survival curves, I estimated an all-cause mortality HR of 0.94 (95% CI: 0.63-
1.14) comparing the routine CT and CEA arm to the minimal arm. Unfortunately, the 
quality of the published figure and thus these results is unclear. However, if 
approximately correct this point estimate would nearly match the model-estimated true 
effect for this comparison. 
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I did not conduct the same formal analysis for the GILDA trial. However, given the 
model-predicted true effect of only a 1.3% mortality hazard reduction at 5 years and the 
demonstrated presence of a small recurrence imbalance that could not be attributed to 
asymmetrical follow-up intensities, the trial result of a nonsignificant 15% increase in 
mortality in the intensive arm is not surprising. 
 It is unclear whether the recurrence imbalance in the FACS trial arose because of an 
imbalance in risk factors for recurrence or because of random variation and a small 
recurrence size. My analyses suggest there would be roughly a 6 percent chance of the 
minimal arm exhibiting a recurrence rate at least as extreme (high or low) as that 
observed in the real trial if both it and the collapsed intensive arm had the same 
underlying risk of recurrence. The randomization scheme involved a minimization 
algorithm to increase the chances of balance among patient age, sex, and adjuvant 
treatment. A relatively good balance was achieved with regards to location of tumor 
(rectum, left colon, or right colon) and stage (I-III). However, it is possible there could 
have been an imbalance in other risk factors such as tumor grade or N and T status within 
stage (e.g., N1 vs N2 or T3 vs T4). Anyhow, regardless of the true cause, the effect was 
the same. 
 My analyses demonstrated that the observed recurrence imbalance was larger than 
any anticipated imbalance due to different intensity of follow-up and that the size of this 
residual imbalance was enough to dominate the model-predicted true effect size. The fact 
that the CT-only and CEA-only (+ 1 CT scan) arms had a cumulative incidence of 
recurrence roughly 3 percentage points higher (20.5% vs 17.1%) than the most intensive 
arm (routine CT + CEA) corroborates this result. There is no reason to expect such an 
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asymmetry to arise from follow-up differences. Moreover, prior empirical work further 
supports the validity of this conclusion. Trials of intensive surveillance have generally 
spanned 5 years after primary surgery. As mentioned earlier, a large majority of 
recurrences of any type will present within 5 years, a statistic that has been observed 
outside of trials of intensive surveillance. This is particularly true among stage II and III 
patients, the very patients who will present with most of the recurrences. The initial 
report on the FACS trial results was published prior to a median of 5 years of follow-
up46, but the recent manuscript summarizing the mature results (which were used in my 
analyses) reported a slightly amplified imbalance after a median (minimum) follow-up of 
8.7 (5) years.45 It is thus very unlikely that there would be many recurrences in either arm 
if follow-up continued. Aside from the smaller imbalance observed in the GILDA trial, 
the only other trial which demonstrated a non-trivial recurrence imbalance had the 
opposite outcome – more recurrences in the control arm.41 A more plausible explanation 
of this phenomenon is that stratification of the randomization procedure on stage (I-III, as 
opposed to say the American Joint Committee on Cancer TNM system) and/or adjuvant 
chemotherapy is insufficient to reduce the chances of a non-trivial recurrence imbalance 
across arms to an acceptable level in the presence of a low risk of recurrence and small 
trial sizes. 
 Still, a skeptic may suggest that perhaps there is a fundamental difference between the 
earlier-detected and later-detected recurrences in that the latter are far less aggressive and 
possibly in some cases not fatal. Perhaps some of these cases never would have even 
presented as clinical disease in a typical patients’ remaining lifetime. That is, perhaps 
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these extra recurrences represent a form of over-diagnosis, similar to the much-discussed 
concept in a screening context.140 
 However, this response is unsatisfactory. It is very unlikely that there is much use for 
the concept of over-diagnosis with respect to CRC recurrence. While there is evidence 
that patients with recurrence diagnosed after 3 years tend to have a slower-moving 
natural history56, a large cohort study found no difference in time to death between 
patients diagnosed with recurrence between 2-5 years and those diagnosed after 5 years54. 
Anyhow, since recurrence generally represents systemic disease, it is almost always fatal 
without curative resection. For example, approximately 75% of patients diagnosed with 
recurrence four years after treatment for the primary cancer will be dead within 5 years 
after recurrence.56 It is also worth noting that the model heterogeneity parameters were 
calibrated so as to recreate the phenomenon of slower-moving natural history among 
patients diagnosed 3 years or after and my analyses still found the recurrence imbalance 
lead to a bias of a magnitude roughly 3-times larger than the model-predicted true effect 
size. 
The argument of this paper is also relevant to the interpretation of two large RCTs 
evaluating intensive follow-up that are currently in progress. The Scandinavian 
COLOFOL trial141 (N = 2,500) has closed enrollment and is likely to report results very 
soon. The trial compares abdominal CT, chest x-ray, and CEA assay at 6, 12, 18, 24, and 
36 months vs. at 12 and 36 months among stage II and III patients. The French FFCD 
PRODIGE 13 trial142 (N = 2,000) is nearing the end of its scheduled follow-up. Like the 
FACS trial it uses a 2x2 design, comparing two intensive imaging strategies (one with 
abdominal/pelvic/thoracic CT and one with just ultrasound) and the use of CEA vs no 
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CEA among stage II and III patients. It is extremely unlikely that either trial will detect 
any significant mortality benefit. If they did, it would suggest that intensive follow-up 
likely confers a survival advantage over and above that attributable to the increased rate 
of curative resection. For example, it was previously suggested143 that intensive follow-
up might improve overall survival via providing increased psychological support or 
through earlier detection and better management of other medical conditions. This would 
be particularly relevant for earlier trials in which patients in the control arm underwent no 
or very limited follow-up. 
Another possible source of benefit from intensive follow-up would be the existence of 
a survival advantage among patients with unresectable and thus terminal disease from 
commencing systemic chemotherapy while the disease was still asymptomatic. There is 
weak evidence from a single randomized control trial to support the existence of such a 
benefit.144 The trial (N = 183) randomized patients with advanced and unresectable yet 
asymptomatic CRC to immediate treatment with chemotherapy (5-FU/LV) or to a 
conservative approach that waited to start chemotherapeutic treatment until symptoms 
developed. The latter mimicked a counterfactual world in which the recurrent disease was 
not detected until symptomatic. There was a borderline significant survival benefit 
(increase of median survival by 5 months) among those randomized to immediate 
chemotherapy. The benefit appeared immediately and then diminished until it had 
completely disappeared by 12-18 months. A log-rank test failed to reject the null 
hypothesis after 3 years, but a Breslow-Gehan test was significant (P < 0.02). This latter 
hypothesis test prioritizes discrepancies between two survival curves that occur earlier 
on.122 There appears to be no further experimental evidence regarding such an effect, 
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perhaps for ethical reasons. Given the small size of the trial, the questionable 
significance, and the reality that treatment of terminal systemic disease has changed 
dramatically (with the development of new chemotherapeutic agents and targeted 
biological agents), it is unclear if such a benefit really exists or, if it once did, would still 
exist in contemporary practice. 
The existence of such a benefit (roughly 5-months of extra life-expectancy from 
stating systemic chemotherapy before symptoms appear) along with the very high 
recurrence rates previously exhibited by CRC patients could help explain the more 
promising results of earlier trials and meta-analyses. That is, if the typical patient with 
recurrence received a 5-month survival advantage from asymptomatic detection (over and 
above any lead time) even if no curative resection was performed, and if 40-70% of 
patients suffered a recurrence, it would not be surprising if intensive follow-up lead to a 
notable mortality reduction. For example, the largest and most precise benefit found in 
the earlier trials was in Secco et al. (2002).41 The description of this trial was somewhat 
unclear, but it appears to have enrolled only rectal cancer patients. Moreover, the trial 
used stratified randomization based upon the risk of recurrence (high vs low risk), and, in 
the high-risk groups, roughly 70% of patients suffered a recurrence. In addition, high-risk 
patients in the experimental arm underwent intensive imaging while the same patients in 
the control arm had no scheduled follow-up. Unfortunately an all-cause mortality HR was 
not reported for either risk-stratified group or overall. However, using the previously 
mentioned methods42 43 and digitized survival curves, I estimated that high-risk 
participants of the experimental arm exhibited a nearly 40% reduction in the mortality 
hazards at 5 years (HR = 0.61; 95% CI: 0.42, 0.87). 
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This combination of factors may shed light on previous results. However, given 
contemporary recurrence rates, and in light of the results presented in this paper, it is 
unreasonable to expect to replicate anything close to the 25% mortality-hazard reduction 
(HR = 0.75; 95% CI: 0.66-0.86) that was reported in a 2015 meta-analysis.37 The 
subsequent review by Jeffery et al., (2016)47 reported a meta-analytic all-cause mortality 
HR of 0.90 (95% CI: 0.78-1.02). Although this estimate does not rule out the possibility 
of no benefit on average, this is consistent with the existence of a benefit of the 
magnitude suggested by my analyses. Moreover, given the extremely large sample size 
that would be needed in order for a single trial to have reasonable power to detect the 
hypothesized effect, even if such a benefit existed it would not be surprising that a meta-
analytic interval estimate was unable to exclude no-effect on average. 
The most recent review by Mohkles et al., (2017)48 estimated an all-cause mortality 
meta-analytic HR of 0.98 (95% CI: 0.87-1.11). A thorough evaluation of the decisions of 
these reviewers is beyond the scope of this paper, but some of them can certainly be 
questioned. Firstly, they excluded the above-mentioned trial Secco et al., (2002). The 
reviewers are right that there was an unexplained imbalance in arm sizes. Though, the 
authors did refer to a randomization process. However, the reviewers oddly and 
incorrectly claim that the trial results did not appropriately address censoring but instead 
excluded all such patients. Anyhow, this trial is not the only trial with a potentially 
concerning risk of bias. The GILDA trial (which they included) suffered from a sizable 
attrition problem with about 27-29% of participants in each arm being lost to follow-up 
over the course of 5 years. This figure does not include patients who exited follow-up 
because they (a) developed a new and unrelated type of malignancy or (b) died from 
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other causes. In fact, no reasons are given for why patients were lost to follow-up. 
Though admittedly there was not any serious asymmetry between trial arms, and the 
analysts did use appropriate methods to adjust for time on study and censoring. However, 
there is no mention or discussion of use of death registries to monitor the vital status of 
lost patients, and so it is unclear if the investigators had access to participants’ health 
records, disease-status, or vital-status. 
 Secondly, the random-effect model reported in Jeffery et al., assigned the CEASL 
trial (mentioned in the introduction) 50% of the weight even though it is unclear how 
relevant the trial is to contemporary practice. The ‘intensive’ arm of the CEASL trial 
bears little resemblance to any surveillance protocol that would be considered today. 
Unlike most of the other earlier trials, it included no imaging studies, e.g., abdominal US 
or chest x-ray, and no endoscopy. It is also unclear if surgeons based decisions on 
whether to operate or not on any type of diagnostic imaging to verify that recurrence was 
causing the elevated CEA levels. The suspicion that these were not performed is 
corroborated by the very high attempted salvage rate in the ‘intensive’ arm. Terminology 
is unclear, but it appears that 68% of the 108 patients randomized to the ‘aggressive’ arm 
underwent at least an exploratory ‘minimal-laparotomy’ and about 84% of these patients 
proceeded to a full laparotomy. In most of the other trials conducted around the same 
time (1980’s), the treatment arm exhibited a salvage rate of under 30%. These other trials 
included routine endoscopy and imaging in their intensive arms and so would have likely 
had a better (i.e., earlier in the natural history process) risk-pool of patients to work with 
and thus higher salvage rates. Thus it seems likely that the ‘aggressive arm’ performed 
what would now be considered inappropriate surgery on a massive scale. At the time of 
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the CEASL trial, 30-day surgical mortality rates of over 5% were common.145 This could 
certainly have watered down any potential benefits from attempted salvage surgery. 
CONCLUSION 
 I have argued that it is misguided to interpret the negative results of the FACS and 
GILDA trials as evidence of no benefit of intensive surveillance and particularly as 
evidence of no benefit from aggressive surgical treatment of recurrence. While it is true 
that the trials failed to show evidence of benefit, the trials likely had no chance of 
detecting the hypothesized effect, and the results of the FACS trial (a median survival 
after curative resection equivalent to that reported in case-series) were consistent with the 
theory that a large portion of patients with recurrence can benefit from curative resection. 
These facts should be considered in future iterations of professional guidelines. 
 Although these conclusions depend on the validity of the microsimulation model 
described in Chapter 2, there is good reason to believe it adequately reflects the important 
characteristics of disease natural history and the process of disease detection and 
treatment to offer valuable insight into the clinical problem. As shown in Appendix B, the 
model was generally able to replicate the time-to-diagnosed-recurrence hazard rates well. 
It also mimicked two important characteristics of natural history that could influence an 
evaluation of surveillance: (1) patients who present with a shorter disease-free interval 
tend to have a quicker time to death in the absence of surgical cure and (2) patients with 
node-positive primary disease face a worse prognosis after an attempted curative 
resection. These matter because most recurrences occur earlier and a higher proportion of 
stage III patients suffer recurrence. The model was also able to recreate differences in the 
R0 salvage rate across disease stage (Table 10) - with more option for salvage among 
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stage I and II patients45 146 - even though I did not explicitly model this phenomenon of 
between-stage variation in salvageability. This suggest that this variation may arise from 
differences in the timing at which patients present with recurrent disease or differences in 
sojourn time rather than say stage III patients tending to exhibit more widely-
disseminated disease. The model also generally was able to recreate the R0 salvage rates 
of the FACS and GILDA trial arms. Finally, the mortality experience of patients treated 
palliatively and with surgical cure mimicked that reported in randomized control trials 
and/or unselected cohort studies, respectively. 
In the absence of a direct RCT of the efficacy of salvage surgery or an extremely 
large and probably impractical trial of intensive follow-up, future guidelines and clinical-
practice decisions will have to be made with only weak and inconclusive evidence. Some 
will balk at continuing to recommend a clinical protocol for hundreds of thousands of 
patients without any clear experimental evidence. The risks here are wasted medical 
recourses, unnecessary morbidity and mortality associated with salvage surgery, and 
wasted patient time. However, there are risks associated with prematurely backing away 
from aggressive follow-up. If there is indeed the projected benefit represented by the 
microsimulation model, reducing the intensity of follow-up or scraping it altogether could 
deprive patients of life-prolonging and in some cases life-saving procedures. 
Given the small size of the hypothesized benefit, it may be the case that intensive 
follow-up regimens are not cost-effective, particularly those involving intensive imaging. 
It is thus worth considering what the optimal schedule of CT imaging follow-up would be 
if the hypothesized benefit did in fact exist. Given the corroborating empirical evidence 
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in support of the efficacy of aggressive salvage surgery discussed above, following such a 
strategy might represent a reasonable compromise. In Chapter 4, I turn to this task. 
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CHAPTER 4:  
A Cost-Effectiveness Analysis of Alternative Post-Diagnosis 
Surveillance Strategies for Colorectal Cancer 
 
INTRODUCTION 
 As explained in Chapter 1 of this dissertation, the stated goal of routine extra-colonic 
surveillance following curative resection for stage I-III CRC is to detect late-occurring 
metastatic disease or extramural local-regional recurrence while the disease is 
asymptomatic and hopefully sufficiently isolated to be amenable to curative resection, 
i.e., salvage treatment. As a reminder, multiple meta-analyses have pooled the results of 
different combinations of the 13 RCTs that have evaluated alternative intensities of 
surveillance, 11 of which evaluated more vs less intensive extra-colonic-focused 
modalities (as opposed to endoscopic surveillance). While earlier meta-analyses found 
intensive follow-up using CEA testing and radiological imaging reduced overall 
mortality, the two most recent analyses concluded that it failed to provide such a benefit. 
This in turn was partially driven by the selection of what studies to include but mostly by 
the recent publication of 3 trials – the FACS, GILDA, and CEASL trials - showing 
intensive surveillance was associated with a non-significant increase in the mortality 
hazard. 
 In Chapter 3 of this dissertation, I argued that there was evidence (albeit arguably 
weak and certainly non-experimental) for the theory that curative surgical resection could 
offer a survival advantage for patients who suffer a recurrence, even when performed at 
aggressive levels (e.g., 30-40% of patients who undergo routine surveillance). Moreover, 
I argued that, even though the FACS and GILDA trials were the largest and most recent, 
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it was a mistake to interpret their negative results as evidence of there being no benefit 
from such follow-up. I showed that if intensive extra-colonic surveillance did in fact 
confer a survival advantage in virtue of increasing the chances of clear-margin surgical 
resection of recurrent disease then the benefit would be extremely small when averaged 
over an entire cohort of patients undergoing such surveillance. As such, even ignoring the 
recurrence imbalance observed in the trials (particularly the FACS trails), the FACS and 
GILDA trials would have had only trivial power to detect such an effect. Moreover, I 
questioned the relevance of the CEASL trial and some of the inclusion/exclusion 
decisions made by the authors of the most recent meta-analyses and suggested that an 
alternative attempt at systematic review and meta-analysis would likely find a small 
(<10%) but non-significant reduction in all-cause mortality hazards on average. Finally, I 
argued that, unfortunately, it likely will not be logistically or financially feasible to enroll 
a sufficient number of patients to settle this issue with a new RCT evaluating intensive 
surveillance. An alternative possibility that some will no doubt find objectionable would 
be to conduct a large RCT directly evaluating surgical resection with curative intent by 
randomizing all patients with ‘resectable disease’ identified in a program of intensive 
surveillance to surgical resection or palliative care. 
In the absence of such evidence, policymakers and panel members responsible for 
issuing professional-society guidelines face a difficult choice. Should they recommend 
patients undergo, and reimburse for, intensive extra-colonic surveillance even though 
such a practice is not supported by anything more than weak evidence? Or should they 
take a more conservative approach and balk at recommending or paying for medical care 
that is not grounded in experimental evidence. In this context, a cost-effectiveness 
100 
 
analysis could be fruitfully used to shed light on the decision-problem. In particular, a 
cost-effectiveness analysis using a decision-analytic model could identify what levels of 
extra-colonic follow-up would be optimal, and thus are worth considering, if extra-
colonic follow-up does in fact offer a survival advantage in the manner hypothesized. 
That is, because of the low number of patients who might benefit, it is possible that 
aggressive extra-colonic surveillance would not be worth the costs even if it was 
beneficial. In this case, establishing evidence of efficacy would be a moot point. 
Several reports have evaluated the cost-effectiveness of competing post-diagnosis 
endoscopic surveillance strategies aimed at preventing and detecting second primary 
CRCs.147 148 However, to date there have been few attempts to evaluate the cost-
effectiveness of alternative extra-colonic-focused follow-up strategies for patients who 
undergo curative resection for locally-advanced (stage II and III) CRC. Using the results 
of one of the earliest meta-analyses, Renehan, et al., (2004)149 compared ‘intensive 
surveillance’ with ‘minimal surveillance’ using a 5-year time-horizon (that of the trials). 
They estimated ICERs of about 3,500-5,500 British Pounds Stirling (2017). However, 
this is of limited value because it is based only on the earliest 5 trials in which recurrence 
rates were much larger. It also does not help settle the question of whether 1, 2, 3, or 
some other number of CT scans should be offered but instead groups together and 
compares a heterogeneous set of strategies. Finally, it is unlikely that cost estimates from 
the UK in 2002 are meaningful for US policymakers in 2018. Park, et al, (2001)150 
evaluated offering a CT + FDG PET scan in place of just a CT scan to patients with 
suspected recurrence due to elevated CEA levels. However, this addresses a different 
decision problem than that considered here. Rose, et al., (2014)151 described a simulation 
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model of CRC recurrence overlain with surveillance and expressed the intention to use it 
to identify optimal follow-up strategies. However, no such analysis has appeared in the 
literature to date. Lee-Ying, et al., (2017)152 evaluated intensive follow-up among patients 
with limited metastatic disease who undergo curative resection. However, these patients 
differ notably from stage II and III patients in that their risk of recurrence is much 
greater. Gazelle, et al., (2003)153 evaluated the cost-effectiveness of surgical resection 
with a curative intent for diagnosed metachronous liver metastases but did not include the 
costs of routine surveillance for an entire cohort of patients following resection for 
primary CRC. The cost-effectiveness of post-diagnosis extra-colonic surveillance for 
locally-advanced CRC thus remains an open question. 
In this paper, I use the microsimulation model described in Chapter 2 to conduct a 
cost-effectiveness analysis of alternative extra-colonic-focused follow-up strategies for 
locally-advanced CRC patients using a lifetime time horizon and taking the perspective 
of the US health care system. I consider six different strategies based largely on the most 
recent US guidelines. Again, the full guidelines are given in Table A.1. While there is 
some discrepancy among different organizations, they generally call for routine clinical 
visits and CEA testing every 3-6 months for 5 years as well as annual CT scans for 3-5 
years for stage II and III patients. 
METHODS 
In this paper, I compare (i) no routine CEA or CT follow-up (no surveillance), (ii), a 
single CT scan at 12-18 months (as considered in the FACS trial), (iii) current US 
guideline-level CEA testing and a single CT scan at 12-18 months, and guideline-level 
CEA testing and annual CT scans for (iv) 2, (v) 3, and (vi) 5 years. The six different 
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strategies are depicted in Table 11. For all analyses in this paper, I assumed compliance 
would be 100%. I justify and comment on the importance of this assumption in the 
discussion section. I did not attempt to compare 4 and 5 years of annual CT to 3 and 4 
years, respectively, because exploratory analyses suggested that the Monte Carlo sizes 
needed to acquire sufficiently precise estimates of the ICERs were prohibitively large. 
For the main analyses, the different surveillance schedules were compared using the 
ICER in terms of costs per additional life-year. This is defined as the ratio of the 
incremental costs to the incremental effectiveness, comparing a more effective (and 
generally more expensive) intervention to a less effective (and generally less expensive) 
intervention. The analyses use a lifetime horizon and thus the incremental effectiveness is 
the increase in remaining life-expectancy (LE) in years. Moreover, the perspective of the 
US healthcare system is taken so the incremental cost is the increase in mean overall 
medical costs. The included costs are discussed in detail below. The ICER is properly 
interpreted as the cost we would pay for each additional year of LE achieved in virtue of 
upgrading from a standard intervention to a more effective yet generally also more 
expensive intervention. 
COHORTS 
As discussed in Chapter 2, stage II patients face better prognosis after clear-margin 
salvage surgery than do stage III patients, and this phenomenon was explicitly 
incorporated into the model. Moreover, as shown in Chapter 3, the model predicts that 
they would have a higher salvage rate than stage III patients (see Table 10). On the other 
hand, stage II patients also face a notably lower recurrence rate. Thus, a priori, it is 
unclear if and how optimal follow-up would differ between stage II and III patients. 
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Similarly, it is unclear if and how optimal follow-up might differ between colon and 
rectal cancer patients. As will be explained below, the two types of disease lead to 
different costs for salvage therapy and surveillance. In addition, stage III colon cancer 
patients might be expected to benefit more from intensive follow-up than stage III rectal 
cancer patients due to the greater recurrence rate among the former population. The same 
idea applies to stage II rectal cancer patients who face a greater recurrence rate than stage 
II colon cancer patients.  
Finally, the age of the patients is relevant because the benefit conferred by 
surveillance is a small chance to notably postpone or even prevent death from cancer. In a 
population with higher background risk of mortality, this benefit will be less valuable. 
Accordingly, different surveillance schedules were thus evaluated separately by stage (II 
and III), location (rectal and colon) and age (60, 65, 70, and 75). Patients in the last age 
group face a greater risk of surgery-related mortality (5% vs 2%), but otherwise the age-
specific cohorts differ with respect to the effectiveness components of the model only in 
their background mortality rates. In the youngest two cohorts (60 and 65 years old), 58% 
of patients were male, and in the other two cohorts 55% were male. This reflects the 
actual age-category-specific sex distribution among new cases of CRC in the US 
population.1  
For stage II and III rectal cancer patients (as described in Chapter 2) the simulated 
cohorts represent the disease experience of patients initially treated with adjuvant 5-
FU/LV and possibly neoadjuvant radiation therapy and patients initially treated with both 
neoadjuvant chemoradiation therapy and adjuvant chemotherapy using a FOLFOX 
regimen, respectively. For the stage II and III colon cancer cohorts, however, it was 
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necessary to select the proportion of patients receiving adjuvant chemotherapy. The goal 
was to mimic the utilization that would occur among the cohort of US colon cancer 
patients of the corresponding stage and age who undergo routine follow-up. The assumed 
rates of utilization of each regimen are given in Table 12. The estimates for stage III 
patients were taken from tables provided by Professor Kuntz based on an analysis SEER-
Medicare data (Personal Communication). While recent estimates in the literature suggest 
only about two-thirds of stage III colon cancer patients in the US actually receive 
adjuvant chemotherapy136, these rates are higher among younger patients and those with 
less serious comorbidity154 - the sort of patients who are more likely to undergo intensive 
surveillance. For stage II, estimates from the literature based on incident cases in the 
National Cancer Database from 1998-2006 put adjuvant utilization at around 40% for 
patients 65 and under, with about 2/3 of these patients receiving double-agent 
regimens.155 Estimates of the utilization of any adjuvant chemotherapy among the 70- 
and 75-year-old stage II cohorts were taken from an analysis of incident cases in the 
SEER-Medicare linked database over the period of 1992-2005.156 I assumed a smaller 
proportion of these patients used double-agent regimens (FOLFOX) since the previous 
reference155 documented a notable decline among patients over 65. 
Table 11: Follow-up Regimens under Investigation 
Follow-up 
Arm 
Test 3 6 9 12 15 18 21 24 30 36 42 48 54 60 
Arm 1: No 
Follow-up 
CT               
Arm 2: 1 
CT 
CT     X          
Arm 3: 
CEA + 1 
CT 
CT     X          
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Arm 4: 
CEA + 2 
CTs 
CT    X    X       
Arm 5: 
CEA + 3 
CTs 
CT    X    X  X     
Arm 6: 
CEA + 5 
CTs 
CT    X    X  X  X  X 
Arms 3-6 CEA  X X X X X X X X X X X X X 
Table 11 depicts the schedules of CEA assays and CT scans for the 6 Arms of extra-colonic 
follow-up evaluated in this cost-effectiveness analysis. Arms 1 and 2 have no CEA follow-up. 
 
Table 12:Utilization of Adjuvant and Palliative Chemotherapy by Cohort Age and Stage 
Disease Context Age FOLFOX 
5-FU/LV 
(Fluoropyrimidine) 
None 
Stage III 
Colon 
Adjuvant 
60 90% 5% 5% 
65 75% 15% 10% 
70 60% 25% 15% 
75 35% 35% 30% 
Stage II 
Colon 
Adjuvant 
60 27% 13% 60% 
65 27% 13% 60% 
70 18.5% 18.5% 63% 
75 9% 19% 72% 
Unresectable 
Recurrence 
(Rectal and 
Colon) 
Palliative 
60 100% 0% --- 
65 100% 0% --- 
70 75% 25% --- 
75 50% 50% --- 
Table 12 gives the percent of colon cancer patients assumed to use FOLFOX, 5-FU/LV, or no 
chemotherapy in an adjuvant setting by the age and stage. By adjuvant setting, I mean as part of 
the initial treatment for the primary CRC tumor. It also gives the percent of patients (colon or 
rectal) with unresectable recurrence treated with FOLFOX and a single-agent fluoropyrimidine 
regimen. 
 
 It was also necessary to make an assumption concerning the treatment (single-agent 
or double-agent cytotoxins) received by patients with unresectable recurrence (Table 12).  
I assume that all patients healthy enough to partake in routine surveillance who then 
develop unresectable recurrence are at least treated with a single-agent first-line regimen 
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of systemic chemotherapy, e.g., 5-FU, and that most are treated with a double-agent 
regimen, namely FOLFOX. Younger and healthier patients are more likely to be treated 
with double-agent chemotherapy157 158, so I assumed all patients in the 60- and 65-year 
old cohort would be treated with FOLFOX. For the 70- and 75-year old cohorts, my 
assumption was based on estimates from an analysis of SEER-Medicare data using 
incident cases of stage IV CRC in 2009.159 
In order to increase the efficiency of the simulations, I used a variance-reduction 
technique. For each cohort e.g., 65-year-old stage III colon cancer patients, I simulated 
six nearly identical arms of patients who were exposed to different surveillance regimens. 
That is, I first defined a heterogeneous cohort of different patients who varied with 
respect to sex, heterogeneity16 terms, recurrence-status, time of death from other causes, 
etc. I then replicated this cohort five times to make a total of six treatment-arms. Thus 
every individual appeared in each of the six different treatment arms. Such replicated 
individuals were identical in terms of age at the start of the simulation, sex, adjuvant 
treatment received, heterogeneity terms, recurrence-status (yes or no), time to detectable 
and clinical disease (if they suffered a recurrence), time of death from other causes (based 
on lifetables), and whether they received 5-FU or FOLFOX in the event of unresectable 
recurrence. The only differences across replications of the same individual were the 
follow-up received and the results of any pseudorandom simulations that were event-
dependent (with the exception of time to detectable and clinical disease). For example, if 
                                                          
16 As a reminder to the reader, there were 3 correlated heterogeneity terms at the individual level. These 
were for the time-to-detectable-disease process (latency time), the time-to-clinical-disease process (sojourn 
time), and the time-to-cancer-death processes. 
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multiple versions of the replicated individual presented with clinically-detected disease, it 
is possible one would have resectable disease while the others might not. Similarly, one 
might die of salvage surgery while another might be cured. 
ANALYSES 
 For each age-, stage-, and location-specific cohort, the model simulates the 
(remaining) life course of patients in the six different treatment arms and calculates the 
cumulative costs of surveillance and treatment for recurrence (explained below). As 
noted in Chapter 2, time of death from other causes was simulated from the most recent 
sex-specific US lifetables available from the National Center for Health Statistics.160 The 
probability of dying during the 100th year was readjusted so that no patients lived to be 
older than 100. 
 The effectiveness of each follow-up regimen is evaluated by the LE among all 
patients in the treatment-arm, and the incremental efficacy is equal to the increase in LE 
in moving to the more intensive intervention, i.e., adding another CT scan. Since the 
proportion of patients who benefit at the margins, i.e., with the addition of the last CT 
scan, is likely to be very small, the change in LE among the entire treatment arm is likely 
to be extremely small for some comparisons. This may lead readers to conclude that more 
intensive follow-up is not clinically relevant. However, this may not be the case. A 
moderate benefit that applies to only a (very) small proportion of patients will appear 
small when it is averaged over a large cohort. And certainly, because costs accrue to all 
patients who undergo the follow-up regimen, the ex-ante expected benefit of the 
intervention (averaged over the entire treatment arm) is the appropriate measure to 
compare with average costs in a decision analysis. However, a very small average benefit 
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should not be dismissed simply because of its size. Rather, that is the point of also 
calculating the mean incremental costs and calculating ICERs. In order to aid the reader 
in avoiding the previously mentioned natural yet problematic intuition, I also estimate the 
incremental mean benefit among patients who suffer a recurrence. That is, I calculate the 
increase in LE, from the beginning of the simulation, among patients who eventually 
suffer a recurrence. The point of calculating LE from the beginning of the simulation 
rather than from the time of recurrence is to avoid lead-time bias whereby patients with 
more intensive follow-up simply have their disease detected earlier. However, I only 
report the results of this calculation for 65-year old stage III colon cancer patients. 
For the reference-case analysis, both life-years and costs were discounted at 3%. 
However, I also performed the analyses with a 0% discount rate. Because of the discrete-
event simulation framework of the model, I used constant exponential discounting161 to 
adjust for the timing of costs and benefits. The instantaneous rate of discounting 𝜆⁡was 
backed out so that the value of the exponential discount function at exactly 1 year was 
equal to the discount factor at 1 year in a discrete-time discounting context using a 
discount rate of 3%, i.e., exp(−𝜆) = ⁡⁡
1
(1+0.03)1
. In the case of life years (which accrue 
continuously), the discounted value of t additional life years (from the perspective of the 
present) is equal to the definite integral of the exponential discounting function from 0 to 
t, i.e., ∫ exp⁡(−𝜆𝑢)𝜕𝑢
𝑡
0
. In the case of costs, the discounted value of a cost C occurring at 
a time t years in the future is equal to the product of the cost and the exponential 
discounting function evaluated time t, i.e., 𝐶 exp(−𝜆𝑡). 
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 For each cohort (age, stage, and location), I ran the simulation multiple times and 
averaged over the results. Each iteration of the simulation required (pseudo)randomly 
drawing a set of parameters for the time-to-detectable-disease and time-to-clinical-
disease processes for each included group of adjuvant treatment. As a reminder to the 
reader, the point of this was to try to average over the nonidentifiability of parameters 
governing the distribution of latency and sojourn times. In the case of rectal cancer, there 
was only one type of adjuvant treatment per cohort and thus only one distribution of 
parameters to sample from. But in the case of colon cancer, there were three types of 
adjuvant treatment per cohort. Again, the breakdown of these is given in Table 12. For 
convenience, for each iteration of the simulation, I sampled from the three parameter sets, 
e.g., stage III colon cancer patients treated with no adjuvant, 5-FU/LV, and FOLFOX, 
independently. 
Monte Carlo sizes and the number of iterations used were selected based upon the 
magnitude of the effect size. To compare arms 2 and 3 to arms 1 and 2 (see Table 11), 
respectively, I simulated 25 iterations with a Monte Carlo size of 600,000 patients per 
arm in each iteration. To compare arms 3, 4, 5, and 6, I used 75 iterations per cohort and 
a Monte Carlo size of 1 million per arm per iteration. After the full simulation, the arm-
specific mean costs and LEs were combined across iterations to form a set of overall arm-
specific mean costs and LEs. The arms were then organized by increasing efficacy, and 
the appropriate incremental costs and incremental LEs were calculated. Finally, I 
calculated the corresponding ICERs. 
In order to aid clinical decision-making, I used the ICER point estimates to identify 
the optimal follow-up regimen for each cohort under a range of values for a life-year. By 
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the value of a life-year I mean a policymaker’s willingness to pay (WTP) for an 
additional expected life-year. In particular, I used increments of $25,000 up to $150,000 
as the value of life-year and determined what follow-up regimen should be used for each 
cohort in each scenario. I did this both for the analyses using a discount rate of 3% and 
for the analyses using a discount rate of 0%. 
By optimal I mean the most intensive follow-up regimen with an ICER less than or 
equal to the assumed value of a life-year. So for example, if the ICER comparing routine 
CEA and 2 CT scans to routine CEA and 1 CT scan was $73,000 for a given cohort, a 
second scan would not be adopted with a WTP of $50,000, but it would be adopted with 
a WTP of $75,000 or more. However, it would only be considered the optimal follow-
regimen (among those under investigation) for a given WTP if there was not a more 
intensive follow-up regimen (e.g., CEA and 3 CT scans) with an ICER that was also less 
than or equal to the same WPT value. 
 The model described in Chapter 2 is a complex microsimulation model. Therefore, 
Monte Carlo sampling must be used to estimate moments or functions of moments for 
outcomes of interest. This differs from a cohort Markov model where analytic solutions 
for such moments exist.162 As with all Monte Carlo analyses, it is important to quantify 
the precision of estimates. I therefore calculated 95% confidence intervals (CI) for 
incremental LEs, incremental costs, and ICERs. This required estimation of empirical 
covariance matrices among arm-specific LEs and among arm-specific mean costs in each 
iteration. There was a very high degree of positive correlation among arms in each 
iteration because of the variance-reduction technique I used (simulating identical 
individuals). Covariance matrices for the overall arm-specific mean costs and LEs were 
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easily constructed from the iteration-specific covariance matrices since the iterations 
were independent. I used the delta method163 to construct an estimate of the sample 
variance of each ICER. This in turn required estimation of the covariance between the LE 
and mean costs, both between and within the two compared arms. I note that, because of 
the variance-reduction technique I used, an estimate of the mean costs in one arm was 
correlated with an estimate of the LE of another arm (within a given iteration). 
I note that the interpretation of confidence intervals for an ICER can be problematic 
when the upper and lower limits are not both positive. This is because a negative ICER 
can mean either that a more effective intervention is cost-saving or that a more costly 
intervention is less effective. However, when the entire 95% CI covers only a positive 
set, the interpretation is clear. It simply quantifies the precision of the ICER estimate 
comparing a more effective and costly intervention to a less effective and costly 
intervention.17 Accordingly, I only present ICER CIs when the entire interval is positive. 
OVERVIEW OF COSTS 
 To conduct the cost-effectiveness analysis, costs were added to the microsimulation 
model described in Chapter 2. Because the analyses were undertaken from the 
perspective of the US healthcare system, they only include direct and indirect medical 
costs. Direct medical costs include costs related to follow-up testing while indirect 
medical costs include costs associated with treatment of recurrence. It is important to 
include the latter costs since the benefit of surveillance accrues specifically from this 
                                                          
17 Strictly speaking, a positive ICER could also result when an intervention is both less efficacious and less 
costly than the comparator (standard care). However, the interpretation is also clear in this case if the ICER 
95% CI includes only positive values. 
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more intensive treatment of recurrence. I did not include medical costs unrelated to 
cancer nor medical costs related to treatment of the primary CRC. For example, the cost 
of the primary surgery and any adjuvant chemotherapy were not included. Nor were costs 
associated with post-treatment but pre-recurrence care for the primary disease.164 The 
reason for this exclusion is convenience and the fact that these costs should be the same 
across arms. This is because intensive follow-up will only affect how recurrence is 
treated and potentially how long a patient will live after being diagnosed with recurrence. 
However, downstream costs associated with care for the patient related to treatment of 
recurrence were included. Finally, other patient-related costs (time and money spent 
traveling to care and time spent getting care), productivity costs, and most survivor costs 
were also not included since a societal perspective was not used. Though again, in the 
case of the survivor costs, CRC-related costs (those associated with the long-term 
treatment of recurrence) incurred in added years of life were included. 
 The two main categories of medical costs include surveillance-related costs and those 
related to treatment of recurrence. The resource utilization associated with surveillance 
was evaluated based on 2017 Medicare reimbursement rates as listed in the Center for 
Medicare & Medicaid Service’s (CMS) Medicare Physician Fee Schedule (MPFS). 
Because routine follow-up testing generally occurs in an outpatient setting, I used the 
national average reimbursement rate for the combined technical and professional 
components of services. Services were identified by their Healthcare Common Procedure 
Coding System (HCPCS) codes – CMS’s adaptation of the American Medical 
Association’s Current Procedural Terminology (CPT) codes. The MPFS reimbursement 
rates represent the maximum allowable fee and include the amount that will be 
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reimbursed by Medicare as well as any amount which must be paid by the patient. I 
included the full cost amount and did not attempt to remove patient contributions, e.g., 
coinsurance or copays, since these would vary from patient to patient depending upon 
whether they have additional coverage, e.g., Medicaid. 
In general resource use related to salvage treatment with a curative intent was also 
evaluated using Medicare reimbursement rates. Other than any neoadjuvant or adjuvant 
therapy, these resources would be consumed in an inpatient setting. They were thus 
evaluated using Medicare’s inpatient prospective payment system for acute care hospital 
inpatient stays. This was done by determining an appropriate diagnosis-related group 
(DRG) for all such services. Each DRG includes a homogenous class of inpatient services 
and has been assigned a payment weight based on the estimated mean resource use 
required to treat Medicare patients included in that DRG. When combined with a national 
base payment rate, these weights determine the hospital reimbursement for non-
physician-related labor, non-labor-related operating costs, and capital costs. For the 
national base payment rate, I used the value of $5,962.9318. Physician costs associated 
with inpatient services were assigned based upon reimbursement rates listed in the MPFS 
for particular procedures identified by HCPCS codes. However, the reimbursement for 
these procedures does not include a technical component. 
All remaining medical costs were taken from the literature. This was true for all costs 
related to treatment of patients with unresectable disease and for costs related to long-
                                                          
18 This combines the 2017 federal capital rate and the 2017 labor and non-labor rates for a Hospital which 
submitted quality data and used Electronic Health Records (EHR’s). According to CMS, over 50% of 
providers used HER’s. 
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term care for patients surviving after salvage surgery. Cost values were inflated to 201719 
US dollars using the medical-component of the Consumer Price Index (CPI).165  
SURVEILLANCE-RELATED COSTS 
 The important surveillance-related costs are given in Table 13. These include the 
costs of an abdominal (abdominal/pelvic) and thoracic CT scan with IV contrast for colon 
(rectal) cancer patients and the cost of a CEA assay. I assume any such regimen would be 
offered over and above routine clinical visits to monitor the surgical wound and any other 
treatment-related morbidity and for the patient to report any symptoms. Thus, routine 
clinical visits were not included in the reference-case analysis since they are assumed to 
be the same across arms. However, I assumed that any positive test result would require 
an additional 30-minute clinical visit. 
In addition, as described in Chapter 2, both a true-positive and false-positive test 
result incur additional costs over and above the additional 30-minute clinical visit.  In the 
case of a CEA assay, a positive result leads to a CT scan (with reduced specificity). For a 
positive CT finding, I assumed the cost differs between a true positive and a false 
positive. In the case of a true positive CT scan, I assume 5% of patients undergo either a 
laparoscopy or thoracoscopy and 5% of patients get a CT-guided fine-needle aspiration 
(FNA). These would be needed in the case of equivocal CT findings before further 
treatment was provided. For rectal cancer patients, I further assume that 25% of true-
positives undergo a pelvic MRI to confirm a pelvic finding on CT and/or to determine the 
                                                          
19 The medical-component of the CPI inflation rate was not available from the source I used for converting 
2016 dollars into 2017 dollars. I therefore assumed 2017 would have the same rate as 2016. 
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appropriateness of pelvic salvage surgery. The expected additional cost of a true-positive 
CT finding (not including any additional 30-minute clinical visit) for rectal and colon 
cancer patients is given in Table 13. 
In the case of a false-positive CT finding, I assume that patients would receive one of 
four further diagnostic procedures in equal proportion: (1) repeat CT scan (of the 
abdomen or chest), (2) an MRI (of the pelvis or abdomen), (3) a CT-guided FNA, or (4) a 
laparoscopy or thoracoscopy. The corresponding expected costs of a false-positive CT 
finding for rectal and colon cancer patients are also given in Table 13. The relevant 
HCPCS codes and reimbursement rates for individual procedures are given in Table D.I. 
The construction of the aggregated costs is illustrated in Table D.3. 
Table 13: Costs of Surveillance and Treatment of Recurrence 
SURVEILLANCE COSTS 
Clinical Visit (30 Min) $109 
CEA Assay $26 
Full CT Scan for Rectal Patients $548 
Full CT Scan for Colon Patients $467 
Cost of a True Positive CT: Colon $40 
Cost of a True Positive CT: Rectal $144 
Cost of a False Positive CT: Colon $374 
Cost of a False Positive CT: Rectal $369 
INITIAL COST OF SALVAGE TREATMENT 
Cost of Failed/R2 Resection: (Colon) $12,215 
Cost of Failed/R2 Resection: (Rectal) $11,287 
Expected Cost of R0-1 Surgical Resection + (Neo)Adjuvant Therapy (Colon) $54,442 
Expected Cost of R0-1 Surgical Resection + (Neo)Adjuvant Therapy (Rectal) $45,192 
DOWNSTREAM COSTS OF SALVAGE TREATMENT 
Expected Cost of Follow-up CT Imaging Per Round of Follow-up (Colon) $486 
Expected Cost of Follow-up CT Imaging Per Round of Follow-up (Rectal) $567 
Expected Cost of Possible Second Surgical Resection with Curative Intent + 
(Neo)Adjuvant Therapy (Colon) 
$9,255 
Expected Cost of Possible Second Surgical Resection with Curative Intent + 
(Neo)Adjuvant Therapy (Rectal) 
$6,779 
Age-Specific Monthly Costs for Patient Care 
< 75 $1,093 
75-85 $656 
≥ 85 $473 
Monthly Costs for Terminal Cancer $4,091 
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COSTS OF PALLIATIVE TREATMENT 
Monthly Costs for Initial Treatment $7,438 
Age-Specific Monthly Costs for Patient Care 
< 75 $3,683 
75-85 $2,210 
≥ 85 $1,473 
Monthly Costs for Terminal Cancer $4,091 
Table 13 gives the aggregate costs used in the cost-effectiveness analyses for surveillance tests, 
salvage treatment, and treatment for patients with unresectable recurrence (‘palliative treatment’). 
Values are in 2017 US dollars. Future costs have not been discounted. 
 
COSTS OF TREATMENT WITH A CURATIVE INTENT 
 Resource use related to treatment with a curative intent can be divided into two 
categories: the initial treatment and long-term care. The initial treatment involves salvage 
surgery, treatment for any resulting serious morbidity (e.g., increased inpatient stay), and 
possibly perioperative radiation or chemotherapy. Long-term care involves additional 
intensive surveillance, the possibility of a second salvage surgery, routine care, and 
treatment of terminal disease among those who ultimately suffer a re-recurrence and die 
from the disease. 
 I evaluated resource use for initial treatment separately depending on the margin 
status of surgery. Patients who undergo a failed or R2 resection are only assigned costs 
associated with the procedure. They are then considered to have unresectable disease and 
are assigned costs accordingly (discussed in the next section). By failed resection I mean 
a laparotomy or thoracotomy that does not proceed to surgical resection due to the 
discovery of previously undetected widely-disseminated disease. An R2 resection refers 
to a macroscopically incomplete resection of the tumor. I combine the two in the model 
since they are assumed to lead to similar outcomes, i.e., no benefit. For the cost analysis, 
these patients are assumed not to be susceptible to serious morbidity or mortality in the 
way that patients who undergo R0-R1 resections are. These latter patients undergo a more 
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significant procedure and generally lose a potentially significant portion of vital organs. 
This is generally not true of the former patients. 
 For patients who undergo an R0-R1 resection (macroscopically clear margin), I 
evaluated resource use separately by anatomical location of salvage surgery and then 
used a weighted average of these costs to represent the expected cost of salvage treatment 
with curative intent. That is, for each anatomical location of recurrence (e.g., liver, lung), 
I calculated an expected cost of salvage treatment which included the costs of surgery, 
extra costs due to mortality and morbidity, and the costs of radiation therapy and 
chemotherapy. I then combined these into an overall expected cost of (macroscopically-
clear margin) salvage treatment of recurrence for both rectal and colon cancer patients. 
For colon cancer patients, I distinguished between hepatic resection, pulmonary 
resection, and abdominal resection of local-regional recurrence. For rectal cancer 
patients, I distinguished between hepatic resection, pulmonary resection, and pelvic 
resection. Thus, there were 4 distinct types of salvage treatment to consider. 
 In the case of resection of local-regional recurrence in the abdomen for colon cancer 
patients, I used an estimate of the mean cost of surgery for stage III colon cancer patients 
taken from the linked SEER-Medicare database as a proxy.166 Salvage surgery for 
abdominal recurrence among colon cancer patients is generally extensive and often 
involves multivisceral resection.106 I selected surgery for stage III patients since it was the 
most expensive among non-metastatic patients. The estimate was based on a 3-month 
period starting in the month of diagnosis and so is unlikely to include adjuvant costs. 
Moreover, preoperative and intraoperative radiation therapy and neoadjuvant 
chemotherapy are not common practice in the case of surgical resection of primary colon 
118 
 
cancer tumors, but they are used in the case of salvage therapy (for local-regional 
recurrence) due to the difficulty of achieving a complete resection. I thus added costs 
associated with intraoperative radiation therapy and neoadjuvant and adjuvant radiation 
therapy and chemotherapy. The relevant assumptions and aggregate costs are given in 
Tables D.2 and D.3, respectively. 
For hepatic, pulmonary, and pelvic resections, I identified appropriate DRGs and 
multiple HCPCS codes. In the case of pelvic resection, separate DRGs were assumed for 
male and female patients and a weighted average was used. For hepatic and pulmonary 
resections, there were three potentially-relevant DRGs depending on if the procedure 
involved major complications or comorbidities (MCC), complications or comorbidities 
(CC), or neither (None). In the case of pelvic salvage, there were only two relevant DRGs 
(CC vs. None). A previous cost-effectiveness analysis of the resection of metachronous 
hepatic metastases in CRC patients estimated that 12% of cases involved no 
complications or comorbidities.153 In the absence of more recent information, I used this 
assumption for all 3 types of salvage surgery, but it was estimated prior to Medicare’s 
adoption of two categories for complication and comorbidities (MCC vs CC). 
Unfortunately, a literature search was not helpful on the distribution of cases with respect 
to these categories, so I assumed that 50% of patients with complication or comorbidities 
would be assigned as MCC and 50% as CC (for hepatic and pulmonary resection). 
For physician reimbursement, I identified several different HCPCS codes for each 
type of salvage surgery. These were selected and assigned weights to reflect the 
distribution of procedures reported in relevant case series. The relevant assumptions and 
sources are given in Table D.2, and the codes and reimbursement rates are given in Table 
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D.1. Aggregate costs are given in Table D.3. In the case of failed or R2 resections, I 
followed the previously mentioned analysis153 and assumed patients were assigned the 
lowest-cost level DRG (no CC) and used a Laparotomy or Thoracotomy for physician 
reimbursement. 
Estimates of the costs associated with surgical morbidity and mortality were taken 
from the literature. These costs represented costs that accrued over and above the costs of 
the initial surgical procedure. They were incorporated into the expected cost of salvage 
treatment20 by multiplying the estimated mean cost per case times the probability of 
serious morbidity and mortality. In the case of hepatic resection, estimates were available 
for the mean cost per case of serious morbidity and per case of 30-day mortality. The 
latter was more than twice the cost of the former. In the case of pulmonary and pelvic 
salvages, only estimates of the average cost per case of serious morbidity were available. 
In the absence of better information, I therefore used 200% of the average cost per case 
of serious morbidity as an estimate for the average cost per case of treatment-related 
mortality.  
A detailed breakdown of procedures and reimbursement rates or costs from the 
literature for each type of salvage treatment is given in Table D.1. This includes the mean 
added cost per case of serious morbidity and mortality. Table D.3 gives the aggregated 
costs and illustrates the appropriate calculations. Table D.2 summarizes important 
auxiliary assumptions and gives the relevant sources in the literature. 
                                                          
20 This was not done in the case of salvage therapy for local-regional recurrence in the abdomen since the 
average cost taken from the literature for surgery for stage III colon cancer already included such costs.   
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 The last component of the initial treatment costs was preoperative and postoperative 
external-beam radiation therapy and chemotherapy. Estimates of the rates of utilization 
and costs of perioperative radiation therapy and chemotherapy were taken from the 
literature. The incremental effectiveness of these treatments over and above salvage 
surgery remains unclear167, but they are routinely used in a subset of patients and 
represent a major cost. An estimate of the mean cost of neoadjuvant radiation therapy 
was taken from an analysis using SEER-Medicare data.168 For chemotherapy, the main 
distinction in the literature is between a double-agent and single-agent form of 
chemotherapy. I assumed all patients using double-agent (single-agent) chemotherapy 
would use FOLFOX (5-FU/LV). For each type of salvage treatment, assumptions about 
the proportion of patients using chemotherapy, the proportion treated preoperatively 
and/or postoperatively, the type of chemotherapy used, and the assumed length of time 
patients undergo treatment are given in Table D.2. The estimated costs per 3 months of 
treatment (and sources) are listed in Table D.1. Finally, Table D.3 lists the ex-ante 
expected cost of (neo)adjuvant (chemo)radiation therapy per patient for each anatomical 
location of salvage treatment. 
Finally, a weighted average was calculated of the expected costs for the different 
anatomical locations of salvage treatments. These values are given in Table 13. 
Unfortunately, the intensive-follow-up trials did not generally provide detailed 
information about the distribution of types of salvage surgeries, and these likely have 
changed since the earliest trials. I therefore estimated weights from a large cancer-
registry-based study of the distribution of isolated recurrences among colon and rectal 
cancer patients.4 For colon cancer, I assumed 60% and 20% of cases were liver and lung 
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resections, respectively, and 5% of patients involved staged resection of both liver and 
lung metastases. This is apparently a viable form of salvage treatment.169 The remaining 
15% of patients were assumed to undergo salvage for local-regional recurrence located in 
the abdomen. For rectal cancer, I assumed 40% and 30% were liver and lung resections 
and an additional 5% underwent staged resection of both hepatic and pulmonary 
metastases. The remaining 25% were assumed to undergo salvage treatment for pelvic 
recurrence. 
Two of the costs characterized above as part of long-term care relate to detection and 
treatment of re-recurrence. The microsimulation model described in Chapter 2 does not 
currently model the re-recurrence process or a re-salvage process. It therefore does not 
model surveillance and detection of re-recurrence. However, it is important that these 
costs are included in the analyses. Thus, all patients who undergo a salvage surgery are 
assumed to partake in intensive routine CT imaging – every 6 months for 2 years and 
then annually for 3 years – while alive and with a cancer-specific life-expectancy of at 
least 10 months. Routine CEA measurement, however, is not included in this schedule. 
The 10-months figure was selected because, in the model, the last 9 months are 
considered a terminal phase during which patients are treated the way patients with 
unresectable disease are treated at the end of their life (discussed below). It is also 
assumed that 15% and 17% of rectal and colon cancer patients, respectively, undergo a 
second attempt at salvage surgery. 11 170-172 The expected costs per CT scan completed 
(including false-positives) and of a second salvage surgery are given in Table 13. 
Another major component of long-term costs is referred to as ‘continuing costs’ in the 
literature. Patients who undergo surgical resection for CRC (of any stage) continue to use 
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more medical resources than comparable cancer-free patients for at least 10 years.164 That 
is, between the periods of initial treatment and any terminal stage during which the 
patient dies of cancer, additional medical resources are required to care for the patient 
because of their CRC diagnosis. Continuing costs are greater for younger patients and 
higher stage patients per unit of time.164 Most of the patients in the microsimulation 
model who undergo salvage treatment with a curative intent would have isolated 
metastatic disease. Continuing costs for such patients are likely less than for patients with 
unresectable disease. For the reference case, I therefore used an estimate of the 
continuing costs for stage III CRC patients as a proxy for the costs of continuing care 
after initial treatment with salvage surgery. These costs are listed in Table 13. The 
reference for these estimates used SEER-Medicare data for patients diagnosed with CRC 
between 1996-2002. It is unlikely that many patients were undergoing routine CT 
surveillance during this period and thus that such costs would be included in the estimate. 
Therefore these continuing costs are assumed to apply over and above the costs of a 
second round of intensive follow-up discussed above. I also assume that costs of possible 
salvage therapy for recurrence are not included. 
In the microsimulation model, continuing costs accrue beginning in the 7th month 
after the salvage surgery until the patient’s cancer-specific life-expectancy drops below 
10 months or until 10 years have passed from the date of salvage surgery, whichever 
occurs first. I assume that the first 6 months represent the initial treatment period during 
which the costs of salvage therapy discussed above are borne. Moreover, the last 9 
months of a patient’s life (among patients who die from cancer) are treated separately. 
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Finally, all patients who die of cancer (i.e., suffer a re-recurrence and die from it) are 
assumed to have the same experience at their end of life as patients who are initially 
treated for unresectable recurrence. During this final phase of life (the ‘terminal’ phase), 
patients accrue costs at a faster rate (Table 13).164 173 The costs presented in Table 13 are 
assumed to include any palliative procedures as well as any chemotherapy given in the 
last stage of life. The terminal phase lasts for up to 9 months and takes priority over 
continuing care in the assignment of months. That is, if a patient lives 15 or fewer months 
after salvage surgery, only terminal phase costs are assigned; the patient never accrues 
continuing costs. In addition, if the patient lives fewer than 15 months after salvage, 
terminal months are only assigned after 6 months (of initial treatment). It is assumed the 
patient simply has a very aggressive re-recurrence. 
COSTS OF TREATMENT FOR UNRESECTABLE DISEASE 
I assume patients in the microsimulation model who present with unresectable 
recurrence incur costs at a rate comparable to patients with stage IV disease. In the 
literature, these costs are generally divided into three phases of the disease: initial, 
continuing, and terminal.164 173 Estimates of the monthly costs for each phase (and their 
source) are given in Table 13. The initial treatment phase is assumed to last up to 8 
months and to include at least the first line of chemotherapeutic treatment. The costs of 
the terminal phase are identical to those used for patients treated with curative resection 
but who ultimately die from cancer. They accrue for up to the last 9 months of the 
patient’s life. In the case of unresectable recurrence, terminal months are prioritized over 
initial treatment months in that up to the first 9 months are classified as terminal disease 
before any initial treatment month are assigned. Finally, any additional months of lifetime 
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are assigned costs at the relevant age-specific rate for continuing costs (for stage IV 
patients). This was the strategy used to estimate the monthly costs in the selected source. 
Moreover, while perhaps unconventional, the durations of 8 and 9 months for the initial 
and terminal phases, respectively, were selected because they were the reported average 
amount of time spent by contributing patients in those phases. This is relevant because 
the authors reported average aggregate costs for the initial and terminal phases rather than 
monthly costs. 
It should be noted that these values were estimated with SEER-Medicare data for 
patients diagnosed with stage IV CRC between 1996-2002.164 I was unable to find a more 
recent US population-level source which estimated the excess costs of CRC for stage IV 
patients. It is very likely that these costs will have increased since the index period, 
potentially significantly, due to the increasing complexity of treatment for unresectable 
disease (e.g., the adoption of targeted therapy such as biological agents).174 However, in 
the event that this does bias results, it is likely to be in favor of less intensive follow-up. 
All patients who die of cancer (from recurrence) will incur these costs, regardless of 
whether they undergo salvage surgery. However, patients who are cured from salvage 
surgery are spared these costs. This is one way in which more intensive upfront resource 
uses – the costs of salvage treatment – may lead to a decrease in downstream CRC-
related medical costs. Thus, a larger value associated with the cost of terminal disease 
would mean greater cost-savings for successful salvage therapy. 
SENSITIVITY ANALYSES 
 To assess the robustness of the simulation results to parameter uncertainty, I 
performed a set of univariate sensitivity analyses. These evaluated the effect of variation 
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of a single cost value. I focused on costs which were deemed both potentially particularly 
important and/or particularly uncertain. These included the initial costs of salvage 
treatment, the cost of palliative care, the cost of routine care (continuing costs) after 
salvage treatment, the cost of a CT scan, the cost of a true positive and false-positive CT 
result, and the cost and utilization of clinical visits. The point of this set of analyses was 
to evaluate the robustness of the results of the decision analysis (i.e., identification of 
optimal follow-up for a given WTP) to uncertainty surrounding these particular 
parameters considered in isolation (that is ignoring uncertainty among other parameters) 
and to assess how important these parameters are in determining the results. They were 
not meant to represent an exhaustive sensitivity analysis. I therefore only performed these 
analyses using the cohort of 65-year old stage III colon cancer patients. This cohort could 
reasonably be considered the most representative cohort. For each analysis, I simulated 
15 iterations of the model with a Monte Carlo size of 600,000 per arm (and thus 3.6 
million per iteration). Results were combined across iterations as they were for the 
reference-case analyses described above. 
For the first two (salvage and palliative treatment), I ran the analyses using values 
that were 50% and 150% of the best-guess parameters described above. For example, 
instead of $54,442 as the mean initial cost of salvage treatment for colon cancer patients, 
I used values of $27,221 and $81,663, respectively. Given the number of assumptions 
that went into calculating the average cost of salvage treatment, it was unrealistic to 
assess the impact of all of the assumptions or even just several of them. Rather, I chose to 
assess the impact of variation in the aggregate estimate. I also adjusted the expected cost 
of a second round of salvage treatment accordingly. In the case of the palliative care, I 
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adjusted all five costs associated with palliative care (bottom of Table 13) by 0.5 or 1.5. 
Because the cost of treating dying patients in the last 9 months of their life was assumed 
to be the same among patients who suffer an incurable re-recurrence after salvage 
treatment as it is among patients who initially present with unresectable recurrence, I also 
adjusted the monthly terminal costs for the former patients (those treated with attempted 
cure who die of cancer). 
In the case of the continuing costs associated with salvage treatment, I ran an analysis 
using the continuing costs associated with stage IV patients (as opposed to stage III 
patients), i.e., the same values used for patients who present with unresectable recurrence 
and survive long enough to incur such costs. As can be seen in Table 13, the continuing 
costs reported in the literature for stage IV patients are notably larger than those for stage 
III patients. I also ran an analysis using continuing costs equal to only 50% of those 
estimated for stage III patients. This would be relevant if (a), as assumed for the 
reference-case analysis, an estimate of the continuing costs for stage III patients was 
more appropriate for patients after salvage therapy than was an estimate based on stage 
IV patients (the vast majority of whom would have had unresectable disease) and (b) the 
estimate from the literature of continuing costs for stage III patients was biased up (with 
respect to the model’s purposes) because, contrary to my assumption, it included costs 
associated with routine surveillance and/or salvage therapy for recurrence. 
I also performed a sensitivity analysis on three surveillance-related cost parameters. 
While Medicare reimbursement rates for an outpatient CT scan are available in the 
MPFS, it is potentially informative to evaluate how sensitive the results are to this cost. 
In particular, this may be relevant for patients with private health insurance where the 
127 
 
reimbursement for a CT scan is likely greater. I therefore ran the simulation using values 
0.5 and 2.0 times the cost listed in Table 13 for colon cancer patients ($234 and $934, 
respectively). I also re-ran the simulation using notably larger values for the cost of a 
true-positive and false-positive CT scan. This would result from a higher proportion of 
patients requiring further diagnostic procedures and/or services before a treatment plan 
was made. For the average cost of a true positive, I used a value ($400) 10x that listed in 
Table 13. I remind the reader that the original value ($40) was based on several 
assumptions, including that only 10% of patients would require further diagnostic work. 
For a false positive, I used 2x the cost given in Table 13. Finally, I ran the analyses 
including the cost of a 60-minute clinical visit ($209) for every surveillance test (using 
only 1 if both CEA and CT were scheduled) and after every positive test result. This 
differed from the reference-case analysis which only included the cost of a 30-minute 
clinical visit ($109) in the case of a positive test result, assuming that patients would still 
attend routine clinical visits in the absence of routine extra-colonic focused surveillance. 
 I also evaluated the importance of the salvage-surgery-related mortality rate and the 
assumed regimen of systemic chemotherapeutic treatment for patients with unresectable 
recurrence – 5-FU vs FOLFOX – to the results. For the former, I used a 30-day mortality 
rate of 5%. In the case of the latter, I did this by re-simulating the same cohort (65-year 
old stage III colon) under the assumption that all such patients were treated with 5-FU (as 
opposed to the reference case where they all receive FOLFOX). This was deemed 
relevant because, as noted in Chapter 2, the calibrated median survival among patients 
with symptomatic unresectable recurrence who are treated with FOLFOX was 15.8 
months. This figure drops to 10.4 months when patients are treated with 5-FU only. Since 
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this represents the expected survival experience of patients treated with salvage surgery 
in the counterfactual reality in which they were not treated with salvage surgery, a 
difference of this magnitude could potentially have a large influence on the results. 
RESULTS 
EFFECTIVENESS 
 Among patients who underwent no routine surveillance, undiscounted LEs from the 
start of the simulation varied from about 8 to 20 years depending on the starting age and 
the stage and location of the primary disease. Relative to baseline LE, changes in LE 
associated with more intensive surveillance regimens (incremental effectiveness) were 
small. The full effectiveness results are given in Table D.4. Below I briefly describe the 
results for the undiscounted analyses as they are generally more intuitively meaningful. 
While I report incremental effectiveness estimates in the unit of days, the ICER 
calculations used the unit of life-years. 
With one or two exceptions, LE increased with each incremental component of 
surveillance. Adding a single CT scan added about 15-50 days of LE. Adding routine 
CEA follow-up in accordance with US guidelines further increased LE by about 27-103 
days. The incremental benefits from further increases in surveillance intensity were very 
small. Adding a second (third) CT scan increased LE by only 2-11 days (0-8 days). 
Finally, adding both a 4th and 5th CT scan increased LE by 0-10 days. Among 75-year-old 
stage III rectal and colon cancer patients, adding both a 4th and 5th CT scan did not 
increase LE. The same was true among 75-year-old stage III colon cancer patients when 
adding a 3rd CT scan. These were the only cohorts and comparisons with a point estimate 
for the incremental effectiveness of 0 or less. 
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Overall, a few further patterns were observed among both the discounted and 
undiscounted effectiveness results. First, for each stage and location combination, e.g., 
stage III colon, the incremental benefit of any given upgrade, e.g., from 1 to 2 CT scans, 
decreased in magnitude as the age of the cohort increased. That is, controlling for disease 
type, a smaller benefit accrued with increasing age. Second, among the 60-, 65-, and 70-
year-old cohorts, stage II rectal cancer patients almost always exhibited the greatest 
incremental benefit from adopting more intensive surveillance. In general, stage III and 
stage II colon cancer patients tended to have the 2nd and 3rd largest benefits on average, 
respectively. However, this result was not replicated among the oldest cohort. 
When averaged over only those patients who suffered a recurrence, as opposed to the 
entire treatment arm, the undiscounted incremental benefits (gains in LE) associated with 
intensifying surveillance for 65-year-old stage III colon cancer patients were about 2 to 
3.5 times as large. For example, patients who undergo a CT scan at 12-18 months and 
who suffer a recurrence could expect to live roughly 3.6 months longer than if they had 
not undergone the CT scan. Averaged across all patients in the treatment arm, this same 
figure is only about 1.3 months. Similarly, by adhering to a schedule of routine CEA 
testing in addition to the 1 CT scan, those who will suffer a recurrence can expect to live 
an additional 6.4 months compared to just undergoing the 1 CT scan. The analogous 
figure averaged across the entire treatment arm is 2.3 months. Although the expected 
incremental benefits of further enhancements to the surveillance schedule are larger when 
averaged only among patients who ultimately get a recurrence, they are still very small. 
By adhering to routine CEA testing and annual CT scans for 2 (3) years, (65-year-old 
stage III colon cancer) patients who will suffer a recurrence can expect to live an 
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additional 2.5 weeks (1 week) compared to if they had just undergone routine CEA 
testing and 1 (2) CT scans. Finally, patients who suffer a recurrence and adhere to 5 years 
of annual CT (and routine CEA testing) can expect to live almost another week compared 
to if they had just undergone 3 years of annual CT (and routine CEA). I remind the reader 
that these results are meant only to be informative and are not used in the cost-
effectiveness analyses. 
COSTS 
The undiscounted (discounted) mean overall costs for patients who underwent no 
routine surveillance ranged from about $12,000-$40,000 ($11,000-$37,000), depending 
on the cohort. For these patients, the costs represent resource use associated with treating 
unresectable recurrence and, for a very small percentage of patients who suffered a 
recurrence, with salvage treatment. I note again that only resource-use related to 
recurrence was included in these analyses (since the patients did not undergo extra-
colonic surveillance of any sort) and that total costs were averaged over the entire group 
of patients, including the up to 85 percent of patients who might not suffer a recurrence. 
Thus, while appropriate for a cost-effectiveness analysis, these values are not 
representative of a typical patient’s recurrence-related costs. 
The full cost results are presented in Table D.5. Relative to the baseline mean costs, 
the undiscounted (discounted) incremental costs associated with intensifying surveillance 
were quite a bit smaller, but definitely not trivial. The first CT scan added about $2,100-
$4,900 ($2,000-$4,700) per person on average. Adding routine CEA testing added 
another $3,900-$6,700 ($3,700-$6,400) per person. This particular increase was 
substantial and generally constituted roughly 15-25% of the baseline costs among those 
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with no surveillance. Further additions lead to notably smaller incremental costs. A 
second CT scan added another $600-$900 ($600-$900) per person, and a third scan added 
between another $500-$1,000 ($500-$900) per person on average. Finally, the expected 
incremental costs associated with the 4th and 5th CT scans ranged from $800 to $1,800 
($700 to $1,600). 
In general, increases in the costs associated with treating recurrence were the biggest 
drivers of the incremental costs associated with more intensive surveillance. That is, the 
increase in the rate of salvage treatment associated with more intensive surveillance lead 
to an increase in the average cost of treating recurrence (both in the short term and long 
term), and this increase was notably larger in magnitude than the level of resources 
consumed for actual surveillance. This was particularly true with the addition of the first 
CT scan and with the adoption of routine CEA testing. For colon (rectal) cancer, only 
about 13-15% (18-20%) of the incremental costs for these two comparisons was due to 
added surveillance tests. The rest was due to the increased utilization of salvage therapy. 
However, as surveillance regimens became more intensive, the difference in magnitude 
between these two components of the incremental costs diminished. In adding both a 4th 
and 5th CT scan, the incremental costs associated with surveillance were greater than the 
incremental treatment costs. This pattern was observed among all age-groups. In some 
cohorts, this phenomenon begun with the addition of the 3rd CT scan. 
 As with the effectiveness results, there were some discernable patterns in the cost 
results. With the exception of the 75-year-old cohort, stage III colon cancer patients had 
the greatest incremental mean costs with the addition of the first CT scan, routine CEA 
testing, and a second CT scan. However, this was not generally the case with the addition 
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of the 3rd CT scan and particularly not with the addition of the 4th/5th CT scan. This is 
likely because stage III colon cancer patients tend to have the shortest time to recurrence. 
In addition, with the exception of the addition of the first CT scan at 12-18 months, stage 
II rectal patients tended to have greater incremental costs than stage II colon cancer 
patients and stage III rectal patients among the younger 3 cohorts. In the oldest cohort, 
stage III rectal cancer patients generally had the highest incremental mean costs. 
Moreover, there was no clear pattern of decreasing (or increasing) incremental costs with 
increasing age as there was for the incremental benefit. That is, controlling for stage and 
disease location, older age did not necessarily mean greater or smaller incremental costs 
the way it meant smaller increases in LE. 
COST-EFFECTIVNESS 
 The full set of ICER results are given in Table D.6. It is worth noting a few trends. 
First, discounted ICERs were categorically greater than undiscounted ICERs. Second, 
within a given cohort and comparison, e.g., routine CEA and 2 CT scans vs. routine CEA 
and 1 CT scan among stage III colon cancer patients, ICERs generally increased with 
age. That is, the cost per additional life-year achieved by upgrading to a more intensive 
surveillance schedule increased with age. Third, the two 75-year-old stage III cohorts 
were the only cohorts in which strategies were dominated. In particular, in the reference-
case analysis, 1 CT scan at 12-18 months was dominated by extension by the 
combination of routine CEA testing and 1 CT scan for stage III rectal patients. Moreover, 
annual CT scans for 5 years was dominated by annul CT scans for 3 years for both stage 
III rectal and colon cancer patients as the former did not confer any survival advantage. 
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 Estimates of the ICERs comparing routine CEA testing and 3 (5) annual CT scans vs. 
just 2 (3) annual CT scans were often very imprecise, particularly among older patients. 
This is because at a discount rate of 3% the already very small estimated incremental 
gains in LE from adding a 3rd or both a 4th and 5th CT scan among older patients flirted 
with negligibility. This in turn is due to the extremely small proportion of patients 
affected by such a change in follow-up care. However, in general the categorization of 
optimal follow-up was robust to this imprecision. Given this fact, it is unclear that much 
would be gained by undertaking the significant computational effort that would be 
required to achieve precise estimates of these ICERS. 
Table 14: Optimal Follow-up by Cohort and Value of a Life-Year 
COHORT 
VALUE OF A LIFE-YEAR 
$25,000 $50,000 $75,000 $100,000 $125,000 $150,000 
Discount Rate = 0% 
Stage III Colon 60 1 CT 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
Stage III Rectal 60 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
Stage II Colon 60 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
Stage II Rectal 60 
CEA + 1 
CT 
CEA + 3 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
Stage III Colon 65 None 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
CEA + 5 
CTs 
Stage III Rectal 65 None 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
Stage II Colon 65 1 CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
Stage II Rectal 65 
CEA + 1 
CT 
CEA + 3 
CTs 
CEA + 3 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
Stage III Colon 70 None 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 3 
CTs 
Stage III Rectal 70 None 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage II Colon 70 None 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
Stage II Rectal 70 None 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
Stage III Colon 75 None 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
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Stage III Rectal 75 None 
CEA + 1 
CT 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage II Colon 75 None 
CEA + 1 
CT 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage II Rectal 75 None 
CEA + 1 
CT 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
Discount Rate = 3% 
Stage III Colon 60 None 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
Stage III Rectal 60 None 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage II Colon 60 None 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
Stage II Rectal 60 1 CT 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
CEA + 5 
CTs 
Stage III Colon 65 None 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage III Rectal 65 None 
CEA + 1 
CT 
CEA + 2 
CT 
CEA + 2 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage II Colon 65 None 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 3 
CTs 
Stage II Rectal 65 None 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 3 
CTs 
CEA + 3 
CTs 
CEA + 5 
CTs 
Stage III Colon 70 None None 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage III Rectal 70 None 1 CT 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage II Colon 70 None 
CEA + 1 
CT 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage II Rectal 70 None 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs  
CEA + 3 
CTs 
CEA + 3 
CTs 
Stage III Colon 75 None None 
CEA + 1 
CT 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage III Rectal 75 None None 
CEA + 1 
CT 
CEA + 1 
CT 
CEA + 1 
CT 
CEA + 2 
CTs 
Stage II Colon 75 None 
CEA + 1 
CT 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
CEA + 2 
CTs 
Stage II Rectal 75 None 
CEA + 1 
CT 
CEA + 1 
CT 
CEA + 1 
CT 
CEA + 2 
CTs 
CEA + 2 
CTs 
Table 14 identifies the optimal surveillance schedule by cohort, discount rate, and the value of a 
life-year. Each cell lists the most intensive regimen of surveillance (for the corresponding cohort) 
that would provide additional life-years at a cost less than or equal to the assumed value of a life-
year. In the event that the ICER for even a single CT scan is greater than the assumed value of a 
life-year, the optimal regimen is no surveillance, i.e., None. The top (bottom) section contains 
results using a discount rate of 0% (3%). 
 
Table 14 gives the optimal surveillance schedule for each cohort of patients under a 
range of WTP thresholds, using both 0% and 3% discount rates. For the reference-case 
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analysis (discount rate = 3%), no surveillance would be optimal in all cases (except stage 
II rectal cancer patients aged 60 or younger) for a WTP of 25,000 per life-year. That is, at 
this value, the benefits of surveillance are not worth the costs. If a life-year were valued 
at $50,000 or more, optimal follow-up would include routine CEA testing and 1-2 CT 
scans for all stage III patients 65 and younger and for all considered stage II cohorts, i.e., 
patients 75 and younger. However, at a WTP just $5,000 higher ($55,000), routine CEA 
testing and at least 1 CT scan would be optimal for all considered cohorts with the 
exception of 75-year-old stage III colon cancer patients. Including this cohort would 
require a WTP of $65,000 or greater. 
It is apparent that aggressive use of CT scans multiple years after the primary 
diagnosis is in general unlikely to be considered a cost-effective use of resources. Unless 
we value a life-year at $100,000 or more, annual CT scans for 5 or even 3 years would 
generally be considered excessive care. Even at a WTP of $125,000, use of 3 or more 
CTs would in general only be justified for patients aged 60 or younger, and it would 
never be optimal for stage III rectal cancer patients (at least among considered ages and 
WTP values). The main exception to this finding is stage II rectal cancer. At $75,000, 
annual CT for 3 years would be optimal among this cohort for patients aged 60 and 
younger. At $100,000 ($125,000), 3-5 CT scans would be optimal for this cohort for 
patients 65 (70) and younger. I note that younger (≤ 65) stage II rectal cancer patients 
are the only cohorts for which 5 years of annual CT scan would ever be considered 
optimal at a WTP value of $150,000 or less. 
Several additional patterns are apparent in Table 14. First, for any combination of 
disease stage and location and the WTP threshold, the optimal follow-regimen generally 
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becomes less aggressive with age. Second, the optimal surveillance protocol for stage II 
and III colon cancer patients and stage III rectal cancer patients was generally the same or 
very similar, particularly among younger cohorts. If parsimonious recommendations were 
desired, it would not be unreasonable to treat these three groups as one. Third, among the 
3 younger age groups, optimal follow-up for stage II rectal cancer patients was at least as 
intensive as, and often more so than, that of the other cohorts. However, in oldest age-
group, this ordering was not consistent. 
If a policy-maker preferred a discount rate of 0%, optimal surveillance intensity 
would increase, but not dramatically. At a WTP of $25,000, routine CEA and 1 CT scan 
would generally only be optimal for patients 60 and younger. At a WTP of $50,000, 
optimal follow-up would include CEA and 1-3 CT scans for all cohorts studied. I note 
again that with 1 exception, the same result was found in the reference-case analysis at a 
WTP of $55,000. The main difference would be that at WTP values of $75,000 and for 
patients 70 and younger, more aggressive use of CT scans in later years would generally 
be optimal. 
SENSITIVITY ANALYSES 
 The results of the sensitivity analyses using a discount rate of 3% are presented in 
Table 15. The undiscounted results are presented in Table D.7 (undiscounted) and are not 
discussed further. It is apparent that the ICER estimates comparing routine CEA and 
annual CT scans for 5 (3) years vs. for 3 (2) years were imprecise. This is again due to 
the extremely small incremental gains in LE associated with these upgrades. However, in 
the case of 5 years of CT scans at least, it is a moot point given that this aggressive 
follow-up regimen would not be considered optimal even at a WTP of $200,000 per life-
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year. At a WTP of $150,000, annual CT scans for more than 2 years would not be 
considered either. 
Among studied cost variables, the costs associated with continuing care for patients 
after salvage treatment had the biggest influence on the cost-effectiveness results when 
considered in isolation. Estimates of the ICERs were particularly very sensitive to the 
choice between using estimates of continuing costs for stage III vs. for stage IV patients. 
Under the latter assumption, ICERs generally increased by at least 100% and no 
surveillance was optimal for any of the considered WTP values less than $100,000. 
Though at a WTP of $100,000, the optimal follow-up regimens were similar (routine 
CEA and 1 CT vs. 2 CTs), and at any higher values they were identical. Using deflated 
continuing costs for stage III patients, optimal follow-up would involve an additional CT 
scan at a WTP of $100,000 or greater but remain unchanged otherwise. 
The results were also sensitive to the price of salvage treatment. Using a WTP value 
of $50,000, if the cost of salvage treatment was 50% larger (smaller) than assumed in the 
reference-case analysis, optimal follow-up would change from routine CEA testing and 1 
CT scan to no surveillance (CEA and 2 CT scans). However, with higher WTP values, 
optimal clinical strategies were more robust. With a WTP value of $75,000, such an 
increase in the cost of salvage treatment would only mean dropping a second CT, and a 
50% decrease in the cost would have no effect on optimal follow-up. In the case of a 
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WTP of $100,000, increased salvage costs did not influence optimal treatment, and 
decreased costs warranted adding a 3rd CT scan.21 
While the ICER estimates exhibited moderate sensitivity to the cost of palliative 
treatment, the clinical-decision results were more robust. As predicted, reduced 
(increased) costs associated with palliative treatment lead to larger (smaller) ICERs. 
However, using a WTP value of $50,000 or $100,000, a 50% increase in the cost of 
palliative treatment would only lead to the inclusion of an additional CT scan in the 
optimal regimen. At a WTP value of $25,000 or $75,000, there would be no change. A 
50% reduction would lead to potentially dropping routine CEA at a WTP of $50,000, but 
an even mildly smaller reduction (e.g, 40%) would likely have no effect. Moreover, a 
50% reduction in the cost of palliative care would have limited to no effect on the results 
of the decision analysis at a WTP of $75,000 or more. 
Clinical-decision results were in general robust to univariate variation in studied 
surveillance-related costs. The only exception to this was the analysis in which the costs 
of all clinical visits were included and they were assumed to run 60 minutes instead of 30 
                                                          
21 The reader may be surprised to see the ICER associated with adding a 3rd CT scan was cheaper in 
the analyses using increased salvage costs than it was in the reference case. In fact, this happened for 
several of the analyses. However, this is an artifact of the unstable, miniscule estimates of the discounted 
incremental effectiveness associated with adding a 3rd CT scan. Mean overall costs were in fact larger in the 
former analysis (1.5⁡𝑥 salvage costs) than in the reference case as would be expected. The difference is due 
to a slightly larger estimate of (discounted) incremental LE in the sensitivity analysis. This matters because, 
when the denominator of a ratio is near 0, slight changes can dominate the effects of larger changes in the 
numerator. This difference in estimates of the incremental LE is likely due to the use of a smaller Monte 
Carlo sample size and a failure of the sensitivity analyses to fully sample from the full distribution of time-
to-detectable-disease and time-to-clinical-disease parameters. 
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minutes. At a WTP of $50,000, optimal surveillance would no longer include routine 
CEA. However, at other considered WTP values, there would be no change.22 
 Table 15: Sensitivity Results:Incremental Cost-Effectiveness Ratios 
(ICER) 
Analysis 
1 CT Scan 
($/LY) 
CEA + 1 CT 
Scan ($/LY) 
CEA + 2 CT 
Scans 
($/LY) 
CEA + 3 
CT Scans 
($/LY) 
CEA + 5 
CT Scans 
($/LY) 
Discount Rate = 3% 
Baseline 
41,061 
(40,649-
41,473) 
46,079 
(45,681-46,477) 
62,115 
(58,895-
65,335) 
183,271 
(142,130-
224,412) 
258,245 
(205,593-
310,897) 
Salvage 
Treatment 
Costs × 1.5 
54,481 
(53,801-
55,161) 
  59,312 
(58,674-59,950) 
83,471 
(72,268-
94,674) 
140,705 
(92,588-
188,822) 
515,867 
(29,849-
1,001,885) 
Salvage 
Treatment 
Costs × 0.5 
24,368 
(23,984-
24,752) 
27,715 
(27,392-28,038) 
42,888 
(37,106-
48,670) 
86,795 
(57,217-
116,373) 
366,000 
(21,323-
710,677) 
Palliative 
Costs × 1.5 
30,975 
(30,401-
31,549) 
35,878 
(35,416-36,340) 
47,711 
(40,857-
54,565) 
98,038 
(64,118-
131,958) 
417,367 
(23,840-
810,894) 
Palliative 
Costs × 0.5 
47,878 
(47,278-
48,478) 
51,145 
(50,609-51,681) 
78,642 
(68,156-
89,128) 
129,474 
(85,328-
173,620) 
464,633  
(27,141-
902,125) 
Salvage 
Continuing 
Costs = 
Stage IV 
84,136 
(83,203-
85,069) 
90,046 
(89,203-90,889) 
122,818 
(107,949-
137,687) 
198,782 
(134,838-
262,726) 
651,467 
(49,362-
1,253,572) 
Salvage 
Continuing 
Costs = 
Stage III × 
0.5 
29,978 
(29,532-
30,424) 
33,685 
(33,283-34,087) 
50,572 
(43,431-
57,713) 
95,808 
((62,240-
129,376) 
396,500 
(20,557-
772,443) 
Cost of CT 
Scan × 2.0 
45,642 
(45,065-
46,219) 
45,020 
(44,536-45,504) 
66,973 
(58,023-
75,923) 
119,538 
(78,720-
160,356) 
461,500 
(26,644-
896,356) 
                                                          
22 The reader may again note that one or both of the ICERs comparing routine CEA and 1 CT scan to 
just 1 CT scan and 1 CT scan to no surveillance were unexpectedly less in the sensitivity analyses with 
inflated surveillance costs (an inflated CT cost and an inflated cost of true and false positives) than they 
were in the reference-case analysis. Further exploration showed that the incremental surveillance costs 
were in fact greater in the sensitivity analyses as would be expected. However, this difference was small 
and was trumped by random variation in incremental LEs and treatment costs due to the sensitivity 
analyses using fewer iterations and smaller Monte Carlo sizes.  
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Cost of CT 
Scan× 0.5 
36,770 
(36,300-
37,240) 
42,107 
(41,654-42,560) 
50,765 
(44,111-
57,419) 
  88,821 
(59,018-
118,624) 
325,567 
(20,842-
630,292) 
More 
Expensive 
Positive CT 
Scan Results 
39,998 
(39,490-
40,506) 
44,299 
(43,821-44,777) 
  64,166 
(55,594-
72,738) 
115,692 
(76,198-
155,186) 
449,200 
(25,961-
872,439) 
More 
Expensive 
Clinical 
Visits 
41,954 
(41,422-
42,486) 
57,732  
(57,097-58,367) 
63,032 
(54,623-
71,441) 
113,667 
(74,903-
152,431) 
443,233 
(25,706-
860,760) 
5-FU for 
Unresectable 
Recurrence 
43,215 
(42,785-
43,645) 
46,712 
(46,316-47,108) 
61,355 
(55,181-
67,529) 
95,911 
(73,253-
118,569) 
233,077 
(132,706-
333,448) 
Salvage 
Mortality 
Rate = 5% 
40,907 
(40,349-
41,465) 
43,206 
(42,723-43,689) 
68,300 
(57,790-
78,810) 
144,271 
(79,553-
208,989) 
281,234  
(116,665-
445,803) 
Table 15 gives the results of the sensitivity analyses using a discount rate of 3%. ICERs are 
reported in 2017 US dollars per additional life-year. The first row (Baseline) gives the reference-
case ICERS for 65-year-old stage III colon cancer patients. Each subsequent row gives the 
ICERS (and 95% CIs) for different univariate sensitivity analyses. The first four involved 
multiplying the assumed cost(s) by a factor of 1.5 or 0.5. The 5th row in each section reports the 
results when the continuing costs among patients treated with salvage treatment were assumed to 
be the same as for patients with unresectable recurrence. For the latter patients, the model used an 
estimate based on stage IV patients. In the reference-case analysis, the model used an estimate for 
continuing costs following salvage treatment based on stage III patients. The row immediately 
below reports the results using continuing costs equal to 50% of those of stage III patients. The 
next two rows present the results using an inflated and deflated cost for a CT scan, respectively. 
In the following two rows, analyses used larger values for the cost of a true-positive (x10) and 
false-positive (2x) CT scan result and an increased cost of routine clinical visits, respectively. 
Finally, the last two rows give the results for an analysis done assuming all (65-year old stage III 
colon cancer) patients with unresectable recurrence are treated with 5-FU rather than FOLFOX 
and for an analysis done using a salvage mortality rate of 5% rather than 2%. To determine the 
impact variation in a given parameter had on the ICERs, the ICERs from the appropriate row 
should be compared to the baseline row. 
 
The results were also robust to the two efficacy parameters studied. First, the 
conclusions of the decision analysis for 65-year-old stage III colon cancer patients would 
not change for any WTP value of $75,000 or less if all patients with unresectable 
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recurrence in that cohort were treated with a single-agent systemic chemotherapy (5-FU) 
rather than a double-agent regimen like FOLFOX. For a WTP of $100,000 or greater, an 
additional (3rd) CT scan would be optimal under this scenario. Second, the decision-
analysis was also robust to an increase in the 30-day mortality rate associated with 
salvage surgery from 2% to 5%. In fact, ICER point estimates actually slightly decreased 
for two comparisons, and for at least one of the comparisons this difference was not due 
to Monte Carlo imprecision. Further exploration showed that, while the incremental LE 
was smaller under this assumption, the incremental costs were also smaller, and the latter 
difference was more important than the former. In particular, the difference in 
incremental costs was driven by a reduction in the costs of treatment, presumably due to 
the absence of the continuing costs. 
DISCUSSION 
The results presented above suggest that, if salvage surgery induced by extra-colonic 
follow-up does confer a survival advantage as predicted by the model, moderately 
intensive surveillance may be cost-effective for stage II and III colon and rectal cancer 
patients, depending upon the value we place on a life-year and the age of the patients. At 
a WTP threshold of $25,000, resources would be better spent on other health-related 
interventions. However, at a WTP of $55,000 or more, routine CEA testing and at least 
one or two CT scans should be offered to all patients aged 75 or younger, with the 
possible exception of 75-year old stage III colon-cancer patients. 
More generally, if we decided our WTP for a life-year was greater than $50,000 but 
less than $100,000, a reasonable and simple guideline would be as follows. All locally-
advanced CRC patients aged 75 or younger who were initially treated with curative 
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resection and are otherwise healthy (i.e., would be candidates for salvage surgery) should 
be offered routine CEA testing in accordance with current US guidelines (every 3 months 
for 2 years and then every 6 months for 3 years using a threshold of 5 μg/L) along with a 
chest and abdominal (abdominal-pelvic for rectal patients) CT scan at 12-18 months. 
Moreover, providers may consider suggesting annual CT scans for 2 years (instead of just 
1) for patients who either (a) present with stage II rectal cancer or (b) are aged 60 or 
younger (and possibly for those aged 61-65). If a patient presented with both of these 
features, a 3rd scan at 3 years might also be considered. 
For a WTP threshold between $100,000 and $150,000, a reasonable recommendation 
would be as follows. All patients aged 70 or younger who were initially treated with 
curative resection and are otherwise healthy should be offered routine CEA testing (as 
above) and annual CT scans for at least 2 years. For patients (a) with stage II rectal 
cancer or (b) who are 60 or younger, a 3rd CT scan at 3 years could be offered. Moreover, 
annual CT scans for up to 5 years might be considered for stage II rectal cancer patients 
aged 60 or younger. Finally, patients between the ages of 71 and 75 should be offered 
routine CEA testing and a single CT scan at 12-18 months.  
While univariate sensitivity analyses are inadequate to assess the full impact of 
parameter uncertainty on results of the cost-effectiveness analysis and to quantify 
decision uncertainty162, they can determine whether a particularly uncertain parameter or 
cost is likely to have a large effect on the results. The results presented above identified 
one clearly very important uncertain set of costs – continuing costs after salvage therapy - 
and one set of uncertain cost variables of potentially modest importance – the upfront 
cost of salvage treatment. 
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 The values used for monthly continuing costs after salvage therapy are important 
because they accrue for a long period of time. A patient who survives 50 months after 
salvage therapy (slightly less than the median survival) but ultimately dies from cancer 
would accrue 35 months of continuing costs. Since this patient would likely be under 75 
for the entire period, this would amount to over $35,000 just in continuing costs if the 
rate for stage III patients was used. At the rate assigned to stage IV patients, this would 
amount to about $125,000. I note again that this amount is over and above the cost of any 
second salvage attempt. 
I was unable to find a source in the literature which directly estimated continuing 
costs for patients after salvage therapy for recurrence generally or for just isolated 
metastatic disease. However, it seems improbable that there would have been many such 
patients in the SEER-Medicare cohort (incidence cases from 1996-2002) that was used to 
estimate continuing costs for stage IV patients, a cohort which had less than 10% survival 
at 5 years. Thus, there is reason to suspect that using the stage IV monthly costs would 
overestimate the true continuing costs that accrue to patients who undergo a clear-margin 
surgical resection of recurrence. I note that the estimate of stage III monthly continuing 
costs for patients under 75 used in this paper is very similar to the estimate of such costs 
used in Gazelle, et al., (2003) once adjusted for inflation.153 Still, further research into the 
true value of these continuing costs should be welcomed as it would help reduce 
significant uncertainty surrounding the value of ICERs and could even lead to a change in 
recommendations. Though at WTP threshold of $100,000 or greater, decision-uncertainty 
attributable to uncertainty surrounding continuing costs is likely to be small. 
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The mean cost of salvage therapy was less important to the clinical-decision results in 
a univariate context than were continuing costs, but it was still an important and uncertain 
cost variable. Of particular concern is whether the costs are notably larger than the values 
used in the reference-case analysis. At a WTP of $75,000 or greater, this seems to be less 
of a concern, but at a WTP threshold of $50,000 it is plausible a significant increase in 
the cost of salvage treatment could render no surveillance optimal. While my estimates 
were based mostly on Medicare reimbursement rates, these estimates inevitably only 
constitute informed guesses at what an average cost would be for salvage treatment of 
recurrence for rectal and colon cancer patients. They are uncertain because of all the 
assumptions (e.g., utilization, types of procedures, the risk of morbidity, the cost 
associated with mortality, etc) that were required to construct them. While I could not 
find any other such estimates in the literature, Gazelle et al., (2003) reported an estimate 
of the mean cost associated with a completed hepatic resection of about $54,000 (inflated 
to 2017 US dollars). This estimate included the expected costs associated with serious 
morbidity and mortality. This estimate is very similar to my estimate of the expected cost 
of hepatic salvage treatment at about $52,000 (Table D.3). However, unlike the estimate 
used in this paper, the former estimate does not include costs associated with 
(neo)adjuvant chemotherapy because the authors did not include any such costs. Even 
though both papers used Medicare reimbursement rates for physician and inpatient 
services, my estimate of the mean surgery-related cost was notably smaller, about 
$35,000. This large difference seems to be the result of a significant decline in the real 
value of relevant Medicare inpatient and physician reimbursement rates. I note that if the 
same costs among patients with private insurance have kept pace with the inflation of 
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medical prices instead of declining in real terms, the sensitivity analysis using a value of 
1.5 times the reference-case estimate for the price of savage treatment might be more 
relevant for such patients. 
An advantage of recommending at least routine CEA testing and a CT scan at 12-18 
months is that it would realize the overwhelming majority of the predicted survival 
benefit attributable to intensive extra-colonic follow-up. For example, for 65-year-old 
stage III colon cancer patients, 91% of the total discounted gains in LE attributable to a 
surveillance schedule including routine CEA testing and annual CT for 5 years (relative 
to no surveillance) was realized by routine CEA testing and a single CT scan at 12-18 
months. Almost a third of that benefit could be realized by just offering a single CT scan. 
More skeptical policymakers or panel members might consider hedging their bet and only 
recommending this surveillance strategy of modest intensity but not further use of CT 
scans, even for younger or stage II rectal cancer patients. The loss to patients from 
denying or dissuading further follow-up (i.e., additional CT scans) would be very small 
even if it proved to be technically efficacious (as the model predicts). On the other hand, 
if the causal theory embodied in the model is correct and policymakers or panel-members 
discourage routine CEA testing and a single CT scan because of lack of experimental 
evidence, the forgone public-health benefits would be quite a bit larger. To help put this 
in perspective, consider that the predicted (discounted) incremental gain in LE (73 days) 
attributable to 65-year-old stage III colon cancer patients undergoing routine CEA testing 
and a single CT scan (vs. no follow-up) is over 3 times larger than the similarly 
discounted predicted gain in LE of 23 days attributable to moving from no CRC 
screening to the most effective regimen identified among 22 possible strategies 
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considered in a cost-effectiveness analysis of CRC screening among average-risk 50 year 
olds.175 This discrepancy is partially driven by the assumption of 100% compliance in 
these analyses and only 60% in the cited report, but clearly this is a health benefit most 
would consider to be of importance. Moreover, over 80% of the incremental costs 
associated with this strategy compared to no surveillance would be attributable to 
treatment cost rather than surveillance costs. While this fact is strictly speaking irrelevant 
to the determination of the optimal strategy, it may make the strategy more palatable to 
the policymakers or panel members. 
The strategy of routine CEA testing and a single CT scan at 12-18 months is identical 
to the recommendation made by the FACS trial investigators who used the trial data to 
conduct a cost-utility analysis from the perspective of the UK NHS using a time-horizon 
of 5 years.45 In addition, the finding that stage II rectal cancer patients should be offered 
at least as intensive and generally more intensive extra-colonic surveillance as is offered 
to the other patients is consistent with the results of two other RCTs evaluating intensive 
surveillance. The trial that reported the largest mortality reduction (and was one of two 
trials to find a statistically significant benefit) appears to have enrolled only rectal cancer 
patients.41 Moreover, a relatively more recent imaging trial conducted in Spain found no 
survival benefit from intensifying follow-up overall, but a subgroup analysis found a 
significant benefit among stage II patients and rectal cancer patients.146 Finally, the 
authors of the FACs trial reported that a similar proportion of enrolled stage III and stage 
II patients underwent salvage surgery.46 That is, even though the recurrence rate was 
greater among stage III patients, the increased salvage rate among stage II patients 
adequately compensated for this. 
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One limitation of the microsimulation model’s inevitably simplified representation of 
disease development and detection is that it does not distinguish among different 
anatomical locations of recurrence. For example, the model does not distinguish between 
pelvic recurrence or hepatic or pulmonary metastases. This is potentially relevant for 
evaluating surveillance among rectal cancer patients because CEA tests appear to have a 
lower sensitivity with local-regional recurrence and pulmonary metastases23 26 and rectal 
cancer patients are more likely to suffer these types of recurrence (and undergo salvage 
treatment for them) than are colon cancer patients. Therefore, it seems likely that if this 
simplification biases the results it would be in the direction of underestimating the 
marginal value of CT scans for rectal cancer patients. Thus, less conservative 
policymakers or panel members might consider recommending a 2nd CT scan for all 
rectal cancer patients (or a 3rd CT scan in the recommendation based on a higher range of 
WTP values). 
Both the above consideration and the results of this paper suggest that oncologists 
might consider more aggressively encouraging appropriate stage II patients (particularly 
stage II rectal cancer patients) to comply at least with a CT scan at 12-18 months and 
routine CEA testing as this group is apparently less prone to comply with suggested 
surveillance.176 This is presumably because of the incorrect belief communicated by 
physicians, or at least implicitly transmitted, to patients that stage II patients will benefit 
much less on average from such surveillance due to their lower recurrence rates. 
Another potential limitation of this paper is that I assumed 100% compliance with 
surveillance tests. In this sense, the cost-effectiveness analyses are based on the expected 
maximum potential benefit. One reason I made this assumption was to increase 
148 
 
computational efficiency. As noted above, the discounted incremental gains in LE 
associated with later CT scans were extremely small when averaged over the entire 
cohort. This tended to lead to imprecise ICER estimates among some cohorts and 
comparisons even with a Monte Carlo size of 75 million per arm. Including poor 
compliance in the analyses would have compounded this problem given that the benefits 
would now be limited to a smaller population. Still, 100% compliance is obviously not a 
realistic assumption and so the consequences should be considered.176-178 Poor adherence 
will undoubtedly lead to a reduction in the impact of recommended surveillance. 
However it is less clear that it will impact the cost-effectiveness of alternative strategies 
and the selection of optimal care. Compliance has been a hot topic in recent analyses of 
alternative CRC screening strategies and for good reason.179 180 There is reportedly 
significant variation in patient compliance depending on the test, e.g., sigmoidoscopy, 
colonoscopy, or CT colonography. In the case of post-diagnosis surveillance, however, it 
is less clear that this is an issue. Patients who stop attending routine clinical visits and 
undergoing CEA testing are also likely to stop getting a CT scan and vise versa. These 
patients would fail to get the residual benefit from further surveillance testing, but they 
would also stop using additional resources associated with surveillance and surveillance-
induced salvage therapy. These patients essentially opt into the baseline treatment arm of 
no surveillance. The most plausible way poor adherence could affect the results of the 
cost-effectiveness analysis would be if patients stopped undergoing CEA testing, say 
after 1-2 years, but would be willing to undergo a second CT scan near the end of that 
period. Additional empirical research on compliance in the Medicare population in 
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contemporary practice would help evaluate this possibility. Still, future research should 
formally investigate such possibilities. 
The recommendations offered above inevitably are limited by the set of interventions 
studied in this paper. For example, in this paper, I did not investigate more intensive CT 
imaging concentrated in the first year or two as has been studied in the FACS and 
GILDA trials. I omitted such strategies because they were not included in any of the most 
recent professional-society guidelines the way that varying lengths of annual CT scans 
were. Moreover, given the already computationally burdensome nature of the analyses of 
this paper, it would have been costly to increase the number of comparisons. I instead 
chose to prioritize performing separate analyses for stage, location, and age. Future 
research could focus on optimizing the timing and frequency of CT scans occurring in the 
first 24 months. 
Similarly, the above recommendations do not apply to stage I patients or patients 
older than 75. It is unlikely that intensive CT imaging would be cost-effective in either 
group, but future research should investigate these questions. For example, it is possible 
that somewhat regular CEA testing and a CT scan at 12-18 months might be appropriate 
for stage I rectal cancer patients. In the cast of patients 80 or older, it is unclear that many 
of the current model parameters would apply to this population. 
The above recommendations accept the causal hypothesis of the model. However, the 
above results obviously do not establish the truth of that hypothesis. In Chapter 3, I 
argued in support of this theory, but clearly it is supported by weak evidence. As noted in 
the introduction, policymakers and payers thus face a decision in the absence of good 
evidence. In the abstract, this decision problem involves making a choice among multiple 
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mutually-exclusive clinical strategies (one of which is offering no extra-colonic follow-
up) with imperfect information about their relative benefits (among other things). In 
principle, a formal decision analysis could be used to resolve this dilemma and determine 
whether further information should be collected. While such an analysis obviously cannot 
create additional evidence, it can be used to identify the optimal strategy given the 
available evidence. In a context where the goal is to maximize health gains within a given 
budget, it has been convincingly argued that the optimal (clinical) strategy is that with the 
highest expected net benefit, regardless of the results of any statistical inference.181 The 
idea then would be to make a probabilistic sensitivity analysis (PSA) the main analysis 
(rather than a sensitivity analysis) and include our full uncertainty about the benefit of 
intensive surveillance in that analysis. We would then select the strategy with the greatest 
mean NMB as optimal (which might be no surveillance) given the evidence we have and 
secondly evaluate whether the expected benefits of gathering further information, e.g., a 
very large RCT, would outweigh the expected costs. Decision scientists might wonder 
why such an approach was not taken. 
Crucially, such an analysis would require formalizing the full extent of our 
uncertainty concerning the benefit of intensive follow-up. A simple approach would be to 
use the meta-analytic predictive distribution of the all-cause mortality hazard ratio (HR). 
However, this approach would be problematic for two reasons. First, the meta-analyses 
include multiple studies performed in an era in which patients faced a notably higher 
recurrence rate than they do in contemporary practice. I showed in Chapter 3 of this 
dissertation that the recurrence rate is an important determinant of the magnitude of the 
reduction in mortality hazards associated with surveillance. Second, any meta-analysis 
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would inevitably include a heterogeneous set of interventions grouped as ‘intensive’, 
‘minimal’, or no surveillance. However, we are really interested in more discriminating 
comparisons, e.g., comparing routine CEA and 1 CT scan to 2 or 3 CT scans. A related 
problem is that the model was constructed in such a way that there is no such single 
parameter governing the benefit of surveillance. Rather, because we are interested in the 
latter type of comparisons, the model explicitly characterizes the development, detection, 
and treatment of recurrence and differing mortality experiences after different treatments 
for recurrence. 
In the current implementation, the benefit of salvage therapy basically consists of the 
discrepancy between two survival curves: one for patients treated with an R0 resection 
and one for patients for which curative resection is not possible. As described in Chapter 
2, the latter were taken from RCTs of systemic chemotherapy for patients with uncurable 
disease. The former set of survival curves are based upon those observed in a large 
community-practice case-series. However, as noted in Chapter 3, they are consistent with 
the survival experience observed among patients treated with curative intent in the FACS 
trial and in other unselected cohort studies involving intensive follow-up. Thus, a full 
decision analysis would require implicitly or explicitly putting a distribution on this 
discrepancy. While technically feasible, it is unclear what sort of distribution would be 
appropriate and non-arbitrary. While it is worth exploring this option in future research, it 
is likely that the results of the analysis would depend heavily on the distribution chosen. 
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Appendix A 
 
Table A.1: Most Recent Professional Society Guidelines for Follow-up 
Organization 
(Reference) 
Stages 
Covered 
Endoscopy 
(Intraluminal) 
CEA  
Clinical 
Visit 
(History 
& 
Physical) 
Imaging 
ASCO13 II, III 
Colonoscopy at 1 
year after surgery 
(before 1 year if 
no clearing 
colonoscopy) and 
then every 5 years 
(depending upon 
results). 
Every 3-6 
months for 5 
years 
(depending 
on risk) 
Every 3-6 
months for 5 
years 
(depending 
on risk) 
Annual CT 
of Abdomen 
and Chest for 
3 years (6 
months if 
high risk). 
For high-risk 
rectal, also 
Pelvic CT 
ASCRS14 
I (high-risk), 
II, III, IV 
(isolated 
metastases 
treated for 
cure) 
Colonoscopy at 1 
year (3-6 months 
if no clearing 
colonoscopy) and 
then in 1 (3) more 
years if adenomas 
(normal). 
For Rectal cancer, 
proctoscopy every 
6-12 months for 
3-5 years 
Every 3-6 
months for 2 
years, and 
every 6 
months until 
5 years 
Every 3-6 
months for 2 
years, and 
every 6 
months until 
5 years 
Annual CT 
of abdomen, 
chest, and 
pelvis for 5 
years for 
colon and 
rectal (6 
months if 
high risk) 
NCCN160 I-III 
Colonoscopy at 1 
year and then 3 
years later and 
then every 5 years 
if clear 
Every 3-6 
months for 2 
years, and 
every 6 
months until 
5 years 
Every 3-6 
months for 2 
years, and 
every 6 
months until 
5 years 
Annual CT 
of abdomen, 
chest, and 
pelvis for 
colon and 
rectal cancer 
for up to 5 
years 
(depending 
on risk)  
ACS182 I-III 
Colonoscopy at 
year 1 and then 
repeat in 3 years 
(1 year) if clear 
(advanced 
adenoma). If clear 
at year 4, then 
repeat every 5 
years. 
Every 3-6 
months for 2 
years, and 
every 6 
months until 
5 years 
Every 3-6 
months for 2 
years, and 
every 6 
months until 
5 years 
Annual CT 
of abdomen, 
chest, and 
pelvis for 
colon and 
rectal  cancer 
for 5 years 
(only high 
risk stage I-
II) 
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ASCO: American Society of Clinical Oncology. ASCRS: American Society of Colon and Rectal Surgeons. 
NCCN: National Cancer Care Network. ACS: American Cancer Society. NICE: National Institute for 
Health and Care Excellence (UK). ESMO: European Society for Medical Oncology. 
 
 
 
 
 
 
 
 
  
NICE (UK)183 
I-III, IV 
(treated with 
potentially 
curative 
intent) 
Colonoscopy at 1 
year. If normal, 
another 
colonoscopy in 5 
years. If 
abnormal, interval 
depends upon 
finding. 
At least 
every 6 
months for 
first 3 years. 
Regular 
follow-up, 
beginning 4-
6 weeks after 
operation. 
CT of 
abdomen, 
chest, and 
pelvis at 
least 2 times 
in first 3 
years for 
rectal and 
colon cancer. 
ESMO16 
Stage I-III, 
Stage IV if 
treated 
with 
curative 
intent. 
Imaging 
for stage 
II-IV 
generally 
At diagnosis 
and then every 
5 years if clear. 
For rectal 
cancer treated 
with local 
excision, 
sigmoidoscopy 
every 3-6 
months for 3 
years and then 
6-12 months 
until 5 years. 
Every 3 
months for 2 
years, and 
every 6 
months until 
5 years 
Every 3 
months for 2 
years, and 
every 6 
months until 
5 years 
CT of 
abdomen and 
chest every 6 
months 
(stage IV) or 
12 months 
(stage II-III) 
for high risk 
patients 
(maybe 
stopping at 3 
years). Might 
replace CT 
of abdomen 
with 
contrast-
enhanced 
ultrasound 
every 3-6 
months. 
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Table A.2: Details of Randomized Control Trials 
Lead 
Author 
(Year of 
Publication) 
& Source 
Sample Size 
Enrollment 
Period 
Country 
Location 
Distribution 
Stage 
Distribution 
Overall 
Recurrence 
  
Makela 
(1995)31 
 
Trt N = 52 
Crl N = 54 
1988-1990 Finland 
Trt Rectal = 
30% 
Crl Rectal = 
28% 
Dukes A = 
26% 
Dukes B = 
45% 
Dukes C = 
28% 
41% 
Ohlsson 
(1995)32 
Trt N = 53 
Ctrl N = 54 
1983-1986 Sweden 
Trt Rectal = 
36% 
Ctrl Rectal = 
32% 
Dukes A = 
18% 
Dukse B = 
44% 
Dukes C = 
38% 
33% 
Kjeldson 
(1997)184 
Trt N = 290 
Ctrl N = 307 
1983-1994 Denmark 
Trt Rectal = 
46% 
Ctrl Rectal = 
49% 
Dukes A = 
23% 
Dukes B = 
49% 
Dukes C = 
28% 
24% 
Pietra 
(1998)33 
Trt N = 104 
Ctrl N = 103 
1987-1990 Italy 
Trt Rectal = 
30% 
Ctrl rectal = 
36% 
Dukes B = 
59% 
Dukes C = 
41% 
40% 
Schoemaker 
(1998)34  
Trt N = 167 
Ctrl N = 158 
1984-1990 US 
Trt Rectal = 
28% 
Ctrl Rectal = 
26% 
Dukes A = 
22% 
Dukes B = 
47% 
Dukes C = 
31% 
37% 
Secco 
(2002)41  
Trt N = 192 
(108 high risk, 
84 low risk) 
Ctrl N = 145 
(84 high risk, 
61 low risk) 
1988-1996 Italy 
Trt Rectal = 
100% 
Ctrl Rectal = 
100% 
Dukes B = 
40% 
Dukes C = 
60% 
55% 
Rodriquez-
Moranta 
(2006)146 
Trt N = 127 
Ctrl N = 132 
1997-2001 Spain 
Trt Rectal = 
23% 
Ctrl Rectal = 
27% 
Stage II = 
61% 
Stage III = 
39% 
27% 
Sobhani 
(2008)28 
Trt N = 65 
Ctrl N = 65 
2001-2004 France 
Trt Rectal = 
44% 
Ctrl Rectal = 
41% 
Unclear 
35% 
(0nly 15 
months 
follow-up) 
Wang 
(2009)185  
Trt N = 165 
Ctrl N = 161 
1995-2001 China 
Trt Rectal = 
47% 
Ctrl Rectal = 
48% 
Dukes A = 
31% 
Dukes B = 
41% 
Dukes C = 
29% 
Unclear 
Primrose 
(2014)45 46 
"FACS Trial" 
CT & CEA N 
= 302 
CT Only N = 
299 
CEA Only N = 
2003-2009 UK 
CEA & CT 
Rectal = 32% 
CT-Only 
Rectal = 34% 
CEA-Only 
Dukes A = 
22% 
Dukes B = 
47% 
17% 
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300 
Min N = 301 
Rectal = 28% 
Minimial Arm 
= 30% 
Dukes C = 
31% 
Rosati 
(2016)35 
"GILDA 
Trial" 
Trt N = 615 
Ctrl N = 613 
1998-2006 Italy 
Trt Rectal = 
24% 
Ctrl Rectal = 
24% 
Dukes B = 
50% 
Dukes C = 
50% 
23% 
Treasure 
(2014)24 
"CEA Second 
Look Trial" 
Trt N = 108 
Ctrl N = 108 
1982-1993 UK Unclear 
Dukes A = 
5% 
Dukes B = 
46% 
Dukes C = 
49% 
Unclear 
Verbone 
(2015)186 187 
"CEAwatch 
Trial" 
Used Stepped-
Wedge Cluster 
Design 
Hospital N = 
11 
Patient N = 
3,223 
2010-2012 Netherlands Overall = 37% 
Dukes A = 
67% 
Dukes B = 
33% 
8% 
Table A.2 gives details of the 13 randomized control trials that have compared more intensive to 
less intensive follow-up regimens. Trt = Treatment-arm; Ctrl = Control-arm 
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Table A.3: Surveillance Schedules of Randomized Control Trials 
Lead 
Author 
(Year of 
Publication) 
& Source 
Imaging 
CEA Assays  
(Medical Exam and 
Physical History 
Implied) 
Endoscopy 
  
Makela 
(1995)31 
 
Trt:  
Chest X-ray: every 3 months for 
2 years, every 6 months for 3 
years 
Ultrasound of Liver: Every 6 
months for 5 years 
Abdominal CT: Annually for 5 
years (pelvic for rectal likely too, 
not clear) 
Crtl:  
Chest X-ray: every 3 months for 
2 years, every 6 months for 3 
years 
Trt: every 3 months for 2 
years, every 6 months for 3 
years 
Ctrl: every 3 months for 2 
years, every 6 months for 3 
years 
Trt:  
Colonoscopy: Annually 
year 1-5 
Flexible 
Sigmoidoscopy (Rectal 
and Sigmoid Only): 
every 3 months for 5 
years 
Ctrl:  
Barium Enema: 
Annually year 1-5 
Rigid Sigmoidoscopy 
(Rectal and Sigmoid 
Only): every 3 months 
for 2 years, every 6 
months for 3 years 
Ohlsson 
(1995)32 
Trt:  
Chest X-ray: every 3 months for 
2 years, every 6 months for 2 
years, and at 5 years 
CT of pelvis: (For rectal patients 
only): at 3, 6, 12, 18, 24 months 
Ctrl: 
--- 
Trt:  
every 3 months for 2 years, 
every 6 months for 2 years, 
and at 5 years  
Ctrl: 
--- 
Trt:  
Colonoscopy or 
flexible 
sigmoidoscopy: at 3, 9, 
15, 21, 30, 42, 60 months 
Ctrl: 
Recommendation to get 
occult blood testing 
every 3 months for 2 
years, and then once a 
year for 3 years 
Kjeldson 
(1997)184 
Trt:  
Chest X-ray: every 6 months for 
3 years, every 12 months for 2 
years, 10 years, 12.5 years, 15 
years  
Ctrl: 
Chest X-ray: 5 years, 10 years, 
15, years 
Trt:  
---  
Ctrl: 
--- 
Trt:  
Colonoscopy: every 6 
months for 3 years, every 
12 months for 2 years, 10 
years, 12.5 years, 15 
years  
Ctrl: 
Colonoscopy: 5 years, 
10 years, 15, years 
Pietra (1998)33 
 
Trt:  
Abomdinal US: every 3 months 
for 2 years, every 6 months for 3 
years 
CT (unclear what type): annually 
for 5 years 
Chest X-ray: annually for 5 
years 
Ctrl: 
Abdominal US: every 6 months 
for 1 year, annually for 4 years 
Trt:  
every 3 months for 2 years, 
every 6 months for 3 years 
Ctrl: 
every 6 months for 1 year, then 
annually for 4 years 
Trt:  
Colonoscopy: annually 
for 5 years 
Ctrl: 
Colonoscopy: annually 
for 5 years 
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Chest X-ray: annually for 5 
years 
Schoemaker 
(1998)34  
 
Trt:  
Abdominal CT: annually for 5 
years 
Chest X-ray: annually for 5 
years 
Ctrl: 
--- 
Trt:  
every 3 months for 2 years, 
every 6 months for 3 years 
Ctrl: 
every 3 months for 2 years, 
every 6 months for 3 years 
 
Trt:  
Colonoscopy: annually 
for 5 years 
Ctrl: 
--- 
Secco (2002)41 
High Risk 
Subset  
Trt:  
Abdominal/Pelvic US: every 6 
months for 3 years, annually for 2 
years 
Chest X-ray: annually for 5 
years 
Ctrl: 
--- 
Trt:  
every 3 months for 2 years, 
every 4 months for 3rd year, 
every 6 months for 4th/5th year 
Ctrl: 
--- 
Trt:  
Rigid Sigmoidoscopy: 
annually for 5 years 
Ctrl: 
--- 
Secco (2002)41 
Low Risk 
Subset 
Trt:  
Abdominal/Pelvic US: every 6 
months for 2 years, annually for 3 
years 
Chest X-ray: annually for 5 
years 
Ctrl: 
--- 
Trt:  
every 6 months for 2 years, 
annually for 3 years 
Ctrl: 
--- 
Trt:  
Rigid Sigmoidoscopy: 
years 1, 2, 4 
Ctrl: 
--- 
Rodriquez-
Moranta 
(2006)146 
Trt:  
Abdominal US: (colon only) 
every 6 months for 2 years, 
annually for 3 years 
Abdominal/Pelvic CT: (rectal 
only) every 6 months for 2 years, 
annually for 3 years 
Chest X-ray: annually for 5 
years 
Ctrl: 
--- 
Trt:  
every 3 months for 2 years, 
every 6 months for 3 years 
Ctrl: 
every 3 months for 2 years, 
every 6 months for 3 years 
Trt:  
Colonoscopy: annually 
for 5 years 
Ctrl: 
Colonoscopy: years 1 
and 3 
Sobhani 
(2008)28 
(trial only 
involved only 
15 months of 
follow-up: 
from 9 to 24 
months post 
surgery) 
Trt:  
Abdominal US: at 12, 18, 21, 24 
months 
Abdominal CT: at 9, 15 months 
FDG-PET: at 9, 15 months 
Chest X-ray: at 9, 15, 21 months 
Ctrl:  
Abdominal US: at 12, 18, 21, 24 
months 
Abdominal CT: at 9, 15 months 
Chest X-ray: at 9, 15, 21 months 
Trt:  
At 9, 12, 15, 18, 21, 24 months 
Ctrl: 
At 9, 12, 15, 18, 21, 24 months 
Trt: 
--- 
Ctrl: 
--- 
Wang (2009)185  
Trt:  
Abdominal US or CT: every 3 
months for 1 year, every 6 
months for 2 years, annually for 2 
years 
Trt:  
every 3 months for 1 year, 
every 6 months for 2 years, 
annually for 2 years 
Ctrl: 
Trt:  
Colonoscopy: every 3 
months for 1 year, every 
6 months for 2 years, 
annually for 2 years 
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Chest X-ray: every 3 months for 
1 year, every 6 months for 2 
years, annually for 2 years 
Ctrl: 
Abdominal US or CT: every 3 
months for 1 year, every 6 
months for 2 years, annually for 2 
years 
Chest X-ray: every 3 months for 
1 year, every 6 months for 2 
years, annually for 2 years 
every 3 months for 1 year, 
every 6 months for 2 years, 
annually for 2 years 
Ctrl: 
Colonoscopy: at 6, 30, 
60 months 
Primrose 
(2014)45 46 
"FACS Trial" 
CT & CEA:  
CT of Chest/Abdomen/Pelvis: 
every 6 months for 2 years, 
annually for 3 years 
CT Only:  
CT of Chest/Abdomen/Pelvis: 
every 6 months for 2 years, 
annually for 3 years 
CEA Only: 
CT of Chest/Abdomen/Pelvis: 
1 scan at 12-18 months 
Minimal: 
CT of Chest/Abdomen/Pelvis: 
1 scan at 12-18 months 
CT & CEA:  
every 3 months for 2 years, 
every 6 months for 3 years 
CT Only:  
--- 
CEA Only: 
every 3 months for 2 years, 
every 6 months for 3 years 
Minimal: 
--- 
CT & CEA:  
Colonoscopy: 2 years 
and 5 years 
CT Only:  
Colonoscopy: 2 years 
and 5 years CEA 
Only: 
Colonoscopy: 2 years 
and 5 years Minimal: 
Colonoscopy: at 5 years 
Rosati (2016)35 
"GILDA Trial" 
Trt:  
Abdominal US: at 4, 8, 12, 16, 
24, 36, 48, 60 months 
Abdominal/Pelvic CT: (rectal 
only) at 4, 12, 24, 48 months 
Chest X-ray: annually for 5 
years 
Ctrl: 
Abdominal US: (colon) at 4, 16 
months 
Abdominal US: (rectal) at 8, 16 
months 
Chest X-ray: (rectal only) at 1 
year 
Trt:  
every 4 months for 2 years, 
every 6 months for 2 years, at 5 
years 
Ctrl: 
every 4 months for 2 years, 
every 6 months for 2 years, at 5 
years 
Trt:  
Colonoscopy: annually 
for 5 years 
Proctoscopy:  (rectal 
only) at 4 and 8 months 
Ctrl: 
Colonoscopy: years 1 
and 4 
Proctoscopy:  (rectal 
only) at 4 months 
Treasure 
(2014)24 
"CEA Second 
Look Trial" 
Trt: 
--- 
Ctrl: 
--- 
All randomized patients had 
elevated CEA-levels. They 
were then randomized to 
second-look surgery or 
conservative treatment 
Trt: 
--- 
Ctrl: 
--- 
Verbone 
(2015)186 187 
"CEAwatch 
Trial" 
Trt:  
Abdominal CT: annually for 3 
years 
Ctrl: 
Abdominal US: every 6 months 
for 3 years, annually for 2 years 
Chest X-ray: every 6 months for 
3 years, annually for 2 years 
Trt:  
every 2 months for 3 years, 
every 3 months for 2 years 
Ctrl: 
every 3-6 months for 3 years, 
annually for 2 years 
Trt: 
--- 
Ctrl: 
--- 
US = Ultrasound; Trt = Treatment Arm; Ctrl = Control Arm;  
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Appendix B 
 
 
 
Figure B.1 depicts the forest plot of the log odds ratio (OR) of the chances of 
asymptomatic (surveillance-based) detection of disease comparing intensive to control 
arms. A log OR of > 0 signifies the intensive arm had a greater proportion of 
surveillance-detected recurrences. The first column on the right gives the weights for 
each trial in the random-effect model. The dashed line that runs horizontally through the 
pooled-effect diamond shows the limits of the prediction interval. 
 
Of the 13 potentially relevant studies, two (Kjeldson 1997 & Wang 2009) were excluded 
due to a focus on endoscopic follow-up. Sobhani (2008) was excluded due to limited 
follow-up time (15 months only). The CEASL trial was excluded for questionable 
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relevance (unclear if CEA lead to CT scans to confirm recurrence), and the CEAwatch 
trial was excluded because it did not use a fully experimental design. Finally, two 
potentially relevant trials (Pietra 1998 and Schoemaker 1998) were excluded due to 
inadequate information. 
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Figure B.2: Forest Plot of the Probability of Asymptomatic Detection in the 
Intervention Arm 
 
Figure B.2 depicts a forest plot for the probability that a patient with recurrence is 
detected asymptomatically in the intensive arm. It uses the same includes/excludes as 
Figure B.1. 
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Figure B.3 depicts the forest plot of the log odds ratio (OR) of the chances of R0 curative 
resection among patients who present with a recurrence within 5 years comparing 
intensive to control arms. A log OR of > 0 signifies the intensive arm had a greater 
proportion of R0 curative resections. Recall an R0 resection means macroscopically and 
microscopically clear margins. The first column on the right gives the weights for each 
trial in the random-effect model. The dashed line that runs horizontally through the 
pooled-effect diamond shows the limits of the prediction interval. 
 
Of the 13 potentially relevant studies, 2 (Kjeldson 1997 & Wang 2009) were excluded 
due to a focus on endoscopic follow-up. Sobhani (2008) was excluded due to limited 
follow-up. The CEASL trial was excluded for questionable relevance (unclear if CEA 
lead to CT scans to confirm recurrence), and the CEAwatch trial was excluded because it 
did not technically use an experimental design.  
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Figure B.4: Forest Plot of the Probability of R0 Curative Resection in the 
Intervention Arm 
 
Figure B.4 depicts a forest plot for the probability that a patient with recurrence 
undergoes R0 curative resection in the intensive arm. It uses the same includes/excludes 
as Figure B.3. 
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Figure B.5 depicts the calibration results for stage III colon cancer patients treated with 
surgery alone. The ‘Best Model’ line is the model-output (smoothed hazard function) 
using the highest-probability parameter sets (for the time-to-detectable-disease and time-
to-clinical-disease processes). The brown dashed lines represent the model-output with 
the other included parameter sets. The y-axis presents the hazard rate and has been scaled 
to cases per 100-person months.  
 
The data for this target was assumed to have been generated in the absence of any routine 
follow-up. 
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Figure B.6 depicts the calibration results for stage III colon cancer patients treated with 
adjuvant 5-FU/LV. The ‘Best Model’ line is the model-output (smoothed hazard 
function) using the highest-probability parameter sets (for the time-to-detectable-disease 
and time-to-clinical-disease processes). The brown dashed lines represent the model-
output with the other included parameter sets. The y-axis presents the hazard rate and has 
been scaled to cases per 100-person months.  
 
The data for this target was assumed to have been generated with under the following 
follow-up schedule: CEA every 3 months for 2 years, then every 6 months for 3 years. 
CT every year for 5 years. 
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Figure B.7 depicts the calibration results for stage III colon cancer patients treated with 
adjuvant FOLOFX. The ‘Best Model’ line is the model-output (smoothed hazard 
function) using the highest-probability parameter sets (for the time-to-detectable-disease 
and time-to-clinical-disease processes). The brown dashed lines represent the model-
output with the other included parameter sets. The y-axis presents the hazard rate and has 
been scaled to cases per 100-person months.  
 
The data for this target was assumed to have been generated with under the following 
follow-up schedule: CEA every 3 months for 2 years, then every 6 months for 3 years. 
CT every year for 5 years. 
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Figure B.8 depicts the calibration results for stage II colon cancer patients treated with 
surgery alone in the old era. The ‘Best Model’ line is the model-output (smoothed hazard 
function) using the highest-probability parameter sets (for the time-to-detectable-disease 
and time-to-clinical-disease processes). The brown dashed lines represent the model-
output with the other included parameter sets. The y-axis presents the hazard rate and has 
been scaled to cases per 100-person months.  
 
The data for this target was assumed to have been generated in the absence of any routine 
follow-up. 
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Figure B.9 depicts the calibration results for stage II colon cancer patients treated with 
surgery alone in the new era. The ‘Best Model’ line is the model-output (smoothed 
hazard function) using the highest-probability parameter sets (for the time-to-detectable-
disease and time-to-clinical-disease processes). The brown dashed lines represent the 
model-output with the other included parameter sets. The y-axis presents the hazard rate 
and has been scaled to cases per 100-person months.  
 
The data for this target was assumed to have been generated in the absence of any routine 
follow-up. 
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Figure B.10 depicts the calibration results for stage II colon cancer patients treated with 
5-FU/LV in the old era. The ‘Best Model’ line is the model-output (Kaplan-Meier 
Survival Curve) using the highest-probability parameter sets (for the time-to-detectable-
disease and time-to-clinical-disease processes). The brown dashed lines represent the 
model-output with the other included parameter sets. 
 
The data for this target was assumed to have been generated in the absence of any routine 
follow-up. 
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Figure B.11 depicts the calibration results for stage II colon cancer patients treated with 
adjuvant 5-FU/LV in the new era. The ‘Best Model’ line is the model-output (smoothed 
hazard function) using the highest-probability parameter sets (for the time-to-detectable-
disease and time-to-clinical-disease processes). The brown dashed lines represent the 
model-output with the other included parameter sets. The y-axis presents the hazard rate 
and has been scaled to cases per 100-person months.  
 
The data for this target was assumed to have been generated with under the following 
follow-up schedule: CEA every 3 months for 2 years, then every 6 months for 3 years. 
CT every year for 5 years.  
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Figure B.12 depicts the calibration results for stage II colon cancer patients treated with 
adjuvant FOLOFX. The ‘Best Model’ line is the model-output (smoothed hazard 
function) using the highest-probability parameter sets (for the time-to-detectable-disease 
and time-to-clinical-disease processes). The brown dashed lines represent the model-
output with the other included parameter sets. The y-axis presents the hazard rate and has 
been scaled to cases per 100-person months.  
 
The data for this target was assumed to have been generated with under the following 
follow-up schedule: CEA every 3 months for 2 years, then every 6 months for 3 years. 
CT every year for 5 years. 
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Figure B.13 depicts the calibration results for stage I colon cancer patients treated in the 
old era. The ‘Best Model’ line is the model-output (Kaplan-Meier Survival Curve) using 
the highest-probability parameter sets (for the time-to-detectable-disease and time-to-
clinical-disease processes). The brown dashed lines represent the model-output with the 
other included parameter sets. 
 
The data for this target was assumed to have been generated with under the following 
follow-up schedule: CEA every 3 months for 2 years, then every 6 months for 3 years. 
CT scans at 1 and 2 years. 
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Figure B.14 depicts the calibration results for stage I colon cancer patients treated in the 
new era. The ‘Best Model’ line is the model-output (Kaplan-Meier Survival Curve) using 
the highest-probability parameter sets (for the time-to-detectable-disease and time-to-
clinical-disease processes). The brown dashed lines represent the model-output with the 
other included parameter sets. 
 
The data for this target was assumed to have been generated with under the following 
follow-up schedule: CEA every 3 months for 2 years, then every 6 months for 3 years. 
CT scans at 1 and 2 years. 
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Figure B.15 depicts the calibration results for stage I rectal cancer patients treated with 
total mesorectal excision surgery. The ‘Best Model’ line is the model-output (Kaplan-
Meier Survival Curve) using the highest-probability parameter sets (for the time-to-
detectable-disease and time-to-clinical-disease processes). The brown dashed lines 
represent the model-output with the other included parameter sets. 
 
The data for this target was assumed to have been generated with under the following 
follow-up schedule: CEA every 3 months for 2 years, then every 6 months for 3 years. 
CT scans at 1 and 2 years. 
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Figure B.16 depicts the calibration results for stage II rectal cancer patients. These 
patients were treated with total mesorectal excision (TME) surgery and adjuvant 5-
FU/LV chemotherapy. Some of them received preoperative or postoperative radiation 
therapy. The ‘Best Model’ line is the model-output (Kaplan-Meier Survival Curve) using 
the highest-probability parameter sets (for the time-to-detectable-disease and time-to-
clinical-disease processes). The brown dashed lines represent the model-output with the 
other included parameter sets. 
 
The target source was a RCT enrolling patients in the late 1990’s which did not call for 
routine surveillance. However, I assumed patients underwent CEA testing every 6 
months for 3 years and once a year for 2 years. 
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Figure B.17 depicts the calibration results for stage III rectal cancer patients. These 
patients were treated with total mesorectal excision (TME) surgery, neoadjuvant 
chemoradiation therapy and adjuvant chemotherapy, both using a FOLFOX regimen. The 
‘Best Model’ line is the model-output (Kaplan-Meier Survival Curve) using the highest-
probability parameter sets (for the time-to-detectable-disease and time-to-clinical-disease 
processes). The brown dashed lines represent the model-output with the other included 
parameter sets. 
 
The data for this target was assumed to have been generated with under the following 
follow-up schedule: CEA every 6 months for 2 years, then every 12 months for 3 years 
and annual CT scans. 
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Table B.1: Surveillance Schedule for the Intensive and Minimal Arms Used 
in Calibration 
Follow-
up Arm 
Test 3 6 9 12 15 18 21 24 30 36 42 48 54 60 
Inten. 
Arm 
CT .08 .75 .04 .88 0 .42 0 .88 0 .75 0 .75 0 .63 
Min. 
Arm 
CT 0 .08 0 .25 0 .25 0 0 0 0 0 0 0 .0 
Inten. 
Arm 
CEA .96 .96 .96 .96 .96 .96 .96 .96 .96 .96 .96 .96 .96 .96 
Min. 
Arm 
CEA .5 .63 .5 .63 .5 .5 .5 .63 .5 .63 .5 .63 .38 .5 
Table B.1 depicts the follow-up schedule for the two regimens used to calibrate the natural 
history model parameters. In particular, these follow-up regimens were used when evaluating 
model-produced surveillance output in relation to the four meta-analytic targets for the purpose of 
assigning a probability mass to each pair of hazard functions (time to detectable and clinical 
disease). The top row gives the time in months (from 3 to 60 months) after the primary resection. 
In each cell, the number (between 0 and 1) represents the proportion of patients in the simulation 
that were assigned each test at each time period. These numbers were derived from combining the 
follow-up regimens for the 8 trials that contributed to the targets depicted in Figure B.3/B.4. 
Inten. = Intensive; Min. = Minimal 
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Table B.2: Description of Distribution of Sojourn Times by Disease Type 
DISEASE 
Overall Mean 
Sojourn Time 
(Range of 
Means) 
Overall Median 
Sojourn Time 
(Range of 
Medians) 
Overall 1st 
Quartile of 
Sojourn Times 
(Range of 1st 
Quartiles) 
Overall 3rd 
Quartile of 
Sojourn Times 
(Range of 3rd 
Quartiles) 
Stage III 
Colon No Adj 
17.8 
(11-31.9) 
10.8 
(6.1-20.5) 
3.1 
(1.5-6.9) 
24.6 
(15.3-45.1) 
Stage III 
Colon 5-FU + 
LV 
18.3 
(10.9-36.7) 
12.1 
(7.2-25) 
4.9 
(2.9-10.2) 
24.9 
(14.7-51.5) 
Stage III 
Colon 
FOLFOX 
21.4 
(10.2-39.3) 
11.6 
(7.3-24.1) 
5.3 
(3.8-8.8) 
28.5 
(13.3-63.8) 
Stage II 
Colon No Adj 
(New) 
23.2 
(14-36.4) 
12.4 
(7.2-20.5) 
4.0 
(2.1-6.8) 
30.4 
(17.9-51.3) 
Stage II 
Colon No Adj 
(Old) 
24 
(14.9-32.6) 
12.9 
(7.7-18) 
4.1 
(2.3-5.9) 
31.7 
(19.2-44.7) 
Stage II 
Colon 5-FU + 
LV (New) 
29.8 
(18.2-54.5) 
19.8 
 (11.5-40.6) 
7.6 
 (4.2-16.0) 
41.9 
(24.6-84.6) 
Stage II 
Colon 5-FU + 
LV (Old) 
23 
(15-32.9) 
12.2 
 (7.8-18.3) 
3.9 
 (2.4-6.0) 
30.3 
(19.3-45) 
Stage II 
Colon 
FOLFOX 
41.5 
(23.4-70.0) 
29.3 
(14.8-59.5) 
11.3 
 (5.6-23.4) 
61.8 
(31.9-123.1) 
Stage I Colon 
(New) 
37.1 
(25.1-62.3) 
27.8 
(17.6-51.5) 
11.4 
 (6.6-22.3) 
53.6 
(36-97.2) 
Stage I Colon 
(Old) 
35.6 
(25-48) 
26.3 
(17.6-36.9) 
10.7 
 (6.7-15.7) 
50.9 
(35.4-70) 
Stage III 
Rectal 
23.4 
(11.3-45.3) 
12.5 
(7.9-27.1) 
6.3 
(4.8-9.3) 
34.5 
(16.1-65.3) 
Stage II 
Rectal 
30.5 
(19.2-56.4) 
20.8 
 (12.3-44.4) 
9.6 
 (6.2-18.0) 
49.4 
(26.3-86.6) 
Stage I Rectal 
36.4 
(25.2-55.4) 
29.2 
(17.5-46.9) 
13.7 
 (6.7-22.7) 
54.1 
(35.9-79.5) 
For each combination of disease location, stage, adjuvant therapy, and period, Table B.2 
gives information about the distribution of patient sojourn times in months. In particular, 
the mean, median, and 1st and 3rd quartiles are given. These point estimates represent the 
model’s best prediction of the moment or quantile of the distribution made by averaging 
over parameter sets. The values in parentheses given below represent the range (across 
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different parameter sets) of each moment or quantile of the distribution. Though it should 
be noted that the values are not necessarily equally likely. 
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Appendix D 
 
Table D1:Costs of Individual Services  
Resource 
Type of 
Cost 
CPT 
Codes 
Physician 
Reimbursement 
or Total 
Outpatient 
Reimbursement 
(2017 US $) 
DRG 
Codes & 
DRG 
Weights 
Total 
Hospital 
Cost  
(2017 
US $) 
Total 
Reimbursement 
(2017 US $) 
FOLLOW-UP & DIAGNOSTIC TESTS 
CT of Pelvis w/ IV Outpatient 72193 $229 --- --- $229 
CT of Abdomen w/ 
IV 
Outpatient 74160 $234 --- --- $234 
CT of Abdomen & 
Pelvis w/ IV 
Outpatient 74177 $315 --- --- $315 
CT of Chest w/ IV Outpatient 71260 $233 --- --- $233 
MRI of Pelvis w/ IV Outpatient 72196 $416 --- --- $416 
MRI of Abdomen 
w/ IV 
Outpatient 74182 $460 --- --- $460 
CEA Assay Outpatient 82378 $26 --- --- $26 
Clinical Visit (30 
Min)  
Outpatient 99203 $109 --- --- $109 
Diagnostic 
Laparoscopy 
Outpatient 49320 $338 --- --- $338 
Diagnostic 
Thoracoscopy w/ 
biopsy of Nodule 
Outpatient 32608 $394 --- --- $394 
CT-guided FN 
Biopsy 
Outpatient 
77012 
47000 
$438 --- --- $438 
HEPATIC RESECTION 
No Resection/R2 
Resection 
(Laparotomy) 
Inpatient 49000 $800 
407 = 
2.0118 
$11,996 $12,796 
Intraoperative Liver 
US 
Inpatient 76998 $65 
Done in 100% Surgery 
($65 * 1) 
$65 
Wedge Resection  Inpatient 47100 $876 405 (MCC) 
= 5.4464 
406 (CC) = 
2.7825 
407 (None) 
= 2.0118 
405 = 
$32,477 
406 = 
$16,592 
407 = 
$11,996 
 
Partial lobectomy Inpatient 47120 $2,424 
Trisegmentectomy Inpatient 47122 $3,568 
Total left lobectomy Inpatient 47125 $3,198 
Total right 
lobectomy 
Inpatient 47130 $3,436 
Liver Resection 
(Use) 
Inpatient 
(0.175, 0.525, 0.1, 0.1, 0.1) 
$2,446 
(0.44, 0.44, 0.12) 
$23,030 
$25,476 
Resection-Related 
Morbidity188 
Inpatient --- --- --- --- $37,425 
Resection-Related 
Mortality188 
Inpatient --- --- --- --- $92,810 
PULMONARY RESECTION 
No Resection/R2 
Resection 
(Thoracotomy) 
Inpatient 32100 $842 
165 = 
1.7898 
$10,672 $11,514 
Mediastinal LN 
Dissection 
Inpatient 38746 $224 
Done in 45% of 
resections ($224 * 0.45) 
$101 
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Wedge Resection 
1st Nodule with 
Thoracoscopy + 2nd 
Nodule 
Inpatient 
32666 
32667 
$904 + $164 = 
$1,068 
163 (MCC) 
= 5.0194 
164 (CC) = 
2.5187 
165 (None) 
= 1.7898  
163 = 
$29,930 
164 = 
$15,019 
165 = 
$10,672 
 
Segmentectomy Inpatient 32484 $1,492 
Lobectomy Inpatient 32480 $1,536 
Pneumonectomy Inpatient 32440 $1,625 
Bilobectomy Inpatient 32482 $1,643 
Lung Resection 
(Use) 
Inpatient 
(0.66, 0.07, 0.25, 0.01, 0.01) 
$1,226 
(0.44, 0.44, 0.12) 
$21,058 
$22,284 
Resection-Related 
Morbidity189 
Inpatient --- --- --- --- $43,898 
Resection-Related 
Mortality189 
Inpatient --- --- --- --- $87,796 
RESECTION FOR PELVIC RECURRENCE 
No Resection/R2 
Resection 
(Laparotomy) 
Inpatient 49000 $800 
735 (F) = 
1.2428 
708 (M) =  
1.3476 
$ 7,754 $8,554 
Excise Sacral Spine 
Tumor 
Inpatient 49215 $2,316 
Done in 32% of 
resections ($2,316*0.32) 
$741 
IOERT190 Inpatient 
77425 
77469 
$483 
$327 
Done in 2/3 of 
resections (2/3 * $810) 
$540 
Transabdominal 
Resection: Partial 
Removal of Rectum 
Inpatient 45111 $1,125 
FEMALES 
734 (CC) = 
2.7192 
735 (None) 
= 1.2428 
MALES 
707 (CC) = 
1.8091 
708 (None) 
= 1.3476 
734 = 
$16,214   
735 = 
$7,411 
707 = 
$10,788 
708 = 
$8,036 
 
 
Abdomino-Perineal 
Resection: Removal 
of Rectum 
Inpatient 45110 $1,926 
Pelvic Exenteration Inpatient 45126 $2,862 
Pelvic Resection 
(Use) 
Inpatient 
(0.23, 0.40, 0.37)  
$2,088 
(0.88, 0.12) * 0.35  +  
(0.88, 0.12) * 0.65 
$12,103 
$14,191 
Resection-Related 
Morbidity191 
Inpatient --- --- --- --- $30,533 
Resection-Related 
Mortality191 
Inpatient --- --- --- --- $61,066 
RESECTION OF COLON LOCAL-REGIONAL RECURRENCE IN ABDOMEN 
No Resection/R2 
Resection 
(Laparotomy) 
Inpatient 49000 $800 
331 = 
1.6491 
$9,833 $10,633 
IOERT190 Inpatient 
77425 
77469 
$483 
$327 
Done in 15% of 
resections  
(0.15 * $810) 
$122 
Abdominal 
Resection for LR 
Recurrence in Colon 
Cancer166 
Inpatient --- --- --- --- $45,239 
(NEO)ADJUVANT THERAPY FOR RESECTABLE DISEASE 
3 Months of 
FOLFOX192 
Drug --- --- --- --- $16,414 
3 Months of 5-
FU/LV192 
Drug --- --- --- --- $3,679 
(Neo)adjuvant 
External-Beam 
Outpatient --- --- --- --- $6,400 
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Radiation 
Therapy
168
 
Table D.1 gives the costs or 2017 Medicare reimbursement rates for individual services. The first section 
gives the values for follow-up and diagnostic tests. These procedures are generally outpatient procedures. 
The third column identifies relevant CPT codes, and the 4th column gives the total costs (professional + 
technical component). The next four sections break down individual services for salvage treatment for 
hepatic, pulmonary, pelvic, and abdominal recurrence, respectively. The last of these relies mostly on an 
estimate from the literature. The other three sections detail CPT codes and reimbursement levels for 
physician fees (column 4). They do not include a technical component. In each of the 3 types of salvage 
surgeries for which a semi-micro-costing approach was taken, there were several CPT codes that might be 
used. For example, for hepatic metastectomy, there were 5 different common types of surgery found in the 
literature. While these 5 different procedures have different physician reimbursement rates, they share a 
common DRG and thus reimbursement for inpatient services. Thus variation in the procedure is assumed 
only to affect the physician fees. For Hepatic and Pulmonary metastectomy, there were 3 levels of each 
type of DRG: one for major comorbidities or complications (MCC), one for comorbidities or complications 
(CC), and one for none of these (None). Columns 5 and 6 give the DRGs and payment weights and 
reimbursement rates for each DRG, respectively, using a base payment rate of $5,962.93 per unit of weight. 
In the case of pelvic salvage, the DRG varies depending upon the sex of the patient. Moreover, only two 
levels were available for each DRG (CC vs None). In each case, the different procedures and levels of 
DRG are combined via a weighted average based on weights taken from the literature. These values are 
given in the row immediately under the set of rows identifying the different procedures and DRGs. These 
summary rows are identified in the first column by the type of salvage followed by ‘(Use)’. For example, 
‘Liver Resection (Use)’. The last column of Table D.1 gives the total costs, combining both physician fees 
and inpatient costs. For each of the three-mentioned types of salvage surgery, the rows immediately below 
this summary row given the average cost per case of treatment-related morbidity and mortality, 
respectively. In the case of surgery for local-regional recurrence in the abdomen (for colon cancer patients 
only), the mean cost per case of treatment is taken from the literature. This includes the expected costs 
associated with morbidity and mortality. For all 4 types of salvage surgery, the first row identifies the CPT 
codes, physician reimbursement rates, the selected level of DRG – None in every case, inpatient 
reimbursement rates, and total costs associated with failed resection or incomplete (R2) resection. Finally, 
the last section gives the costs for neoadjuvant and adjuvant radiation therapy and chemotherapy. In the 
latter case, costs are given per 3 months of treatment. These values were taken from the literature. The 
assumed utilization rates for these are given in Table D.2, and they are aggregated with salvage surgery 
costs in Table D.3. 
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Table D.2: Important Utilization Assumptions Regarding Salvage Surgery 
TYPE of 
RESOURCE 
SALVAGE SITE ASSUMPTIONS 
Distribution of DRGs 
Liver/Lung Surgery
153
 44% MCC, 44% CC, 12% None 
Pelvic Surgery67 153 
88% CC, 12% None  
65% Male, 35% Female 
Distribution of CPT 
Codes 
Liver Surgery
193
 
70% partial (<3 segments), 30% major 
Among partial: 75% Partial Lobectomy, 25% 
Wedge 
Among major: 1/3 Total Left, 1/3 Total Right, 1/3 
Trisegmentectomy 
Lung Surgery
194 195
 
66% Wedge (2 lesions), 25% lobectomy, 7% 
Segmentectomy,  
1% Pneumonectomy, 1% Bilobectomy 
Pelvic Surgery8 10 11 67 
23% Transabdominal Resection, 40% 
Abdominal-Perineal Resection, 37% Pelvic 
Exenteration 
Cumulative Incidence of 
30-day Treatment-
Related Mortality and 
Morbidity 
Liver Surgery
65 188 193
 
Mortality = 2.5% 
Morbidity = 20% 
Lung Surgery
66 196 197
 
Mortality = 0.9% 
Morbidity = 17.5% 
Pelvic Surgery
8 61
 
Mortality = 2.2% 
Morbidity = 17% 
Additional Inpatient 
Services 
Liver Surgery
153 198
 100% get Intraoperative Ultrasound 
Lung Surgery
90 194
 45% get Mediastinal Lymph Node Dissection 
Pelvic Surgery
8 67
 31% get Removal of Sacral Tumor 
Utilization of 
Chemotherapy 
Liver Surgery
193 199
 
16% neoadjuvant, 28% adjuvant, 19% both; 
90% double-agent, 10% single agent; 
Neoadjuvant = 3 months, Adjuvant = 6 months,  
Both = 3 + 3 months 
Lung Surgery
90 194 195
 
56% adjuvant; 
90% double-agent, 10% single-agent; 
Adjuvant = 6 months 
Liver + Lung 
Surgery
169
 
55% neoadjuvant;  
60% double-agent, 40% single-agent 
Neoadjuvant = 3 months 
50% adjuvant;  
50% double-agent, 50% single-agent 
Adjuvant = 3 months 
Pelvic Surgery
8
 
33% neoadjuvant;  
100% single-agent 
Neoadjuvant = 1 month 
Local-Regional 
Abdominal Surgery
200
 
20% neoadjuvant; 
100% single-agent; 
Neoadjuvant = 1 month; 
60% adjuvant; 
90% double-agent, 10% single-agent; 
Adjuvant = 6 months 
Utilization of Radiation 
Therapy 
Pelvic Surgery
8 10
 
33% neoadjuvant EBRT 
67% IOERT 
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Local-Regional 
Abdominal Surgery
200
 
25% neoadjuvant or adjuvant EBRT 
15% IOERT 
Re-Salvage Rates 
Liver Surgery171 14% 
Lung Surgery90 197 201 20% 
Liver + Lung Surgery 10% 
Pelvic Surgery
11
 10% 
Local-Regional 
Abdominal Surgery
200
 
25% 
Distribution of Salvage 
Sites 
Colon4 
Liver = 60%, Lung = 20%, Liver + Lung = 5%, 
LR = 15% 
Rectal4 
Liver = 40%, Lung = 30%, Liver + Lung = 5%, 
LR = 25% 
Table D.2 identifies important assumptions (and their sources in the literature) regarding utilization of 
resources for the different types of salvage treatment. These assumption were necessary to translate the 
costs associated with individual services given in Table D.1 into the aggregate cost estimates given in Table 
D.3. The terms ‘double-agent’ and ‘single-agent’ refer to the number of chemotherapy agents used (2 or 1, 
respectively). In the model, I use FOLFOX for all double-agent regimens and 5-FU/LV for all single-agent 
regimens. EBRT and IOERT stand for external-beam radiation therapy (outpatient radiation therapy) and 
intraoperative electron-beam radiation therapy (given during surgery). MCC, CC, and None stand for major 
complication or comorbidity, complication or comorbidity, and no complication or comorbidity, 
respectively. 
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Table D.3: Aggregate Costs of Surveillance and Salvage and Palliative 
Treatment 
AGGREGATE 
RESOURCE 
CATEGORY 
COST (2017 US $) CALCULATIONS/NOTES 
FOLLOW-UP TESTS 
Full CT Scan for 
Rectal Patients 
$548 $315 + $233 
Full CT Scan for Colon 
Patients 
$467 $234 + $233 
Cost of a True Positive 
CT: Colon 
$40 ((
338 + 394
2
) × 0.05) + ($438 × 0.05) 
Cost of a True Positive 
CT: Rectal 
$144 
($416 × 0.25) + ((
338 + 394
2
) × 0.05)
+ ($438 × 0.05) 
Cost of a False Positive 
CT: Colon 
$374 (
(
234 + 233
2 ) +
(460) + (438) + (
338 + 394
2 )
4
) 
Cost of a False Positive 
CT: Rectal 
$369 (
(
234 + 233
2 ) + (
416 + 460
2 ) +
(438) + (
338 + 394
2 )
4
) 
TREATMENT WITH CURATIVE INTENT 
Cost of Failed/R2 
Resection: (Colon) 
$12,215 
($12,796 × 0.65) + ($11,514 × 0.2)
+ ($10,633 × 0.15) 
Cost of Failed/R2 
Resection: (Rectal) 
$11,287 
($12,796 × 0.4) + ($11,514 × 0.35) + ($8,554 ×
0.25)  
Expected Cost of 
Hepatic Resection: 
Surgery 
$35,346 
($25,476 + $65) + ($37,425 × 0.2)
+ ($92,810 × 0.025) 
Expected Cost of 
Hepatic Resection: 
(Neo)Adjuvant 
Therapy 
$16,655 
0.16 × ((0.9 × $16,414) + (0.1 × $3,679)) +⁡⁡ 
0.47 × 2 × ((0.9 × $16,414) + (0.1 × $3,679)) 
Total Expected Cost of 
Hepatic Salvage 
Treatment 
$52,001 $35,346 + $16,655 
Expected Cost of 
Pulmonary Resection: 
Surgery 
$30,857 
($22,284 + $101) + ($43,898 × 0.175)
+ ($87,796 × 0.009) 
 
Expected Cost of 
Pulmonary Resection: 
(Neo)Adjuvant 
Therapy 
$16,957 0.56 × 2 × ((0.9 × $16,414) + (0.1 × $3,679)) 
Total Expected Cost of 
Pulmonary Salvage 
Treatment 
$47,814 $30,857 + $16,957 
Expected Cost of 
Staged Hepatic & 
Pulmonary Resection: 
Surgery 
$66,203 $35,346 + $30,857 
Expected Cost of 
Staged Hepatic & 
Pulmonary Resection: 
$11,249 
0.55 × (0.6 × 16414 + 0.4 × 3679) +⁡ 
0.50⁡ ×⁡(0.5 × 16414 + ⁡0.5⁡ × ⁡3679) 
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(Neo)Adjuvant 
Therapy 
Total Expected Cost of 
Staged Hepatic & 
Pulmonary Salvage 
Treatment 
$77,452 $66,203 + $11,249 
Expected Cost of 
Pelvic Resection: 
Surgery 
$22,159 
($14,191 + $74 + $540) + ($30,533 × 0.175)
+ ($61,066 × 0.022) 
Expected Cost of 
Pelvic Resection: 
(Neo)Adjuvant 
Therapy 
$ 2,542 1/3 × ($6,400 +
$3,679
3
) 
Total Expected Cost of 
Pelvic Salvage 
Treatment 
$24,701 $22,159 + $2,542 
Expected Cost of 
Abdominal Resection 
of Colon LR 
Recurrence: Surgery 
$45,361 $45,239 + $122 
Expected Cost of 
Abdominal Resection 
of Colon LR 
Recurrence: 
(Neo)Adjuvant 
Therapy 
$20,014 
0.2 ×⁡(
$3,679
3
)⁡+⁡ 
0.25⁡ ∗ $6,400⁡ +⁡ 
0.6⁡ ∗ ⁡2⁡ ∗ ⁡ (0.9⁡ ∗ $16,414⁡⁡ + ⁡0.1⁡ ∗ $3,679) 
Total Expected Cost of 
Abdominal Salvage 
Treatment of Colon LR 
Recurrence 
$65,375 $45,361 + $20,014 
Expected Cost of R0-1 
Surgical Resection + 
(Neo)Adjuvant 
Therapy (Colon) 
$54,442 
($52,001 × 0.6) + ($47,814 × 0.2)
+ ($77,452 × 0.05)
+ ($65,375 × 0.15) 
Expected Cost of R0-1 
Surgical Resection + 
(Neo)Adjuvant 
Therapy (Rectal) 
$45,192 
($52,001 × 0.4) + ($47,814 × 0.3)
+ ($77,452 × 0.05)
+ ($24,701 × 0.25) 
ADDITIONAL DOWNSTREAM COSTS FOR PATIENTS TREATED WITH CURATIVE INTENT 
Expected Cost per 
Round of CT Follow-
up (Colon) 
$486 
Includes Expected False-Positive Costs. Unless patient is 
in terminal phase (last 9 months), applies every 6 months 
for 2 years and then annually for 3 years. 
Expected Cost per 
Round of CT Follow-
up (Rectal) 
$567 
Includes Expected False-Positive Costs. Unless patient is 
in terminal phase (last 9 months), applies every 6 months 
for 2 years and then annually for 3 years 
Expected Cost of 
Possible Second 
Surgical Resection 
with Curative Intent + 
(Neo)Adjuvant 
Therapy (Colon) 
$9,255 $54,442 × 0.17 
Expected Cost of 
Possible Second 
Surgical Resection 
$6,779 $45,192 × 0.15 
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with Curative Intent + 
(Neo)Adjuvant 
Therapy (Rectal) 
Age-Specific 
Monthly Costs for 
Patient Care164 
< 75 = $1,093 
75 − 84 = $656 
≥ 85 = $473 
Applies starting in 7th month after the date of salvage 
surgery until the last 9 months of the patient’s life (in the 
case of cancer-death) or in all remaining lifetime until 10 
years (if no cancer death). 
Monthly Costs for 
Terminal Cancer164 
$4,091 
Applies for last 9 months of patient’s life in the cast of 
cancer death. If patient lives 9 or fewer months, only this 
cost is applied, not patient-care. 
PALLIATIVELY-TREATED PATIENTS 
Monthly Costs for 
Terminal Cancer164 
$4,091 
Applies for last 9 months of patient’s life in the cast of 
cancer death. If patient lives 9 or fewer months, only this 
cost is applied, not patient-care or initial treatment costs. 
Monthly Costs for 
Initial Treatment164 
$7,438 
Applies from the time of diagnosis of unresectable 
recurrent disease up to at most the next 8 months. 
However, applies only if patient lives at least 10 months 
because terminal disease gets priority. 
Age-Specific 
Monthly Costs for 
Patient Care164 
< 75 = $3,683 
75 − 84 = $2,210 
≥ 85 = $1,473 
Applies to any month patient is alive that is not attributed 
a terminal-cancer or initial-treatment cost. 
Table D.3 shows the aggregate costs for surveillance, salvage treatment, and palliative treatment. The last 
column shows the calculations used to derive the costs or provides notes about the use of the value. The 
first section shows the aggregate surveillance costs. The second section builds up to the expected cost of 
salvage treatment for rectal and colon cancer patients. The third section gives additional aggregate costs 
associated with salvage treatment over and above the initial treatment. The last section gives costs 
associated with palliative treatment. LR Recurrence = local-regional recurrence. 
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Table D.4: Incremental Increases in Life-Expectancy (Days) by Cohort 
Cohort 
Discount 
Rate 
No 
Surveillance: 
Life-
Expectancy 
(Years) 
1 CT 
Scan 
(Days) 
CEA + 
1 CT 
Scan 
(Days) 
CEA + 
2 CT 
Scans 
(Days) 
CEA 
+ 3 
CT 
Scans 
(Days) 
CEA 
+ 5 
CT 
Scans 
(Days) 
Stage III Colon 
60 
0% 
16.342  
(16.334-16.350) 
48.9 
(48.2-
49.6) 
87.6 
(86.5-
88.7) 
9.5 
(8.8-9.9) 
4.4 
(4.0-4.7) 
3.6 
(3.3-4.4) 
Stage III Colon 
60 
3% 
11.733 
(11.728-11.738) 
30.3 
(29.9-
30.7) 
53.3  
(52.6-
53.7) 
5.5 
(5.1-5.8) 
2.2 
(1.8-2.6) 
1.8 
(1.5-2.2) 
Stage III 
Rectal 60 
0% 
17.167 
(17.159-17.175) 
40.9 
(40.1-
41.6) 
74.8 
(73.7-
75.9) 
8.0 
(7.3-8.4) 
2.9 
(2.2-3.3) 
4.0 
(3.6-4.4) 
Stage III 
Rectal 60 
3% 
12.263 
(12.258-12.268) 
25.6 
(24.8-
25.9) 
46.0 
(45.3-
46.4) 
  4.7 
(4.4-5.1) 
1.1 
(0.7-1.5) 
  1.8 
(1.5-2.2) 
Stage II Colon 
60 
0% 
19.602 
(19.595-19.610) 
46.0 
(45.6-
46.7) 
79.9 
(78.8-
81.0) 
8.0  
(7.7-8.8) 
4.0 
(3.6-4.4) 
  4.0 
(3.6-4.4) 
Stage II Colon 
60 
3% 
13.818 
(13.813-13.822) 
29.2 
(28.5-
29.6) 
49.3 
(48.9-
50.0) 
5.1 
(4.7-5.1) 
2.2 
(1.8-2.6) 
1.8  
(1.8-2.2) 
Stage II Rectal 
60 
0% 
18.980  
(18.972-18.988) 
49.6 
(48.9-
50.7) 
103.7 
(102.6-
104.8) 
10.6 
(9.9-
10.9) 
7.7  
(6.9-8.0) 
9.5 
(8.8-9.9) 
Stage II Rectal 
60 
3% 
13.459 
(13.454-13.463) 
31.4 
(30.7-
31.8) 
63.5 
(63.1-
64.2) 
6.2 
(6.2-6.6) 
4.4 
(4.0-4.7) 
5.1 
(4.7-5.5) 
Stage III Colon 
65 
0% 
13.453 
(13.448-13.458) 
40.9 
(40.1-
41.2) 
71.5 
(70.8-
72.3) 
7.3 
(6.9-7.7) 
2.6 
(2.2-2.9) 
2.6 
(2.2-2.9) 
Stage III Colon 
65 
3% 
10.159 
(10.156-10.163) 
26.6 
(26.3-
27.0) 
46.0  
(45.6-
46.7) 
4.4 
(4.4-4.7) 
1.1 
(0.7-1.5) 
1.5 
(1.1-1.5) 
Stage III 
Rectal 65 
0% 
14.422 
(14.417-14.427) 
31.0 
(30.7-
31.4) 
58.4 
(58.0-
59.1) 
5.8 
(5.5-6.2) 
1.8 
(1.5-2.2) 
1.8 
(1.5-2.2) 
Stage III 
Rectal 65 
3% 
10.822 
(10.819-10.825) 
20.4 
(20.1-
20.8) 
38.0 
(37.6-
38.3) 
3.6 
(3.3-3.6) 
0.7 
(0.7-1.1) 
0.7 
(0.4-0.7) 
Stage II Colon 
65 
0% 
16.333 
(16.328-16.338) 
36.1 
(35.8-
36.5) 
61.0 
(60.2-
61.3) 
5.8 
(5.8-6.2) 
2.6 
(2.2-2.9) 
2.2   
(1.8-2.6) 
Stage II Colon 
65 
3% 
12.109 
(12.106-12.112) 
24.1  
(23.7-
24.5) 
39.8  
(39.4-
40.1) 
3.6  
(3.6-4.0) 
1.5 
(1.1-1.5) 
1.1 
(1.1-1.5) 
Stage II Rectal 
65 
0% 
15.895 
(15.89-15.90) 
38.7 
(38.3-
39.1) 
78.1 
(77.7-
78.8) 
7.3 
(6.9-7.3) 
5.5 
(5.1-5.8) 
6.2 
(5.8-6.2) 
Stage II Rectal 
65 
3% 
11.845 
(11.842-11.848) 
25.6 
(25.2-
25.9) 
50.4  
(50.0-
51.1) 
4.4 
(4.4-4.7) 
3.3 
(2.9-3.6) 
3.3 
(3.3-3.6) 
Stage III Colon 
70 
0% 
10.858 
(10.854-10.862) 
34.7 
(34.3-
35.0) 
58.4 
(57.7-
59.1) 
5.8 
(5.5-6.2) 
1.8 
 (1.5-
1.8) 
1.5 
(1.1-1.5) 
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Stage III Colon 
70 
3% 
8.598 
(8.595-8.600) 
24.1 
(23.7-
24.5) 
40.5 
(40.1-
40.9) 
4.0 
(3.6-4.0) 
0.7 
(0.7-1.1) 
0.7 
(0.4-0.7) 
Stage III 
Rectal 70 
0% 
11.865 
(11.861-11.869) 
24.5 
(24.1-
24.8) 
44.2 
(43.4-
44.5) 
4.4 
(4.0-4.7) 
1.5 
(1.1-1.5) 
1.1 
(0.7-1.5) 
Stage III 
Rectal 70 
3% 
9.328 
(9.325-9.331) 
16.8 
(16.8-
17.2) 
30.3 
(29.9-
30.7) 
2.9 
(2.6-2.9) 
0.7 
(0.4-0.7) 
0.4 
(0.4-0.7) 
Stage II Colon 
70 
0% 
13.229 
(13.225-13.233) 
28.8 
(28.5-
29.2) 
47.1 
(46.7-
47.8) 
4.7 
(4.4-4.7) 
1.8 
(1.5-2.2) 
1.5 
(1.1-1.5) 
Stage II Colon 
70 
3% 
10.291 
(10.289-10.294) 
20.4 
(20.1-
20.8) 
32.9 
(32.5-
33.2) 
2.9 
(2.9-3.3) 
1.1 
(1.1-1.5) 
0.7 
(0.4-0.7) 
Stage II Rectal 
70 
0% 
12.997 
(12.993-13.001) 
29.2 
(28.8-
29.6) 
58.0 
(57.3-
58.4) 
5.8 
(5.5-6.2) 
3.6 
(3.3-3.6) 
3.6 
(3.6-4.0) 
Stage II Rectal 
70 
3% 
10.153 
(10.150-10.156) 
20.4 
(20.1-
20.8) 
39.8 
(39.4-
40.1) 
4.0 
(3.6-4.0) 
2.2 
(2.2-2.6) 
2.2 
(2.2-2.6) 
Stage III Colon 
75 
0% 
8.243 
(8.239-8.246) 
29.9 
(29.6-
30.3) 
48.5 
(47.8-
48.9) 
4.0 
(4.0-4.4) 
0.7 
(0.7-1.1) 
0.0 
(-0.4-
0.4) 
Stage III Colon 
75 
3% 
6.844 
(6.841-6.846) 
21.9 
(21.5-
22.3) 
36.1 
(35.8-
36.5) 
2.9 
(2.6-2.9) 
0.4  
(0.4-0.7) 
-0.4 
(-0.4-
0.0) 
Stage III 
Rectal 75 
0% 
6.758 
(6.755-6.761) 
42.0 
(41.6-
42.7) 
59.9 
(59.5-
60.6) 
2.6 
(2.6-2.9) 
0.4 
(0.4-0.7) 
0.0 
(0.0-0.4) 
Stage III 
Rectal 75 
3% 
5.69 
(5.687-5.692) 
31.0 
(30.7-
31.0) 
44.5 
(44.2-
44.9) 
1.8 
(1.8-2.2) 
0.0 
(0.0-0.4) 
0.0 
(-0.4-
0.0) 
Stage II Colon 
75 
0% 
10.315 
(10.312-10.319) 
23.0 
(22.6-
23.4) 
35.8 
(35.4-
36.1) 
3.3 
(2.9-3.3) 
1.1 
(0.7-1.1) 
0.7 
(0.4-0.7) 
Stage II Colon 
75 
3% 
8.411 
(8.408-8.413) 
17.2 
(16.8-
17.2) 
26.6 
(26.3-
27.0) 
2.2 
(2.2-2.6) 
0.7 
(0.4-0.7) 
0.4 
(0.4-0.7) 
Stage II Rectal 
75 
0% 
10.156 
(10.153-10.160) 
24.8 
(24.5-
25.2) 
37.2 
(36.9-
37.6) 
3.6 
(3.3-3.6) 
2.2 
(1.8-2.2) 
1.8 
(1.8-2.2) 
Stage II Rectal 
75 
3% 
8.286 
(8.283-8.288) 
18.6 
(18.2-
19.0) 
27.7 
(27.4-
28.1) 
2.6 
(2.2-2.6) 
1.5 
(1.1-1.5) 
1.1  
(1.1-1.1) 
Table D.4 contains the results of the efficacy analyses. For each cohort, the third column gives 
the baseline life-expectancy (LE) in years (discounted at 0% and 3%). By baseline, I mean in the 
absence of any routine surveillance. The next five columns give the incremental increases in LE 
in days comparing the surveillance-schedule identified by the column title, e.g., ‘CEA + 2 CT 
Scans’, with the previous regimen (the one to the left). In each cell, the first entry is the point 
estimate, and 95% confidence intervals are given in the second row in parentheses. These 
quantify the precision of the point estimate with respect to Monte Carlo error. 
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Table D.5: Incremental Increases in Mean Total Costs (2017 US $) by 
Cohort 
Cohort 
Discount 
Rate 
Ex-Ante 
Expected 
Costs of 
Recurrence 
& 
Surveillance 
with No 
Surveillance 
1 CT 
Scan 
CEA + 
1 CT 
Scan 
CEA 
+ 2 
CT 
Scans 
CEA 
+ 3 
CT 
Scans 
CEA + 
5 CT 
Scans 
Stage III Colon 
60 
0% 
35,034  
(34,988 35,079) 
3,003 
(2,961-
3,046) 
6,222  
(6,179-
6,264) 
757 
(741-
773) 
614 
(598-
630) 
1,009 
(993-
1,025) 
Stage III Colon 
60 
3% 
30,623 
(30,584-30,662) 
2,881 
(2,846-
2,917) 
5,792  
(5,757-
5,828) 
745  
(732-
759) 
583 
(569-
596) 
901 
(888-915) 
Stage III Rectal 
60 
0% 
30,642 
(30,599-30,685) 
2,244  
(2,205-
2,283) 
4,593 
(4,555-
4,632) 
716 
(701-
731) 
605 
(590-
620) 
1,120 
(1,105-
1,135) 
Stage III Rectal 
60 
3% 
26,745 
(26,708-26,782) 
2,155 
(2,122-
2,188) 
4,286 
(4,253-
4,318) 
706  
(694-
719) 
578 
(566-
591) 
998   
(986-
1,011) 
Stage II Colon 
60 
0% 
17,706 
(17,671-17,740) 
2,259 
(2,228-
2,289) 
4,467 
(4,436-
4,498) 
674 
(662-
685) 
605 
(594-
617) 
1,108 
(1,096-
1,119) 
Stage II Colon 
60 
3% 
15,397 
(15,368-15,427) 
2,140 
(2,115-
2,166) 
4,099 
(4,073-
4,125) 
655 
(645-
665) 
566 
(556-
576) 
977 
(967-986) 
Stage II Rectal 
60 
0% 
22,082 
(22,044-22,120) 
2,173 
(2,139-
2,206) 
5,180 
(5,147-
5,214) 
749 
(737-
760) 
741 
(729-
752) 
1,389 
(1,377-
1,400) 
Stage II Rectal 
60 
3% 
18,727 
(18,696-18,759) 
2,065 
(2,037-
2,092) 
4,721 
(4,693-
4,749) 
727 
(717-
736) 
693 
(683-
702) 
1,224 
(1,215-
1,234) 
Stage III Colon 
65 
0% 
35,580 
(35,547-35,612) 
3,112 
(3,082-
3,142) 
6,246 
(6,216-
6,275) 
783 
(769-
797) 
602 
(588-
616) 
1,024 
(1,010-
1,038) 
Stage III Colon 
65 
3% 
31,404 
(31,376-31,432) 
2,994 
(2,968-
3,020) 
5,826 
(5,801-
5,852) 
771 
(759-
783) 
574 
(562-
586) 
912 
(900-925) 
Stage III Rectal 
65 
0% 
29,394 
(29,364-29,424) 
2,177 
(2,150-
2,204) 
4,590 
(4,563-
4,617) 
719 
(707-
730) 
622 
(611-
634) 
1,089 
(1,078-
1,101) 
Stage III Rectal 
65 
3% 
25,809 
(25,783-25,835) 
2,100 
(2,077-
2,123) 
4,285 
(4,263-
4,308) 
709 
(699-
719) 
591 
(582-
601) 
972 
(962-981) 
Stage II Colon 
65 
0% 
16,946 
(16,922-16,971) 
2,194 
(2,173-
2,215) 
4,300 
(4,278-
4,321) 
668 
(659-
677) 
588 
(579-
597) 
1,066  
(1,057-
1,075) 
Stage II Colon 
65 
3% 
14,840 
(14,819-14,861) 
2,083 
(2,065-
2,100) 
3,958 
(3,940-
3,977) 
649 
(641-
656) 
 550 
(542-
557) 
941 
(934-949) 
Stage II Rectal 
65 
0% 
20,775 
(20,749-20,801) 
2,166 
(2,144-
2,188) 
4,993 
(4,970-
50,16) 
755 
(745-
765) 
756 
(746-
766) 
1,399 
(1,389-
1,409) 
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Stage II Rectal 
65 
3% 
17,744 
(17,722-17,766) 
2,056 
(2,037-
2,075) 
4,576  
(4,557-
4,595) 
735 
(727-
743) 
708 
(700-
716) 
1,239 
(1,231-
1,248) 
Stage III Colon 
70 
0% 
31,786 
(31,758-31,814) 
3,462 
(3,436-
3,487) 
6,388 
(6,362-
6,413) 
853 
(842-
864) 
648 
(638-
659) 
909 
(899-920) 
Stage III Colon 
70 
3% 
28,374 
(28,349-28,399) 
3,321 
(3,299-
3,344) 
5,979 
(5,957-
6,001) 
834 
(825-
843) 
611 
(602-
620) 
810 
(801-819) 
Stage III Rectal 
70 
0% 
24,775 
(24,750-24,801) 
2391 
(2,370-
2,413) 
4,771 
(4,749-
4,793) 
755 
(745-
764) 
639 
(630-
648) 
1,006 
(997-
1,016) 
Stage III Rectal 
70 
3% 
21,916 
(21,894-21,939) 
2,308 
(2,289-
2,327) 
4,469 
(4,449-
4,488) 
737 
(729-
745) 
600 
(592-
608) 
895 
(887-903) 
Stage II Colon 
70 
0% 
14,754 
(14,733-14,775) 
2,183 
(2,165-
2,200) 
3,966 
(3,948-
3,984) 
686 
(678-
694) 
  594 
(587-
602) 
983 
(975-990) 
Stage II Colon 
70 
3% 
13,089 
(13,071-13,108) 
2,077 
(2,061-
2,092) 
3,673 
(3,657-
3,689) 
665 
(658-
672) 
552 
(546-
559) 
868 
(861-874) 
Stage II Rectal 
70 
0% 
17,205 
(17,183-17,226) 
2,102 
(2,084-
2,120) 
4,568 
(4,549-
4,586) 
783 
(775-
790) 
754 
(746-
762) 
1,264 
(1,257-
1,272) 
Stage II Rectal 
70 
3% 
14,851 
(14,832-14,870) 
2,005 
(1,990-
2,021) 
4,213 
(4,197-
4,229) 
758 
(751-
764) 
704 
(697-
710) 
1,120 
(1,114-
1,127) 
Stage III Colon 
75 
0% 
29,020 
(28,996-29,044) 
3,784 
(3,762-
3,805) 
6,436 
(6,415-
6,457) 
835 
(827-
844) 
583 
(574-
592) 
809 
(801-818) 
Stage III Colon 
75 
3% 
26,228 
(26,207-26,250) 
3,609 
(3,590-
3,628) 
5,994 
(5,975-
6,012) 
818 
(811-
826) 
547 
(539-
555) 
717 
(709-725) 
Stage III Rectal 
75 
0% 
40,351 
(40,325-40,378) 
4,878 
(4,853-
4,902) 
6,728 
(6,704-
6,752) 
729  
(722-
736) 
593 
(586-
600) 
970 
(963-977) 
Stage III Rectal 
75 
3% 
37,053 
(37,029-37,076) 
4,712 
(4,690-
4,734) 
6,398 
(6,376-
6,419) 
713 
(707-
719) 
558 
(552-
564) 
860 
(854-867) 
Stage II Colon 
75 
0% 
12,434 
(12,417-12,451) 
2,208 
(2,193-
2,222) 
3,927 
(3,912-
3,941) 
643 
(637-
649) 
523 
(517-
529) 
883 
(877-889) 
Stage II Colon 
75 
3% 
11,134 
(11,119-11,150) 
2,087 
(2,075-
2,100) 
3,614 
(3,601-
3,626) 
622 
(616-
627) 
485 
(480-
491) 
776 
(771-781) 
Stage II Rectal 
75 
0% 
13,707 
(13,689-13,725) 
2,155 
(2,140-
2,170) 
3,524 
(3,509-
3,538) 
717 
(711-
723) 
685 
(679-
691) 
1,190 
(1,184-
1,196) 
Stage II Rectal 
75 
3% 
12,396 
(12,379-12,412) 
2,058 
(2,045-
2,071) 
3,284 
(3,271-
3,297) 
696 
(690-
701) 
639 
(633-
644) 
1,051 
(1,046-
1,056) 
Table D.5 contains the results of the cost analyses. For each cohort, the third column gives the 
baseline mean-costs in 2017 US dollars (discounted at 0% and 3%). By baseline, I mean the 
average costs associated with treatment of recurrence. The next five columns give the incremental 
increases in mean costs comparing the surveillance-schedule identified by the column title, e.g., 
‘CEA + 2 CT Scans’, with the previous regimen (the one to the left). In each cell, the first entry is 
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the point estimate, and 95% confidence intervals are given in the second row in parentheses. 
These quantify the precision of the point estimate with respect to Monte Carlo error. 
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Table D.6: Incremental Cost-Effectiveness Ratios (ICERs) in US $ per Life-
Year by Cohort 
Cohort 
Discount 
Rate 
1 CT 
Scan 
($/LY) 
CEA + 1 
CT Scan 
($/LY) 
CEA + 2 
CT Scans 
($/LY) 
CEA + 3 
CT Scans 
($/LY) 
CEA + 5 
CT Scans 
($/LY) 
Stage III 
Colon 60 
0% 
22,395 
(22,073-
22,717) 
25,950 
(25,664-
26,236) 
29,553 
(28,159-
30,947) 
51,083 
(45,680-
56,486) 
97,775 
(85,116-
110,434) 
Stage III 
Colon 60 
3% 
34,736 
(34,265-
35,207) 
39,797 
(39,343-
40,251) 
48,521 
(46,080-
50,962) 
93,112 
(80,785-
105,439) 
190,945 
(155,758-
226,132) 
Stage III 
Rectal 60 
0% 
20,089 
(19,729-
20,449) 
22,428 
(22,147-
22,709) 
33,083 
(31,284-
34,882) 
79,634 
(66,487-
92,781) 
101,446  
(89,625-
113,267) 
Stage III 
Rectal 60 
3% 
30,962 
(30,448-
31,476) 
34,122 
(33,690-
34,554) 
55,703 
(52,381-
59,025) 
173,096  
(130,574-
215,618) 
190,504  
(160,185-
220,823) 
Stage II 
Colon 60 
0% 
17,863  
(17,611-
18,115) 
20,399 
(20,178-
20,620) 
29,941 
(28,501-
31,381) 
55,534 
(49,760-
61,308) 
102,554 
(91,380-
113,728) 
Stage II 
Colon 60 
3% 
26,857 
(26,509-
27,205) 
30,317 
(29,989-
30,645) 
48,514 
(46,059-
50,969) 
95,290 
(83,705-
106,875) 
180,852 
(155,777-
205,927) 
Stage II 
Rectal 60 
0% 
15,922 
(15,673-
16,171) 
18,227 
(18,053-
18,401) 
26,165 
(25,160-
27,170) 
36,071  
(34,080-
38,062) 
54,383  
(51,872-
56,894) 
Stage II 
Rectal 60 
3% 
24,062 
(23,722-
24,402) 
27,078  
(26,822-
27,334) 
41,689 
(40,046-
43,332) 
59,043  
(55,447-
62,639) 
89,047  
(84,233-
93,861) 
Stage III 
Colon 65 
0% 
27,884 
(27,599-
28,169) 
31,865 
(31,601-
32,129) 
39,360 
(37,492-
41,228) 
91,466 
(77,363-
105,569) 
140,869  
(120,533-
161,205) 
Stage III 
Colon 65 
3% 
41,061 
(40,649-
41,473) 
46,079 
(45,681-
46,477) 
62,115 
(58,895-
65,335) 
183,271 
(142,130-
224,412) 
258,245 
(205,593-
310,897) 
Stage III 
Rectal 65 
0% 
25,610 
(25,270-
25,950) 
28,602 
(28,331-
28,873) 
45,578 
(43,268-
47,888) 
119,069  
(99,529-
138,609) 
228,835 
(186,206-
271,464) 
Stage III 
Rectal 65 
3% 
37,555 
(37,073-
38,037) 
41,299 
(40,896-
41,702) 
74,079 
(69,849-
78,309) 
257,907 
(191,348-
324,466) 
520,557 
(351,168-
689,946) 
Stage II 
Colon 65 
0% 
22,102 
(21,875-
22,329) 
25,771 
(25,554-
25,988) 
40,516 
(38,739-
42,293) 
84,319 
(75,099-
93,539) 
169,441 
(148,173-
190,709) 
Stage II 
Colon 65 
3% 
31,650 
(31,343-
31,957) 
36,302 
(35,995-
36,609) 
61,892 
(59,034-
64,750) 
141,704 
(122,932-
160,476) 
299,119 
(248,646-
349,592) 
Stage II 
Rectal 65 
0% 
20,419 
(20,189-
20,649) 
23,284 
(23,111-
23,457) 
38,644 
(37,026-
40,262) 
49,815 
(47,047-
52,583) 
84,670 
(80,166-
89,174) 
Stage II 
Rectal 65 
3% 
29,220 
(28,912-
29,528) 
33,044  
(32,797-
33,291) 
60,491 
(57,786-
63,196) 
78,699 
(73,787-
83,611) 
135,904 
(127,190-
144,618) 
Stage III 
Colon 70 
0% 
36,453 
(36,099-
36,807) 
39,913 
(39,574-
40,252) 
53,624 
(51,207-
56,041) 
140,928 
(117,349-
164,507) 
248,938 
(195,007-
302,869) 
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Stage III 
Colon 70 
3% 
50,230 
(49,727-
50,733) 
53,925 
(53,450-
54,400) 
79,364 
(75,449-
83,279) 
246,398 
(190,883-
301,913) 
493,829 
(321,322-
666,336) 
Stage III 
Rectal 70 
0% 
35,757 
(35,287-
36,227) 
39,535 
(39,126-
39,944) 
63,090 
(59,644-
66,536) 
179,517 
(144,359-
214,675) 
344,639 
(260,179-
429,099) 
Stage III 
Rectal 70 
3% 
49,832 
(49,154-
50,510) 
53,968 
(53,384-
54,552) 
93,805 
(88,168-
99,442) 
362,823 
(251,917-
473,729) 
652,010 
(407,408-
896,612) 
Stage II 
Colon 70 
0% 
27,631 
(27,354-
27,908) 
30,675 
(30,407-
30,943) 
54,416 
(51,759-
57,073) 
122,290 
(106,009-
138,571) 
262,293 
(215,672-
308,914) 
Stage II 
Colon 70 
3% 
37,191 
(36,827-
37,555) 
40,668 
(40,311-
41,025) 
79,240 
(75,123-
83,357) 
182,423 
(154,786-
210,060) 
446,348 
(338,006-
554,690) 
Stage II 
Rectal 70 
0% 
26,307 
(26,012-
26,602) 
28,786 
(28,558-
29,014) 
49,203 
(47,160-
51,246) 
77,160 
(71,745-
82,575) 
120,954 
(112,757-
129,151) 
Stage II 
Rectal 70 
3% 
35,760 
(35,366-
36,154) 
38,608 
(38,298-
38,918) 
71,051 
(67,961-
74,141) 
113,514 
(104,689-
122,339) 
185,499 
(170,237-
200,761) 
Stage III 
Colon 75 
0% 
46,299 
(45,858-
46,740) 
48,475 
(48,062-
48,888) 
74,854 
(70,856-
78,852) 
261,790 
(186,368-
337,212) 
8,669,429 
(NA) 
Stage III 
Colon 75 
3% 
59,947 
(59,342-
60,552) 
60,689 
(60,156-
61,222) 
105,836 
(99,563-
112,109) 
466,125 
(270,646-
661,604) 
Dominated 
Stage III 
Rectal 75 
0% 
Dominated 
by 
Extension 
41,519^ 
(41,331-
41,707) 
98,718 
(91,793-
105,643) 
523,471 
(267,922-
779,020) 
6,615,091 
(NA) 
Stage III 
Rectal 75 
3% 
Dominated 
by 
Extension 
53,804^ 
(53,550-
54,058) 
139,640 
(128,805-
150,475) 
2,091,750 
(NA) 
Dominated 
Stage II 
Colon 75 
0% 
35,176 
(34,830-
35,522) 
39,985 
(39,618-
40,352) 
  75,128 
(71,030-
79,226) 
195,244 
(159,317-
231,171) 
444,450 
(331,428-
557,472) 
Stage II 
Colon 75 
3% 
44,833 
(44,384-
45,282) 
49,637 
(49,176-
50,098) 
98,763 
(93,256-
104,270) 
313,802 
(238,430-
389,174) 
669,000 
(450,582-
887,418) 
Stage II 
Rectal 75 
0% 
31,653 
(31,324-
31,982) 
34,585 
(34,255-
34,915 
75,350 
(71,372-
79,328) 
118,064 
(107,439-
128,689) 
230,623 
(206,488-
254,758) 
Stage II 
Rectal 75 
3% 
40,445 
(40,021-
40,869) 
43,235 
(42,820-
43,650) 
104,136 
(98,292-
109,980) 
169,247 
(151,810) 
(186,684) 
342,643 
(297,873-
387,413) 
Table D.6 contains the results of the cost-effectiveness analyses. Each row gives the incremental 
cost-effectiveness ratios (ICERs) for a given cohort and discount rate. ICERs are presented in 
2017 US dollars per incremental life-year. Each ICER represents the cost per additional life-year 
achieved in virtue of using the surveillance-schedule identified by the column title, e.g., ‘CEA + 2 
CT Scans’ instead of the previous, less-intensive regimen (the one to the left). In each cell, the 
first entry is the point estimate, and 95% confidence intervals are given in the second row in 
parentheses. These quantify the precision of the point estimate with respect to Monte Carlo error. 
In the event that the incremental efficacy was negative, the intervention (more intensive 
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surveillance) is dominated by the comparison (less-intensive surveillance) and the cell simply 
says ‘Dominated’. If this was not the case but the 95% CI for the ICER included negative values, 
a CI is not given.  
^  = this ICER was recalculated because it dominated by extension the next least effective 
intervention. 
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Table D.7: Sensitivity Results: Incremental Cost-Effectiveness Ratios (ICER) 
Analysis 
1 CT Scan 
($/LY) 
CEA + 1 CT 
Scan ($/LY) 
CEA + 2 CT 
Scans 
($/LY) 
CEA + 3 CT 
Scans ($/LY) 
CEA + 5 
CT Scans 
($/LY) 
Discount Rate = 0% 
Baseline 
27,884 
(27,599-28,169) 
31,865 
(31,601-32,129) 
39,360 
(37,492-41,228) 
91,466 
(77,363-105,569) 
140,869  
(120,533-
161,205) 
Salvage 
Treatment 
Costs × 1.5 
37,387 
(36,935-37,839) 
41,528 
(41,100-41,956) 
53,970  
(47,334-60,606) 
80,303 
(58,913=101,693) 
217,650 
(106,006-
329,294) 
Salvage 
Treatment 
Costs × 0.5 
16,372 
(16,076-16,668) 
  19,130 
(18,902-19,358) 
26,966 
(23,545-30,387) 
48,455 
(35,530-61,380) 
152,663 
(74,419-
230,907) 
Palliative 
Costs × 1.5 
20,359 
(19,910-20,808) 
24,351 
(24,022-24,680) 
29,144 
(25,010-33,278) 
53,228 
(38,496-67,960) 
171,663 
(83,227-
260,099) 
Palliative 
Costs × 0.5 
33,402 
(33,020-33,784) 
36,307 
(35,950-36,664) 
51,782 
(45,529-58,035) 
75,517 
(55,591-95,443) 
198,650 
(97,029-
300,271) 
Salvage 
Continuing 
Costs = 
Stage IV 
60,748 
(60,137-61,359) 
66,055 
(65,478-66,632) 
83,282 
(74,278-92,286) 
118,779 
(89,767-147,791) 
283,500 
(143,351-
423,649) 
Salvage 
Continuing 
Costs = 
Stage III × 
0.5 
19,722 
(19,396-20,048) 
22,787 
(22,512-23,062) 
31,396 
(27,213-35,579) 
52,876 
(38,210-67,542) 
164,400 
(78,986-
249,814) 
Cost of CT 
Scan × 2.0 
31,140 
(30,747-31,533) 
31,455 
(31,127-31,783) 
42,983 
(37,704-48,262) 
67,786 
(49,754-85,818) 
194,000 
(94,485-
293,515) 
Cost of CT 
Scan× 0.5 
25,076 
(24,740-25,412) 
29,354 
(29,045-29,663) 
32,289 
(28,363-36,215) 
49,703 
(36,713-62,693) 
135,763 
(66,884-
204,642) 
More 
Expensive 
Positive CT 
Scan Results 
27,273 
(26,918-27,628) 
30,876 
(30,552-31,200) 
41,117 
(36,063-46,171) 
65,503 
(48,077-82,929) 
188,700 
(91,910-
285,490) 
More 
Expensive 
Clinical 
Visits 
28,598 
(28,230-28,966) 
40,219 
(39,795-40,643) 
40,352 
(35,397-45,307) 
64,297 
(47,210-81,384) 
186,125 
(90,690-
281,560) 
5-FU for 
Unresectable 
Recurrence 
31,986 
(31,657-32,315) 
35,030 
(34,731-35,329) 
43,802 
(39,391-48,213) 
62,468 
(49,521-75,415) 
135,281 
(92,148-
178,414) 
Salvage 
Mortality 
Rate = 5% 
27,727 
(27,341-28,113) 
29,960 
(29,635-30,285) 
42,114 
(36,375-47,853) 
82,257 
(53,396-111,118) 
156,326 
(90,587-
222,065) 
Table D.7 gives the results of the sensitivity analyses using a discount rate of 0%. ICERs are 
reported in 2017 US dollars per additional life-year. The first row (Baseline) gives the reference-
case ICERS for 65-year-old stage III colon cancer patients. Each subsequent row gives the 
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ICERS (and 95% CIs) for different univariate sensitivity analyses. The first four involved 
multiplying the assumed cost(s) by a factor of 1.5 or 0.5. The 5th row in each section reports the 
results when the continuing costs among patients treated with salvage treatment were assumed to 
be the same as for patients with unresectable recurrence. For the latter patients, the model used an 
estimate based on stage IV patients. In the reference-case analysis, the model used an estimate for 
continuing costs following salvage treatment based on stage III patients. The row immediately 
below reports the results using continuing costs equal to 50% of those of stage III patients. The 
next two rows present the results using an inflated and deflated cost for a CT scan, respectively. 
In the following two rows, analyses used larger values for the cost of a true-positive (x10) and 
false-positive (2x) CT scan result and an increased cost of routine clinical visits, respectively. 
Finally, the last two rows give the results for an analysis done assuming all (65-year old stage III 
colon cancer) patients with unresectable recurrence are treated with 5-FU rather than FOLFOX 
and for an analysis done using a salvage mortality rate of 5% rather than 2%. To determine the 
impact variation in a given parameter had on the ICERs, the ICERs from the appropriate row 
should be compared to the baseline row. 
 
 
 
 
 
